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Dendrimers are a class of polymers with high potential as drug delivery systems due to 
their unique scaffold and properties. Despite their early potential, dendrimer-based 
therapies have been limited in part due to the considerable lack of understanding of 
their in vivo behavior and in particular, how they interact and cross cellular membranes. 
Therefore, designing dendrimers with an attached fluorophore would allow their 
tracking while studying their behavior with lipid bilayers. This work explores the 
potential of fluorescent dendrimers as carriers for the anti-cancer drug cisplatin, which 
is known to interact with lipids and induce phase changes in cellular membranes.  To 
this end, fluorescent poly(glutamic acid) (PG) dendrimers were designed in silico and 
suitable candidates were attempted to be synthesized. Furthermore, effects of cisplatin 
in phase change and integrity of lipid model bilayers was studied to further drive the 
design of these dendrimers. The choice of PG dendrimers backbone was driven by 
their ability to fully cover a small fluorophore from the external environment. To quickly 
generate dendrimers scaffolds a set of computational tools were created to automate 
this process and facilitate the modeling of any class of dendrimers. Different 
generations and architecture of PG dendrimers with a fluorophore attached to the core 
and different terminal groups were created and submitted to all-atom simulations. Data 
from molecular dynamics showed that generation 4 was necessary to fully cover a low 
molecular weight fluorophore and partially cover a high molecular weight fluorophore 
as measured by the solvent accessible surface area. However, the synthesis of these 
candidates was shown to be difficult due to the amount of side reactions and possible 
steric hindrance that arises at high generations. Furthermore, the attachment of NBD 
was required to be carried out at lower generations since its reactivity with higher 
generations of PG dendrimers was lower. Therefore, analogues of glutamic acid with 
NBD (nitrobenzoxadiazole) were synthesized to be used as the initial core. Finally, 
platinum-membrane interactions were characterized by measuring the fluorescence 
anisotropy of different probes embedded in liposomes composed of different lipid 
mixtures. Results suggested that both cisplatin and its cationic aquated analogue had 
low perturbation on the lipid phase and integrity of model membranes. However, 
cisplatin was able to further reduce the membrane fluidity when a gel phase was 
present in the membrane. Furthermore, at high concentrations, platinum complexes 
were shown to compromise the permeability of lipid bilayers without inducing collapse 
of the membrane. This effect was again dependent on membrane lipid composition. 
Altogether, these findings were used as a proof-of-concept for designing dendrimers as 
potential tools to carry and study cisplatin interactions at the lipid membrane. 
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Os dendrímeros são macromoléculas sintéticas com uma estrutura tridimensional 
regular bem definida e ramificada. Estes são tipicamente descritos por um crescimento 
radial a partir de um monómero central (geralmente denominado núcleo) ao qual são 
incorporados de forma sucessiva e iterativa camadas (geralmente referidas como 
geração) de monómeros até à última camada, designada de grupos terminais. Devido 
às suas características estruturais, os dendrímeros têm demonstrado potencial em 
várias áreas e em particular no transporte de moléculas terapêuticas e de imagiologia 
sendo que também podem demonstrar actividade biológica. Apesar de extensamente 
estudados, o mecanismo de interacção dos dendrímeros com componentes biológicos, 
e em particular com as membranas lipídicas, é relativamente pouco conhecido. Vários 
estudos com dendrímeros de poli(amido aminas) (PAMAM) demonstraram que para 
dendrímeros de maiores gerações estes interagem fortemente com camadas lipídicas 
causando poros na membrana e que estes efeitos estão correlacionados com os 
efeitos de toxicidade observados em células. Uma vez que a maioria dos dendrímeros 
têm tamanhos na escala de outros componentes biológicos tais como as proteínas, 
existe uma dificuldade acrescida de os estudar nas células. Uma maneira de contornar 
este problema é pela incorporação de sondas fluorescentes na estrutura dos 
dendrímeros. Contudo, adicionar as sondas à superfície pode não só alterar as 
propriedades de superfície, que por sua vez podem contribuir por si só para a 
interacção destes com a membrana, como também a adição é feita de maneira 
estatística e por isso existe um controlo menor da estrutura. Assim sendo, a 
incorporação de sondas fluorescentes no interior central do dendrímero é vantajoso. 
No entanto, isto requer que o monómero central tenha capacidade de ligação a um 
fluoróforo. Por outro lado, dependendo do tamanho do fluoróforo em relação ao 
tamanho e estrutura do dendrímero existirá uma geração mínima capaz de incorporar 
totalmente o fluoróforo no seu interior. Os modelos computacionais da estrutura de 
dendrímeros são assim úteis para definir estruturas promissoras para a incorporação 
do fluoróforo no seu interior anteriormente à sua síntese. Assim sendo, o ácido 
glutâmico foi escolhido para constituir a base estrutural dos dendrímeros a serem 
construídos in silico. O uso de aminoácidos como monómeros oferece vantagens em 
aplicações biológicas uma vez que os produtos de degradação têm grande 
probabilidade de serem biocompatíveis. Por outro lado, o ácido glutâmico é 
assimétrico e apresenta 3 grupos funcionais (2 ácidos carboxílicos e 1 amina) que 
permitem explorar variadas estruturas dendríticas deixando sempre um grupo do 
monómero central para reagir com o fluoróforo.  
Um dos problemas na criação de modelos computacionais de dendrímeros ocorre a 
grandes gerações onde a adição manual de ligações entre monómeros facilmente 
pode criar erros na estrutura por erro humano. Para isso, várias metodologias têm sido 
descritas na literatura para a construção de dendrímeros mas requerem sempre um 
nível elevado de construção manual. Com o objectivo de colmatar este problema 
foram desenvolvidas ferramentas computacionais para automatizar este processo. 
Este método foi então posteriormente testado com os dendrímeros de ácido poli-
glutâmico ligados a um fluoróforo com a construção de vários modelos de diferentes 
gerações e com diferentes grupos terminais. A ferramenta desenvolvida gerou a 
descrição do dendrímero como uma sequência linear de monómeros e uma tabela de 
conectividade que indica ao programa de software XPLOR-NIH como “montar” o 
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dendrímero na sua forma tridimensional. Após construção dos vários modelos de 
dendrímeros estes foram submetidos a simulação com o uso da parametrização 
CHARMM. Os resultados das simulações demonstraram que estruturalmente apenas 
a partir da geração 4 foi possível a capacidade de evitar o contacto de um fluoróforo 
pequeno com o meio exterior, sendo que este efeito seria apenas parcial no caso de 
um fluoróforo de dimensões maiores. Os efeitos da alteração dos monómeros 
terminais com triptofano e lisina revelaram ainda que no caso do triptofano este 
aumentou o tamanho do dendrímero e reduziu a flexibilidade com evidência de 
interacções do tipo π-π. 
Os candidatos gerados pelas simulações computacionais foram de seguida 
sintetizados por métodos divergentes e convergentes pelo uso de reagentes 
comumente utilizados na síntese peptídica. Em geral os vários reagentes 
demonstraram elevados rendimentos para as gerações pequenas de dendrímeros. No 
entanto, para dendrímeros de geração 2 e superiores, várias reacções incompletas 
dos grupos terminais foram verificadas. Isto foi atribuído ao espaçamento curto entre 
os grupos carboxílicos na molécula de ácido glutâmico que restringe a reacção de 
ambos os lados quando a superfície começa a ficar congestionada pelos vários 
monómeros ao redor. Por outro lado, os resultados indicaram que o fluoróforo teria de 
ser incorporado nas primeiras gerações do dendrímero uma vez que para dendrímeros 
de geração superior o rendimento da reacção foi baixo. Assim sendo, o fluoróforo foi 
introduzido no monómero central. No entanto, nestas condições a amina secundária 
formada teve capacidade de reacção pelo que outras alternativas de transformação da 
amina do monómero central foram testadas. Contudo, estas reacções apresentaram 
um rendimento baixo pelo que outras alternativas devem ser exploradas. Por outro 
lado, diferentes grupos terminais foram sintetizados com os mesmos protocolos 
usados para a estrutura central do dendrímero, sendo obtidos em rendimento elevado. 
No entanto, foi verificado que para monómeros com grupos de protecção de elevado 
caracter hidrofóbico, que o produto recuperado apresentou solubilidade limitada nos 
solventes testados pelo que dificultaria a sua acoplagem à estrutura central. Outros 
grupos de protecção deverão portanto ser explorados.  
Uma das aplicações para este tipo de dendrímeros é o transporte de fármacos. Em 
particular os dendrímeros aniónicos de ácido glutâmico oferecem vantagens para a 
incorporação de cisplatina. A cisplatina em solução aquosa com baixa concentração 
de cloro forma espécies carregadas positivamente que poderiam complexar com o 
dendrímero de ácido glutâmico. A cisplatina é um anticancerígeno muito utilizado no 
tratamento de vários tumores sólidos mas cujo uso é limitado pelos efeitos 
secundários geralmente observados. Apesar de ser estruturalmente simples a 
cisplatina demonstra um comportamento complexo nas células. Como anticancerígeno 
a cisplatina atua primariamente no ADN genómico por reacção com as bases e 
formação de complexos. No entanto, o contributo dos lípidos da membrana plasmática 
tem sido reportado tanto para os efeitos no mecanismo de acção da cisplatina por 
indução da apoptose através da oligomerização de receptores à superfície da 
membrana, bem como nas diferenças lipídicas da composição das membranas 
celulares que levam a mecanismos de resistência por menor acumulação de platina no 
interior da célula. Contudo, o efeito da cisplatina na alteração de fase verificada nas 
células não é completamente compreendida. Assim sendo, os efeitos na fluidez da 
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membrana pela cisplatina e da sua forma catiónica foram testadas em modelos lípidos 
na forma de lipossomas pela medição da anisotropia e tempos de vida de 
fluorescência de várias sondas com localização em diferentes regiões da bicamada 
lipídica e com partição distinta para diferentes fases lipídicas. A formação das 
espécies de carga positiva em tampões sem cloro foi verificada em misturas de lípido 
com carga negativa onde se observou uma redução da carga negativa à superfície dos 
lipossomas que foi atribuída à neutralização de cargas. O efeito da redução de cargas 
foi proporcional à concentração e transitório sendo que após 24 horas os valores 
retornaram a valores semelhantes ao controlo. O mesmo efeito transitório foi 
observado na fluidez de membranas de POPC onde entre os 60-100 minutos se 
verificou um ligeiro aumento da ordem tendo posteriormente retornado a valores 
semelhantes ao controlo. Por outro lado, os complexos de platina não demonstraram 
alterações significativas da fluidez, excepto para os sistemas de fase gel onde uma 
diminuição significativa da fluidez foi observada com o aumento de concentração dos 
complexos de platina(II) em lipossomas de DPPC. Por outro lado, os complexos de 
platina aumentaram a permeabilidade das camadas lipídicas a concentrações mais 
altas e este efeito foi dependente da composição lipídica.  
Em suma, os efeitos dos complexos de platina nas alterações de fase e propriedades 
biofísicas das membranas parecem ser limitados, sugerindo que as alterações de 
fluidez reportadas nas células pela cisplatina que levam a uma fluidificação da 
membrana não parecem ser devido ao aumento da ceramida mas sim a outros 
factores. Estes resultados constituíram importantes avanços na perspectiva de 
desenvolvimento de dendrímeros e a sua possível utilização no estudo das 
interacções de cisplatina com membranas lipídicas e para o desenvolvimento de novas 
abordagens como terapias anticancerígenas. Neste contexto os dendrímeros oferecem 
uma vantagem porque não só podem ser concomitantemente complexados com 
cisplatina e moléculas sinergísticas à sua acção como também podem ser usados 
para evadir os mecanismos de resistência que geralmente surgem em tratamentos 
prolongados.  
Keywords: cisplatin, dendrimer modeling, peptide dendrimers, membrane fluidity, 
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Figure 1.1  
 
Typical theoretical drug development program. Over the course of the 
development program the number of potential candidates that reaches 
the clinical setting is relatively low due to the inherent problems of most 
drugs. Specifically designed DDS introduced at the pre-clinical 
development stage or as a repurposing strategy could potential improve 
the number of drugs 
2 
Figure 1.2  
 
Schematic topology representation of different types  of 
hyperbranched polymers. Dendrimers can be generated by attaching 
dendrons to a multifunctional core and are generally differentiated from 
other hyperbranched polymers where the growth is more random.   
4 
Figure 1.3  Topology description of a typical dendrimer. The backbone is grown 
from the central core unit and the terminal groups define the overall 
charge displayed at the surface (red spots). At this generation, void space 
(pockets) created by the backbone or the terminal branches allow space 
for small molecules to be incorporated.  
5 
Figure 1.4  Types of G0 for a series of different dendrimers wi th the same core 
(●) and branches ( ■) but with different terminal groups and core 
modifications. The scaffold of dendrimers is flexible to modification 
which can be valuable to display different surface properties. PTG: 
protecting group; Tag: Tag molecule 
6 
Figure 1.5   Examples of dendrimers synthesized from different st arting cores 
and different branching monomers. Since the limiting factor for 
synthesis is based on the reactivity of the active groups used, a wide 
diversity of scaffolds can be generated 
8 
Figure 1.6  Glutamic acid protonation at different pH. The variation of pH results 
in different protonation of the amine and carboxyl groups which 
modulated the effective final charge of the  
12 
Figure 1.7  Schematic representation of “spheres” and “springs” and their 
contribution to the potential energy function . a) bond length term; b) 
dihedral angle term; c) bond angle term; d) improper angle term; e) van 
der Waals term; f) coulomb term 
17 
Figure 1.8  Figure 1.8 – Dendrimers size scale in comparison to other biolog ical 
molecules. Dendrimers have the approximate size of small proteins, 




Figure 3.1  Synthesis of PLL dendrimers G0. The core lysine amino acid with the 
carboxyl group capped with a protecting group is reacted with amine-
capped branching lysines using the Boc protecting group to prevent further 
reaction of the amines. 
120 
Figure 3.2  Examples of PG dendrimers G0 described in the literat ure using 
different cores and different capping groups. Despite Glu being used to 
grow the different dendrimers, the use of different cores resulted in very 
different scaffolds. In fact the type of core can have (A-B) mono-, (C) bi- 
and (D) tri-functionality meaning that for the same generation the 
architecture and size of the dendrimer vary. (E): Similarly using a core 
composed of a di-glutamic acid results in a different final scaffold. 
120 
Figure 3.3  Mechanism reaction of acyl halides for amide format ion. During the 





Figure 3.4  Side product of carbodiimides  reacting with carboxyl group resulting 
in the formation of the N-acylurea.  
123 
Figure 3.5  Neighboring effect of HAOt with the precursors favo ring the homing 
effect. This orientates both precursor reagents and facilitates their reaction.   
123 
Figure 3.6  Mechanism of reaction of CDI with carboxyl to form an amide bond.  123 
Figure 3.7  Reaction scheme of coupling the NBD to the amine. The nucleophilic 
nature of amines displaces the chloride of NBD.   
126 
Figure 3.8  Initial intended synthetic approach to generate N -protected PG -Ester 
G2; a) coupling reagents (typically DCC/NHS; HBTU/HOBt; CDI); b) basic 
hydrolysis with NaOH or LiOH; c) acid hydrolysis with TFA or concentrated 
HCl/sulfuric acid; d) Fmoc-removal with piperidine 
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Figure 3.9  Chemical structure of two synthesized intermediates . (Fmoc-GLU-NHS 
(1) and Fmoc-GLU(OtBu)-GLU-OEt (2)) and first generation Fmoc-PG-OEt 
G0 (4) dendrimer 
128 
Figure 3.10  1H NMR of Fmoc -PG-OEt G0 (4) in deuterated chloroform as single 
pure product; the esters were used as reference and are in a proportional 
ratio to the Fmoc groups. Under these conditions the amides (7.97, 7.56 
and 5.28 ppm) (h, i, g) were visible further evidencing the coupling to both 
sides of glutamic acid and the different microenvironment these amines are 
exposed to. 
130 
Figure 3.11  Chemical scheme of Fmoc removal mechanism. This reaction releases 
the free amine and the fulvene intermediate that subsequently reacts with 
piperidine to form a stable product 
131 
Figure 3.12  1H NMR of Fmoc -piperidine that is formed as a side product when 
reacting with the fulvene released. Particularly, the Fmoc peaks (7.18-
7.63 ppm) (a-d) are at slightly different position to those when coupled to 
the dendrimer. 
132 
Figure 3.13  1H NMR of Fmoc -piperidine that is formed as a side product when 
reacting with the fulvene released. Particularly, the Fmoc peaks (7.18-
7.63 ppm) (a-d) are at slightly different position to those when coupled to 
the dendrimer. 
133 
Figure 3.14  1H NMR of Fmoc -PG-OMe G0 (5) in deuterated chloroform.  The 
protecting ester groups were differentiated between 3.5-.3.7 ppm (a) and 
the amides were clearly observed at 7.89, 7.51 and 5.31 ppm further 
evidencing coupling to both sides of the core. All other peaks were similar 
to Fmoc-PG-OEt G0 (4) 
134 
Figure 3.15  Theoretical synthesis of NH 2-PG-OH G0 using a single de -protection 
reaction to remove all t-Boc groups with an acid  
135 
Figure 3.16  Reaction mechanism of basic hydrolysis of methyl es ters using LiOH 
and acidic hydrolysis N-Boc and tert-butyl esters using TFA 
135 
Figure 3.17  1H NMR of N-Boc -PG-OH G0 (9) in deuterated methanol.  the N-Boc 
peak at 1.43 ppm was used as reference; solvent peaks are still present. 
136 
Figure 3.18  1H NMR of Fmoc -PG-OH G0 (7) in deuterated methanol.  Fmoc group 
was used as reference and no evidence of hydrolysis of this group was 
evident in the spectra. 
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Figure 3.19  1H NMR of Fm oc-PG-OEt G1 (13) in chloroform.  urea was still present in 
significant amounts as it can be observed by the peaks at 1.0-1.7 ppm; 




exponential growth of signaling by each monomer. However, the Fmoc 
groups were still distinct and in proportional ratio to the ester groups which 
suggested complete reaction of all branches. 
Figure 3.20  1H NMR of NH2-PG-OMe G0 (11) in deuterated methanol; the N-Boc 
was not visible suggesting complete hydrolysis 
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Figure 3.21   2D structure of the Fmoc -PG-OH G1 (16) (left) and N -Boc -PG-OH G1 
(21) (right) 
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Figure 3.22  1H NMR of the Fmoc -PG-OtBu G2 (24) in deuterated chloroform. The 
NMR spectra starts became very complex. However, high amounts of urea 
can be observed demonstrating the difficulty in purification for the bigger 
dendrimers. 
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Figure 3.23  Possible complex between urea the carboxylic groups of the PG 
dendrimer  
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Figure 3.24  1H NMR of Fmoc -PG-OtBu G1 (15). The NMR showed the Fmoc group 
signal between 7.29-7.66 ppm and around 4.26-4.51 ppm similarly to the 
previous PG dendrimers. Solvent peaks were still present.  
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Figure 3.25  1H NMR of Fmoc -PG-OH G1 (16) in deuterated methanol.  solvent peaks 
were still present; the tert-butyl ester groups were not present at 1.40 ppm 
indicating that the hydrolysis was complete.  
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Figure 3.26  1H NMR of Fmoc -PG-OH G2 (18) in deuterated methanol. The tert-butyl 
ester groups were not present at 1.40 ppm showing that the hydrolysis was 
complete. 
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Figure 3.27  1H NMR N-Boc -PG-OMe G0 (8) in deuterated methanol. The 3 amides 
and 3 α-carbon hydrogens can be observed as distinct signals.  
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Figure 3.28  1H NMR N-Boc -PG-OMe G2 (24) in deuterated chloroform.  the N-Boc at 
0.770 ppm as well as the methyl groups at 3.610 ppm  were used as 
reference.  
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Figure 3.29  Reaction scheme of the different obtained products tested to optimize 
GLU coupling to NBD  
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Figure 3.30 1H NMR of a side product from the reaction of glutam ic acid with NBD 
where the methanol directly substitute the chloride . 
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Figure 3.32  1H NMR of N-alkyl -NBD-GLU-OtBu (40) in deuterated chloroform. The 
NBD peaks have a ratio of 1:1 to the α-carbon hydrogens and 1:2 ratio to 
the β and γ carbon hydrogens. Solvent peaks are still present 
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Figure 3.33  1H NMR of N-alkyl -NBD-GLU-OH (41) in deuterated methanol. The 1.39 
ppm single peak corresponds to the alkyl group in a ratio of 1:3 of NBD to 
Alkyl. Solvent peaks are still present   
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Figure 3.34  1H NMR of N-Sulfonamide -GLU-OMe (43) in chloroform. The singlet 
peak at 2.88 ppm corresponds to the CH3 of the sulfonamide group and the 
amide group can be observed at 4.98 ppm. 
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Figure 3.35  Structure of the hydrophobic terminal group synthesi zed as a small 
branch that would be coupled to the PG dendrimer.  
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Figure 3.36  2D structure of the positive analogue  to attach to the PG backbone  157 
Figure 3.37  2D structure of the zwitterionic intermediate to subsequently attach to 







Figure 5.1 From left to right: 3D structure of PURE G3, G4 and G 5. Dendrimers 
were created using the same protocol for PG dendrimers in chapter 1. The 
topology files was carried using XPLOR-NIH and were modified with 
ParamChem parameters. Dendrimers were then loaded to Maestro and 
automatic attribution of atom types was carried. 
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Figure 5.2 AFM of supported lipid bila yer composed of POPC:DPPC (1:1) . Images 
were obtained (A) before and (B) after addition of 300 µM of cisplatin. Blue 
arrows point towards some examples where cisplatin expanded existing 
defects at the interface of fluid and gel phase. In situ tapping-mode imaging 
were performed at room temperature using a Multimode Nanoscope IIIa 
Microscope (Digital Instruments, Veeco) using a similar protocol previously 
established4. Scale: 5.5x5.5 µm 
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Figure 5.3 Fluorescence intensity of PURE G3 (green), G4 (red) a nd G5 (blue) 
dendrimers under the same experimental conditions ( final 
concentration of 0.1 mM). The fluorescence intensity of both emission (A) 
and excitation (B) increased with pH decrease and were dependent on the 
generation of PURE dendrimers. 
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Figure 5.4 Release of CF from control (black) of (A) POPC; (B) POPC:POPS (7:3)  
and (C) POPC:DPPC (1:1) with 1 mol% of PURE dendrimers G3 (red), 

















Table 3.1 Reaction yield obtained for Fmoc-PG-OtBu G0 (6) reaction 
using different coupling reagents  
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Table 3.2 Different conditions tested for coupling of NBD to different 
glutamic acid derivatives; R1 and R2 denote the carboxyl 








































Aims and outline of the thesis 
 
The main goal of this thesis is to evaluate the potential use of fluorescent dendrimers 
as drug delivery systems (DDS) for the anti-cancer drug cisplatin and study the 
interactions of platinum(II) complexes with lipid model membranes. For this approach, 
different methodologies from molecular modeling to biophysical properties changes 
induced by cisplatin were tested. Due to the multidisciplinary approach taken in this 
work, this thesis is divided into three distinct (and almost independent) chapters that 
outline the common goal of designing a DDS based on dendrimers. Therefore, a brief 
introduction outlining the general fields related to this thesis is described in chapter 1 
followed by specific and more detailed introductions concerning each subject at the 
beginning of each chapter. Moreover, for chapter 2 and 4, introductions are given in the 
form of review papers as these have directly been devised from the work described 
herein. Finally, the final remarks concerning all chapters is provided in chapter 5.   
Chapter 1 outlines a brief summary of the state-of-the-art regarding the development 
and properties of dendrimers as potential drug carriers and their interaction with 
biomembranes. It also describes computational tools that have been employed in the 
design of dendrimers and general strategies to synthetize these branched polymers. 
Finally, it outlines the importance of the lipid bilayer to both anti-cancer drugs and 
dendrimers.  
In chapter 2, peptide dendrimers composed of GLU backbone were designed by 
molecular modelling to carry a single fluorophore attached to the core, protected from 
the external environment. Furthermore, different terminal groups were tested to display 
different surface properties (charge and hydrophobic characteristics) and their 
contribution the overall conformation of PG dendrimers. Because one of the current 
problems with modeling of dendrimers is the quick generation of their molecular 
structure, a set of tools were developed to increase the automation process of 
generating the 3D structure of dendrimers. PG dendrimers with a fluorophore attached 
to the core were then submitted to molecular dynamic simulations to generate 
candidate structures to be synthesized.  
Chapter 3 describes attempts to synthesize the PG dendrimer candidates generated by 
molecular modelling in chapter 2. Both divergent and convergent approaches were 
tested to achieve the PG generation 4 in the lowest amount of reactions. Moreover, the 
attachment of the fluorophore to the core at different generations was tested as well as 
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different modification to the GLU of the core. Finally, attempts to synthesize the 
terminal groups were carried.  
In chapter 4, cisplatin influence on the fluidity and integrity of lipid model bilayers of 
different composition were tested with the aim to further elucidate its mechanism of 
interaction with biological membranes, and help resolving conflicting data in the 
literature regarding cisplatin effects in membrane properties. Furthermore, cisplatin and 
its aquated analogues were tested on their ability to modulate permeability of lipid 
bilayers.  
Chapter 5 outlines the final remarks of all individual chapters and describes ongoing 
research of this thesis. Furthermore, the overall conclusions and future work from this 
thesis are provided. 
Overall, this thesis exemplifies a proof-of-concept workflow that could typically be 
employed in the design of novel DDS as it covers both the design of carrier as well as 
the mechanisms of interaction of the drug at the membrane interface and how these 
DDS could improve it. This issue is further discussed in chapter 5, where a critical 
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Chapter I – General Introduction  
1.1. Drug development and nanomedicine  
The drug development pipeline is a complex, time consuming and costly program with 
a high attrition rate (Figure 1.1). It generally starts with the characterization of a medical 
problem, identification of potential targets and its targeting compounds. However, at 
this point there are no guarantees about their efficacy and safety in vivo. Common 
problems that molecules face are related to them failing to reach their primary target, 
interacting in off-target receptors or tissues (causing side effects) or simply not having 
the right biophysical properties. These problems can however be minimized with the 
use of different drug delivery systems (DDS)1–4. In effect, the repertoire of drugs 
available could probably be greatly extended with the use of new DDS. The premise is 
that they are theoretically able to overcome the physiological barriers, avoid rapid 
clearance and mask the problems related to physicochemical properties of drugs. This 
includes the three most predominant ones: solubility, stability and bioavailability. 
Furthermore, the possibility of combining targeting moieties to re-direct the drug onto 
specific tissues where it is required is of utmost importance as it makes the 
development of drugs focused solely on their pharmacological effects while minimizing 
off-target toxicity.  
 
Figure 1.1 – Typical theoretical drug development p rogram. Over the course of the 
development program the number of potential candidates that reaches the clinical setting is 
relatively low due to the inherent problems of most drugs. Specifically designed DDS introduced 
at the pre-clinical development stage or as a repurposing strategy could potential improve the 
number of drugs 
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A particular area within drug delivery that has raised increased attention is the use of 
synthetic polymers in nanomedicine. The key feature for their success is their 
multivalence and their structure that can be modified to have suitable biological 
properties. However, despite all the successes associated with polymeric 
nanomedicines, there has been an increased concern over the balance between 
efficacy and potential biological risks1. This mainly results from a lack of knowledge of 
their biological interactions, particularly at biological interfaces, as well as the impact of 
their long term use. Consequently, the development of the next generation of polymeric 
drug delivery systems should be carried concomitantly with the understanding of their 
interactions with the major components of the biological milieu. In this regard, 
dendrimers are viewed as suitable DDS due to their precise structure that can be 
further tuned to have desired biophysical properties. This allows the study of specific 
modification to the backbone and how these interact at the interface of biological 
membranes, which can provide value insights that may unravel ways to improve 
targeting. Furthermore, dendrimers can also be made of biocompatible and 
biodegradable building blocks such as amino acids which facilitate their degradation 
process for long term use.  
1.2. Dendrimer definition and applications  
Dendrimers belong to a subclass of synthetic macromolecular hyper-branched 
polymers that include random-hyperbranched polymers, hypergraft and dendrigraft 
polymers as well as dendrons (Figure 1.2). One of the main distinctions compared to 
other polymers has been the precise substitution from a multifunctional core that can 
be achieved. With the exception of hyperbranched-based dendrimers, this type of 
polymers also generally demonstrates a well-defined radial branching architecture. 
Notably, a key factor for their advantage over conventional polymers that rely on 
statistical characterization of their molecular structure is that dendrimers can be 
synthesized with no batch differences5. This unmatched topology control is highly 
desired since high homogeneous populations of very narrow molecular weight 
distribution can be achieved6,7. Modification of the surface functional groups also allows 
a control over the physicochemical properties of dendrimers. In fact, the degree of 
substitution at the surface can be studied for their contribution to activity as well as 




Figure 1.2 – Schematic topology representation of d ifferent types of hyperbranched 
polymers. Dendrimers can be generated by attaching dendrons to a multifunctional core and 
are generally differentiated from other hyperbranched polymers where the growth is more 
random.   
The concept of dendrimers was first introduced in 1978 by Vögtle8 referring to the 
description of “cascade molecules” due to the repetitive branching of the “arms” in the 
polymer in an analogy to a water cascade of a fountain9. Mono- or diamines were used 
as starting units to which subsequent addition of branching monomers resulted in the 
growth of the polymer. The word “dendrimer” was then first introduced by Tomalia et al. 
in 198610, which was derived from the Greek words “dendros”, meaning tree or branch, 
and “meros”, meaning part. Historically, other names have also been suggested for this 
type of macromolecules including arborols, “cauliflower polymers”, shell topological 
compounds or starburst polymers but have been rarely used. Initially, a number of 
patents describing the synthesis of poly(lysine) (PLL)11–13 dendrimers via divergent 
synthesis (outward from the core) were registered. Later, polyamidoamine (PAMAM) 
dendrimers were introduced to study host-guest interactions (similar to interactions 
between proteins and small ligands) and have since been used in a wide variety of 
other applications10. In particular, dendrimers have received an increased amount of 
attention over the past decades as materials in nanomedicine (e.g. DDS or as 
therapeutics) due to their unique vast array of properties that can be optimized for a 
variety of fields.  
The application of dendrimers in the biomedical field has been extensive and includes 
catalysis (or synthetic enzymes)14, metal-binding15, biosensors and contrast agents for 
imaging16, drug delivery agents and solubilizing agents17, transfection agents18 and as 
therapeutics19,20. In particular, as DDS these molecules have shown the ability to: (i) 
enhance aqueous solubility; (ii) provide controlled release; (iii) protect drugs from 
enzymatic degradation; (iv) improve drugs’ pharmacokinetics; (v) enhance permeation 
of drugs through biological barriers and (vi) improve the toxicity profile of drugs21. 
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Moreover, their ability to form polyvalent and cooperative binding combined with the 
possibility for specific attachment of functional moieties22 has been shown to be useful 
for targeting specific molecular pathways20,23–25 and avoid non-specific distribution26. 
Overall, this substantially increases the repertoire of drugs that can theoretically be 
used in human administration by minimizing their negative intrinsic properties. In fact, 
docetaxel- and cabazitaxel- conjugated to PEGylated PLL dendrimers are currently in 
phase 2 and phase 1/2 clinical trials respectively27. In animals studies these have 
shown enhancement of the anti-cancer activity, prevented side-effects and 
preferentially accumulated in the cancer tissues.  Furthermore, VivaGel® a PLL-based 
dendrimer with mucoadhesive properties has also been approved against bacterial 
vaginosis28,29. These results increase the confidence of the potential of dendrimers as 
DDS or imaging agents and serve as a platform to further explore their clinical use. 
1.3. Dendrimers topology and nomenclature  
Structurally, dendrimers are characterized by a repetitive radial growth of branched 
monomers connected to a central core, and are defined by the following: (i) core; (ii) 
internal monomers or backbone; (iii) terminal groups; and (iv) void space or 
cavities/pockets (Figure 1.3). The core defines the 3D topology through its size and 
branching multiplicity, while the terminal groups define mostly the physicochemical 
properties and which can be further modified with active functional moieties30,31. On the 
other hand, the internal structural backbone defines the density of dendrimers and can 
result in free space cavities for “guest” molecules. Also, an interesting property of the 
interior chemistry is that the selected monomers can be sensitive to triggers (pH, 
solvent, light) resulting in controlled release or other necessary functionality (e.g. 
catalysis)32.  
 
Figure 1.3 – Topology description of a typical dend rimer. The backbone is grown from the 
central core unit and the terminal groups define the overall charge displayed at the surface (red 
spots). At this generation, void space (pockets) created by the backbone or the terminal 
branches allow space for small molecules to be incorporated.  
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Due to their iterative nature, dendrimers are often described by their generation 
number which describes the number of layers added from the core, i.e. counting the 
number of branching points from core to the periphery. What constitutes a layer or a 
generation is however not completely agreed upon throughout the literature, tending to 
be specific to individual work and by authors’ preferences. This is partly due to the 
complex chemistry nature that can be used to generate a dendrimer and the further 
modifications that can be carried to the main backbone and core. Similarly, the exact 
definition of what constitutes a generation 0 (G0) is not fully agreed upon, with some 
authors defining the G0 essentially as the core, while others defining it as the core 
together with the first layer. In this work G0 is defined by the first layer added to the 
core (e.g. glutamic acid (GLU)), as it allows the same naming regardless of the 
modifications of the core (Figure 1.4). It is also common to describe certain 
modifications to the terminal groups as half-generation. For example, when terminal 
groups are altered from an amine-terminated to a carboxyl-terminated group it is 
common to find this described as G1.5 or G1.5-COOH. This informs that the 
functionality of the terminal groups has been altered. In the framework of this 
dissertation, this nomenclature will however not be used since the terminal groups are 
not modified but rather de-protection modifications will be described.  
 
Figure 1.4 – Types of G0 for a series of different dendrimers with the same core ( ●) and 
branches ( ■) but with different terminal groups and core modif ications. The scaffold of 
dendrimers is flexible to modification which can be valuable to display different surface 
properties. PTG: protecting group; Tag: Tag molecule 
Finally, naming and describing the 2D structure of these molecules is also still 
debated33. The IUPAC nomenclature is the accepted way of naming small molecules 
that enable their reconstruction and identification. Even though the IUPAC 
nomenclature can be applied to small dendrimers and dendrons, it is clear that with the 
higher generations, the naming of dendrimers becomes complex and leads to 
difficulties in understanding all the structural features. Similarly, the nodal 
nomenclature, which is based on graph theory, struggles to describe at higher 
generations and more complex dendrimers34,35. For this reason, Newkome-
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nomenclature, cascadane and dotted cap notation (see references35–37 for more 
details) have been specifically adapted to describe dendrimers. These nomenclatures 
are capable of representing the hyper-branched and repetitive nature of dendrimers to 
some degree and offer clear advantages representing the core, monomers and 
capping groups. However, this nomenclature can still be complex and therefore have 
not been fully adopted. As a result, in order to facilitate the description of dendrimers in 
this work, poly(glutamic acid) (PG) dendrimers will be named according to the amine-
modification of the core and the carboxyl-modification of the terminal monomers, as 
well as the generation. Therefore, different dendrimers and generations will be named 
as follow: [N-coupled group]-[name of the backbone]-[Carboxyl-protecting group] 
[Generation number] (Figure 1.4). For example, one dendrimer would be named Fmoc-
PG-Methyl ester G1 for denoting Fmoc-capped to the amine of the core, GLU modified 
as a backbone for 2 layers, and methyl ester protecting the carboxyl groups for the 
terminal groups. 
1.4. General considerations for synthesis of dendri mers 
The synthesis of dendrimers is commonly carried out by cyclic repetitive addition of 
layers of monomers to branches connected to a multifunctional core, where each new 
layer forms new generations. The precise nature of monomer additions during 
synthesis is what differentiates from other hyperbranched polymers and results in 
ideally monodisperse populations. However, both the synthesis and characterization of 
dendrimers are still presenting a challenge. Dendrimers’ synthesis strategies involve 
either growing a molecule from the core by addition of layers of branches (divergent 
synthesis) or growing the branches and attaching them onto the core in the final step 
(convergent synthesis). Alternatively, a mix of both strategies can be used to minimize 
the number of reactions that need to occur where the pre-formed branches generated 
using a convergent manner are then attached to a product of a partial divergent 
synthesis from the core.  
The chemical reaction routes that can be used in the synthesis of dendrimers depend 
on the type of chemistry of the monomers. Since dendrimers can be generated as long 
as the monomers have branching functional groups (branching units) there is a wide 
variety of scaffolds that can be synthesized (Figure 1.5). However, despite the 
numerous possibilities of scaffolds, PAMAM and poly(propylene imine) (PPI) 
dendrimers have been by far the most studied dendrimers and for which high 




Figure 1.5 – Examples of dendrimers synthesized fro m different starting cores and 
different branching monomers. Since the limiting factor for synthesis is based on the 
reactivity of the active groups used, a wide diversity of scaffolds can be generated.  
Albeit lower generation dendrimers can be easily obtained and purified, minor defects 
in the branches can arise at higher generations due to a plethora of chemical 
constraints. This produces defective, but structurally very similar dendrimers that are 
difficult to separate, thus not being able to obtain a pure final product. Therefore, highly 
selective reactions with high yields are necessary for growing dendrimers and to 
minimize the occurrence of defective branches. As an example, using divergent 
synthesis (from the core to the terminal groups), assuming a core of multiplicity 4, 
branch monomers with multiplicity of 2 and a reaction for growth of 99% selectivity, this 
results in the following statistical amount of pure dendrimers: 96% (G0), 92% (G1), 
85% (G2), 72% (G3), 52% (G4), 27% (G5) and 7% (G6). In this theoretical example, 
the defects arising from de-protecting reactions that are usually necessary are not 
accounted for. Therefore, even for highly selective reactions the yield for high 
generations drops considerable.  
Finally, the structural characterization of dendrimers is complex and limited due partly 
to their flexible and symmetrical nature38,39 that result in multiple and broad identical 
signal peaks for structure based characterization. As a result, multiple analytical 
methods, such as, nuclear magnetic resonance (NMR), mass spectrometry (MS), 
infrared (IR) and X-Ray as well as computational methods are generally employed to 
correctly assign the structure and dynamics of these macromolecules. In particular, 
these techniques have provided quantitative analysis of chemical transformations as 
well as quantification of side reactions and defective branching. Moreover, these have 
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been used to evaluate the degree of substitution, as well as, the mobility and 
backfolding of the terminal groups and their effect on the hydrodynamic volume7,40,41. 
Finally, precise structural characterization has been carried in dendrimers where the 
molecular arrangement and the density distribution of monomers within the backbone 
have been determined40.  
1.5. Dendrimers biological interactions and drug de livery  
Drug delivery is an area of continuous research and development towards avoiding the 
possible problematic pharmacokinetics properties shown by a variety of drugs. 
However, designing functional dendrimers is still challenging since both the core and 
surface groups determine not only the topology but also the physicochemical nature 
and ultimately the biological activity of dendrimers42. In fact, the safety and precision 
has to be adequate even for nanocarriers, which has been the major impediment 
encountered during translation into a clinical setting43,44. In this regard, dendrimers as a 
type of branched polymers offers advantages over conventional polymers since they 
are a monodisperse population of structures and both their size, shape and surface 
properties can be controlled. Moreover, whereas linear polymers usually adopt 
random-coil structures, the architecture of dendrimers has a defined 3D shape despite 
their intrinsic flexibility. This unique feature predisposes them to be good candidates as 
nanocarriers for delivery of drugs or as imaging agents.  
Dendrimers have been used as DDS for a variety of biological routes (e.g. oral, 
pulmonary, transdermal and ocular) for small molecules, peptides and nucleic acids45–
50. Comprehensive understanding of their molecular mechanisms of action should allow 
the design of these carriers to have specific tissue accumulation profiles, and optimized 
drug release rates and elimination rates. Furthermore, dendrimers have the possibility 
to be designed to established specific dendrimer-drug (host-guest) interactions and 
therefore minimize the solubility problems of these drugs51,52. In fact, drugs can 
establish interactions with the dendrimers by complexation in the interior branches 
(also known as dendrimer acting as an endo-receptor) or at the dendrimers’ surface 
(also known as an exo-receptors), which typically occurs through hydrophobic or 
electrostatic interactions. The electrostatic forces can then be controlled to release 
drugs as a function of gradients of pH (e.g. acidic environment in the endosome) or by 
using counter-charged groups53,54. Although the number of guest molecules 
incorporated into a dendrimer will depend to some extent on the architecture and the 
size of a dendrimer, the loading capacity may be dramatically increased through 
complexation with the large number of groups on the dendrimer surface. Alternatively, 
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therapeutics can be conjugated to the scaffold backbone. This is necessary in cases 
where the drug may not complex with the dendrimer or when the release of the drug 
needs to be precise and limited to a certain reaction, such as an acid-labile cleavage in 
the matured endosome23. In general, both these strategies result in prolonged 
circulation half-time of a drug by reducing clearance from the bloodstream, as well as 
preventing hepatic clearance and rapid filtration through the glomerular membrane55–57. 
Finally, dendrimers have multiple terminal groups that can produce multivalent 
coordination with biological motifs (peptides, proteins, sugars). Generally this can 
enhance the avidity and selectivity in a similar way to multivalent mechanisms that exist 
in nature58,59. This constitutes a versatile approach to drug delivery as it improves their 
ability to overcome physiological barriers, while enabling preferential accumulation in 
specific cells or intracellular compartments. Even though increasing functionalization 
can be used as a strategy to enhance tissue targeting, these factors might not always 
follow a linear relationship. For example, while arginylglycylaspartic acid (RGD) 
functionalization increases affinity of the dendrimers to the receptor, a higher number of 
RGD peptides can create steric hindrance of their binding surface and thus reducing 
the overall affinity23. 
One of the most attractive applications for dendrimers is the targeted delivery of 
cytotoxic drugs for cancer therapy. The aim of this approach is to have a high partition 
of drug molecules into the cancer tissue, while having low amounts in other (healthy) 
tissues. Dendrimers are particularly suited for this since multiple molecules of the drug 
or combination of drugs with synergistic effects can be complexed to a single 
scaffold60,61. Moreover, these carriers usually exhibit enhanced permeation and 
retention into the pathogenic tissue and bypass the efflux transporters commonly 
overexpressed in cancer cells62. As a result, it may be possible to reduce the dosage of 
drug necessary while increasing the effectiveness of these drugs at the same time60,61. 
To illustrate this point, cisplatin is a widely used anti-cancer drug that acts through 
interaction with DNA63, but it is very promiscuous and binds to a large number of other 
targets, which will typically result in side effects64 (further discussed in topic 1.11). 
Moreover, cells develop resistance mechanisms in long term. Therefore, using anionic 
dendrimers or complexing cisplatin directly at the DDS surface could allow controlled 
and targeted delivery and bypass resistance mechanisms. In fact, cisplatin-complexed 
dendrimers have shown reduced off-target toxicity while maintaining significant anti-
proliferative activity65. Furthermore, cisplatin-terminated dendrimers accumulated 50 
fold more in solid tumors but showed less undesired off-target toxicity than free 
cisplatin, which was attributed to suboptimal release65. In another example, cisplatin 
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was complexed to the surface groups of a carboxylate-terminated PAMAM dendrimer 
which led to a 10 fold increase in the solubility of cisplatin compared to the free drug65. 
1.6. Peptide Dendrimers  
Amino acid-based dendrimers (also known as peptide dendrimers) are an interesting 
polymeric system to be developed as biomaterials due to their inherent protein-like 
nature. In fact, they are expected to have an acceptable biocompatibility and 
biodegradability66 since upon partial decomposition or degradation they are broken 
down to low molecular weight fragments that are expected to be non-toxic. Also, due to 
their similarity to biomolecules they have shown to be able to mimic proteins activities 
(e.g. enzymatic activity, synthetic vaccines and ion-channels), as well as having 
therapeutic activity of their own67 while maintaining water solubility. 
The synthesis of peptide dendrimers depends on the type of amino acids used 
(including non-natural amino acids), as well as in which step they are used. In terms of 
synthetic approaches these can be differentiated into: (i) backbone amino acids that 
have two branching points for dendrimers growth (i.e. trifunctional amino acids); (ii) 
backbone amino acids with one branching point that are connected to branching unit 
monomers; (iii) backbone of a mixture of amino acids with both single and double 
branching unit points; (iv) grafting of amino acids or peptides on the periphery of a 
conventional/classical dendrimers68.This results in a diverse variety of peptide classes 
that can be used in a variety of applications.  
In fact, PLL have been extensively used as the backbone for many scaffolds with 
success. These have shown anti-angiogenic activity with retardation of tumor growth40 
and PLL with the arginine conjugated to the terminal groups (8 and 16 groups) showed 
ability to bind to heparin69. Similarly, different PLL generations (with 4, 8 and 16 
terminal groups) were modified terminally with shikimic and quinic acid to bind to 
lectin70. PLL has also been modified with PEG chains that self-assembled with DNA to 
form complexes with 50-150 nm in size71. Other interesting modification has been the 
use of PLL dendrimer with naphthalene sulfonic acid terminal groups (SPL7013, 
VivaGel®), which has shown antiviral activity against Herpes Simplex Virus (HSV) and 
human immunodeficiency virus (HIV) in vitro29 and in vivo72. Furthermore, dendrimers 
terminated with tryptophan have shown to inhibit early steps of the viral infections 
namely the entry into its target cell73. Finally, cyclic multiple antigenic peptides (MAPs) 
dendrimers have been synthesized by attachment of antigenic peptides to a dendritic 
lysine dendrimer scaffold with different amounts of terminal groups as a mean of 
producing an immune response74. 
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As a monomer, glutamic acid (GLU) is also interesting to be used as a building block of 
a dendrimer scaffold. This is because GLU is anionic and negatively charged species 
have been associated with enhanced circulation in vivo and superior biocompatibility75. 
Thus anionic dendrimers are expected to have enhanced passive accumulation in 
target tissues instead. Indeed, other anionic dendrimers with encapsulated drugs have 
shown enhanced uptake in different human cell lines76,77. PG dendrimers with different 
cores and surface modification have also been shown to be good candidates as drug 
delivery systems and in particular for anti-cancer drugs such as doxorubicin78–82. GLU 
is also a suitable monomer for synthesis of dendrimers since it has a trifunctional 
structure, presenting two carboxyl groups and one amine group that can be further 
modified. This is advantageous since PG dendrimers can be grown from both 
carboxylic acid groups and the amine in a variety of ways. To achieve this, the groups 
that are not used for branching must be protected to be compatible with the coupling 
reagents and to avoid racemization. This is usually carried by using ester forms of the 
carboxyl group  or using protecting groups such as fluorenylmethyloxycarbonyl (Fmoc-
), tert-Butyloxycarbonyl (Boc)-, carboxybenzyl (Cbz) for the amine83. Those protecting 
groups have advantageous properties over other alternatives due to their superiority in 
terms of cleavage83 and ability to withstand common peptide coupling chemistry 
reagents. Moreover, the use of alkyl esters are better suited for protection since 
aromatic esters can hydrolyze (due to its electrophilicity)84. Other property that makes 
PG dendrimer desirable is that GLU has several protonation states depending on the 
pH (Figure 1.6). This can be an interesting property to modulate in DDS making them 
pH-sensitive. In fact, this was previously explored by attaching a sequence of glutamic 
acids to a dendrimer G3 backbone which adopted a helical conformation or random coil 
in water depending of the pH85. Similarly, dendrimers have also been created with 
amphiphilic L-glutamic acid analogues that can self-assemble and form gels at specific 
conditions86,87. 
 
Figure 1.6 – Glutamic acid protonation at different  pH. The variation of pH results in different 
protonation of the amine and carboxyl groups which modulated the effective final charge of the 




1.7. Dendrimers and fluorescence tagging  
For any drug delivery application, knowledge of the fundamental mechanisms of 
cellular uptake is essential for improving their design and efficacy23. Having a way to 
track macromolecules in the biological milieu could aid elucidation of relevant 
mechanisms and inform the design of delivery systems. In particular, tracking a single 
macromolecule should allow selective and non-invasive monitoring of cellular fate. 
Because many dendrimers do not present inherent fluorescence properties, 
fluorescence tagging is a technique commonly used and in rapid expansion in the 
biomedical field. The addition of a fluorophore allows the observation of dynamic 
processes within a useful space and time resolution. Conjugation of fluorophores to the 
dendrimer also allows to probing their topological and biochemical features88, which is 
valuable to track during their intracellular trafficking89. This also includes determining if 
the dendrimer crossed biological barrier and entered the cells instead of remaining 
bound to the cell membrane. Contrary to most of other polymers, dendrimers can be 
modified to contain one single probe per dendrimer, and thus reducing undesired 
effects, such as self-quenching, while enabling precise monitoring of mobility and 
rotation of the attached molecule90. In fact, the number and type of fluorescence probes 
has to be taken into account when designing the dendrimers. Fluorescence intensities 
can decrease with the increasing number of coupled fluorophores. This has been 
attributed to the self-quenching that can arise from their proximity in the polymer 
backbone90. Furthermore this type of attachment is carried by a so called statistical 
loading that can increase the variability of the dendrimers’ signals. On the other hand, 
having a significant amount of fluorophores attached to the surface of the dendrimer 
can result in alterations of surface properties that can affect the biological interaction, 
stability and solubility. In fact, it was recently reported that the transfection of luciferase 
was enhanced by the incorporation of different amounts of Oregon green 488 at the 
surface of a PAMAM dendrimer in a concentration dependent manner91, showing the 
importance in terminal group substitution for their efficacy.  In addition, since probes 
can have charge or have a lipophilic character, these features may influence the 
interaction with membranes for small dendrimers. Therefore, the “encapsulation” of the 
fluorophore and isolation from the exterior environment could be a way to avoid such 
type of problems.  In fact, these potential disadvantages can be addressed by loading 
the fluorophore into the core. However, this raises problems in the early stages of the 
dendrimer design since modifications have to be carried in a rational design approach 
to account for the incorporation of the fluorophore. This means that the core and the 
generation at which the fluorophore has minimal interactions with the external 
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environment have to be chosen accordingly. Computational rational design using 
molecular modeling is suitable for this kind of approach since it can ideally study the 
topological features of using different building blocks before attempt bench 
experimental studies.  
1.8. Molecular modelling  
Computational methods to investigate complex biological systems have been an 
important tool in the discovery of new drugs and unveiling the biological mechanisms 
that govern cell function. Molecular simulations can also enable the understanding of 
dynamic processes in biological systems within the atomic scale resolution33. 
Moreover, the combination between bench experiments and simulation data has 
reinforced many areas of drug development where results are not accessible through 
bench experiments. 
A number of theoretical approaches have been developed to describe molecules. As 
with any computational approach, the central question is the quality of the model and 
the level of complexity to be achieved, as well as how much information needs to be 
predicted.  Although the laws governing atoms’ motion are described by quantum 
mechanics, it was the realization that simpler models built using classical mechanics 
principles could predict some molecular properties that has enabled the revolution of 
computer simulations applied to drug discovery. In summary, more detailed theoretical 
models can describe more complex systems with higher accuracy, but less detailed 
ones allow simulations of larger systems. 
Quantum mechanics (QM) is so far the most accurate theory to describe the geometry 
and energetics associated with the probability of a position of a wave with a mass and 
charge in the interaction of electrons and nuclei. The key equation in quantum 
mechanics is the time-independent form of Schrödinger equation (equation 1), which 
should predict the properties of any molecule and the energetics associated with it.  
Ĥ Ψ=EΨ                                              (Eq. 1) 
The wavefunction, Ψ, describes the shape of the electron distribution, Ĥ is the 
Hamiltonian operator (composed of kinetics and potential energy) and E is the 
energy92,93. The Hamiltonian is very important in QM, and is the first term to be solved. 
Only then the equation is solved by finding a wavefunction that satisfies it94. The 
solutions from the Schrödinger equation belong to the area of ab initio quantum 
calculations and are able to describe the orbitals of the electron92,93. However, the 




simplifications of these equations were introduced, and one of the most important 
contributions was the Born-Oppenheimer approximation. This model treats the motion 
of electrons decoupled from the motion of the nuclei, since electrons are much faster 
and thus the motion of electrons becomes a constant. When many electrons are 
involved other approximations can be made which require the use of a basis set of 
Gaussian functions (mathematical functions that when combined are able to represent 
orbitals) such as the Hartree-Fock (HF) method. In its essence, the HF method solves 
the many-electron problem by replacing it by one-electron calculations. The atomic 
basis sets are first used to estimate the initial guest at the orbital, and then the electron 
motion is treated as in an average electron distribution, and the energy is calculated 
until it reaches a minimum95. However, even with the simplifications above, it still 
requires a lot of computational resources to solve these equations, especially for larger 
molecules. As a result, QM calculations are used mostly for small molecules to 
calculate geometries and equilibrium constants, which provide a reference value for 
simpler models. In an effort to compute larger sets of molecules, empirical methods 
were introduced by using a classical view of atoms by fitting them into a potential 
energy function.  
Molecular mechanics is an approach used to calculate the structure and energy of 
molecules based on nuclear motions only. In this method electrons are not considered 
explicitly, meaning that quantum effects are ignored, and the motion of “hard spheres” 
that interact to each other through “springs” is treated with Newton’s equations of 
motion. Simulations can be performed by different methods including (i) Brownian 
Dynamics; (ii) Monte Carlo (MC); or (iii) Molecular Dynamics (MD). In Brownian 
simulations, macromolecules are treated as a Brownian particle and evaluated for its 
friction in the surrounding solvent96. For MC simulations, macromolecules are 
simulated to find a low-energy conformation by iterative random atomic displacements 
which are evaluated for their energetics and accepted or rejected within a probability 
Boltzmann statistics function96–98. Finally, in MD simulations atoms are allowed to move 
and interact over time through integration of classical mechanics. During MD 
simulations the atoms (the “spheres”) will interact with other atoms through 
mathematical harmonic functions (“springs”) that keep bonds and angles within an 
equilibrium. This is a useful way of representing the motion as it requires energy to pull 
atoms apart or push them closer92. In order to calculate the energy associated with it, 
the whole mathematical function will be populated by these various terms related to 
each atom and their interactions with other atoms. These terms are parametrized and 
validated using experimental data, and stored into a data set named the force field. 
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Various mathematical models have been devised to calculate a potential energy of a 
system, and choosing one is a compromise between simplicity vs. accuracy. In 
general, these functions calculate energy based on the atom positions and are 
composed by terms representing the bonded and non-bonded interactions. Extensions 
to the main functions of the energy function can be added but these may not yield 
significant accuracy gain99,100 and in general Class I force fields (e.g. used by 
CHARMM and AMBER where the harmonic terms are restricted) have been adequate 
to treat intermolecular distances and their energetics100. In this work NAMD software 
was used for MD simulation, which employs a common potential energy function that 
contains the following terms (equation 2 and figure 1.7): 
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The first two terms (Ubond and Uangle) describe the stretching (1-2 interaction, i.e. two 
adjacent atoms) and the bending (1-3 interaction, i.e. between 3 atoms) between 
molecules through their respective constants (Kbond and Kangle) from an equilibrium 
length (r0i and θ0)
101,102. The third term, the dihedral angle, describes the 1-4 interaction. 
Dihedral terms are described in terms of multiplicity (n) and phase (φ) that characterize 
the height of energy barrier to rotation (e.g. larger for double bounds than for single 
bond) and the maximum and minima of such rotations between two planes to 
atoms101,103. Finally, the last two terms describe the non-bonded interactions. These are 
of paramount importance for modeling macromolecules since they govern much of their 
structure and properties, and therefore should be properly parameterized100. These are 
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the forces that govern for example the base pairing of the DNA, as well as protein-
protein interactions. In the van der Waals term, the Lennard-Jones potential is 
commonly used to describe the attractive London dispersion forces that arise from 
neighbor dipoles. There are various ways of describing this potential but commonly the 
12-6 potential is used. Finally, the electrostatic interactions are treated through the 
Coulombic terms by using static partial charges. The method by which charges are 
calculated are a matter of great debate since this is not experimentally observable and 
therefore various methods of calculations have been proposed. For example, 
CHARMM charge assignment makes use of supramolecular structures of water-
molecules interactions at idealized distances between the polar groups104. The charge 
calculation should be consistent and should be representative of the environment for 
which they will be used (most charge calculations are performed in vacuum)101. For 
dendrimers, this is very important as simulations are carried out in the condensed 
phase. Since the force field employed by NAMD does not account for explicit treatment 
of polarization terms, it is necessary to reproduce this electrostatic interaction by other 
means100. Luckily, it was observed that HF in conjunction with a 6-31G* basis set 
include an overestimation that cancels underestimation error, and as such suitable for 
describing charges in force fields.  
 
Figure 1.7 – Schematic representation of “spheres” and “springs” and their contribution 
to the potential energy function; a) bond length term; b) dihedral angle term; c) bond angle 
term; d) improper angle term; e) van der Waals term; f) coulomb term 
The potential energy is then calculated iteratively to find a low-energy region within a 
thermal equilibrium105. These energy calculations are a function of the position of the 
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atoms and hence treated by classical mechanics of Newton’s law. These simulations 
allow probing the motions and distribution of the different atoms of the structure in a 
biologically relevant system as well as predicting potential bonding networks with the 
surrounding environment.  
1.9. Molecular modeling and dynamics of dendrimers  
When designing a dendrimer, computational simulations offer a major advantage since 
one can perform several MD simulations before empirical decision on the overall 
structure to be synthesized. These simulations can provide detailed insights at atomic 
resolutions, including size and shape, which can then be corroborated by experimental 
data. To date, computational studies have been applied to study dendrimers with two 
main focuses: (i) dendrimers’ conformation in solution; and (ii) dendrimers interaction 
with molecules. As an example, efforts have been made in order to correctly predict the 
structure of PAMAM dendrimers in different solvent conditions. This arises from the 
evidence that due to its flexible nature, dendrimers have a vast range of conformations 
with similar potential energy making it difficult to probe the spatial and geometrical 
configuration by experimental techniques106–111. For PAMAM dendrimers it was recently 
reported that MD simulations could explain experimental data obtained by small-angle 
neutron scattering (SANS)112. Using the Dreiding FF with accurate QM calculations for 
hydrogen interactions, it was observed that various conformational changes occur in 
PAMAM dendrimers with alteration in pH, without changing the overall size113.  MD 
simulations were able to reveal that some groups reorganize internally, ending up in a 
different distribution that can be more extended (“dense-shell”) or more compacted 
(“dense-core”)7. 
Another interesting approach of molecular simulations is the interaction with other 
biomolecules and applies to many fields of research. These have included MD 
simulations studies on the interaction of dendrimers with peptides114, drugs109, small 
molecules (for catalysis)110, polymers115, nucleic acids116 and membranes117. In all 
cases, MD simulations were able to elucidate the network of interactions at the atomic 
resolution and corroborate bench experimental data, serving as a guide for further 
improvements.  
However, there is still not a consistent way to prepare in silico models of dendrimers. 
Different studies use different ways to construct dendrimers (i.e. software), select force 
field parameters and finally setup different simulation conditions (water model type, use 
of ions, etc…). To construct a dendrimer, any molecular drawing software may be 
suffice and only depends on the level of automation intended. However, in the case of 
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selecting parameters, these should be carefully chosen and there is not enough data to 
appropriately select one. Furthermore, details about selection, optimization and 
validations of parameters are not always provided in the literature therefore making it 
difficult to evaluate and compare. Often dendrimers have been parameterized with 
force fields that have been developed for proteins and small molecules including 
CHARMM118, AMBER119, CVFF120, Dreiding113, GROMOS108 and OPLS121. In general, 
this type of parameterization has shown to give enough details to corroborate bench 
experimental data and study the different forces involved (electrostatic, hydrogen, van 
der Waals and hydrophobic). In particular, simulations of PAMAM dendrimers with lipid 
membranes have provided insights into the mechanisms of toxicity of these 
dendrimers33,111,122. In this regard, studying the dendrimer-lipid interactions with the use 
of both computational and bench experiments could provide interesting insights on how 
to overcome the lipid membrane barrier to better deliver drugs. 
1.10. Biophysical properties of cell lipid bilayers  with anti-cancer drugs  
More than acting as a barrier that compartmentalizes organelles there has been 
growing evidence that cellular membranes have a direct role in cell function, regulating 
uptake mechanisms, signaling pathways and determining cellular response to stress 
signals. Cellular membranes are heterogeneous and dynamic, presenting asymmetric 
distribution of lipids between membrane leaflets. In addition, it is now recognized that 
biological membranes are compartmentalized into functionally distinct domains123–125. 
At these domains specific lipid-lipid and lipid-protein interactions take place and result 
in distinct lateral organization and composition. In particular, some of these domains 
composed of sphingolipids, cholesterol and distinct proteins, named lipid rafts, have 
shown to actively modulate signaling pathways involved in cellular proliferation and 
growth, but also in trafficking and clustering of cell death receptors126–131. Furthermore, 
lipids might directly bind to proteins (e.g. ADP/ATP carriers, cytochrome C oxidase)132 
or act as protein co-factors (e.g. Na+/K+ ATPase and protein kinases). In addition, some 
proteins require specific lipids in their vicinity to regulate their conformation and 
“solubility” in the membrane (annular lipids)133, and some proteins have shown greater 
affinity for their substrate in specific lipid phases, including in lipid gel phases compared 
to fluid phases134. It is therefore not surprising that de-regulation of lipid metabolism 
and consequently the membrane lateral organization is also associated with several 
diseases including cancer135–138. In certain cancer cells, alterations in the lipid 
metabolism results in changes of the biophysical properties of the plasma membrane, 
which in turn can affect how drugs interact with the cell 139,140.  In fact, alterations in 
membrane fluidity have been implicated in resistance of cancer cells to drugs141–147, 
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which can result in reduced accumulation compared to sensitive cells148. This is 
however a complex process and not fully understood. On the other hand, differences in 
lipid composition can also be beneficial for treatment and specific targeting. For 
example, anionic lipids, such as, phosphatidylserines (PS) are normally present in the 
inner leaflet of the plasma membrane of normal cells. This lipid is crucial for many 
cellular events as it anchors proteins to the inner monolayer of the plasma 
membrane149. It also influences the activity of enzymes including Na+/K+-ATPase150, 
which has been reported to be involved in the uptake of drugs, such as cisplatin151,152. 
However, in cancer cells there is an increased level of PS in the external leaflet153,154, 
which can directly interact with drugs155–159. In fact, drugs, such as, cisplatin and 
daunorubicin have shown to specifically bind to PS155–159.  
On the other hand, drugs can also alter lipid metabolism and cause alterations of 
plasma membrane biophysical properties, such as fluidity, permeability and lateral 
organization that can result in a cascade of cellular events. For example, formation of 
ceramide-enriched domains induced by drugs have shown to be important in inducing 
apoptosis160,161. Therefore, targeting lipid metabolism and/or membrane biophysical 
properties might be an effective strategy to overcome resistance mechanisms137,162–170. 
In addition, since anti-cancer drugs activity starts at the plasma membrane, this 
biological barrier is nowadays regarded as a good target to develop new therapies or 
improve old ones. However, to attain this stage it is necessary to study drug-membrane 
interactions to understand (i) how membrane lipid composition and biophysical 
properties affect the mechanisms of drugs action; and (ii) how the interaction of the 
drug with the membrane influences membrane organization, properties and lipid 
composition. This should provide further information on how new molecules and/or 
DDS can be designed to improve their uptake and evade resistance mechanisms in 
cell membranes. On the other hand, it may also enable the identification of membrane 
targets.  In this regard, cisplatin is a good model candidate to study due to its multitude 
of interactions at cellular milieu, including membrane lipids. Moreover, several 
mechanisms of resistance have been described for this chemotherapeutic, some of 
which associated with membrane lipid composition and/or membrane properties171–173. 
1.11. Cisplatin interactions with lipid membranes  
Cisplatin is an anti-cancer drug used  to treat a variety of cancers. However, it displays 
severe adverse effects and cancer cells are prone to develop cross-resistance against 
platinum(II) compounds after long term treatment174. Inside the cell, cisplatin exerts its 
primary action by targeting the genomic DNA with which it forms cross-links that 
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prevent further DNA replication175. As a response, cells develop resistance by (i) 
triggering responses to the effects of DNA damage; (ii) directly remove the formed 
adducts; or (iii) preventing the steps preceding the DNA binding related to off-targets175. 
In this regard, lipids have shown to play an important role in both the toxicity associated 
with platinum(II) compounds, as well as, in the resistance mechanisms.  
In solution cisplatin exists in a state of multiple species in equilibrium known as 
“aquated” species. Particularly, at low chloride concentration and/or pH, this equilibrium 
favors the formation of positively charge species176,177. The latter have different 
properties and therefore are expected to behave differently with other biomolecules 
including lipids. Indeed, the diffusion of cisplatin in phosphocholine membranes was 
shown to be much slower for the charged species in comparison to neutral cisplatin 
species178. On the other hand, these positively charged species were shown to have 
preferential binding to negatively charged lipids, such as, DOPS (1,2-dioleoyl-sn-
glycero-3-phospho-3-L-serine)155,176, by directly binding to the serine headgroup and 
complexing with the carboxyl and amine groups155,157,179.  This mode of binding is 
different for zwitterionic lipids, such as DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine), where cisplatin binds to the phosphate groups and forms a 2:1 
complex (lipid:platinum)63,180,181. Studies have shown that in cells, cisplatin is able to 
accumulate at the surface and bind to cell membranes, ultimately crossing the 
membrane through passive diffusion152,182. This is likely to be due to interactions with 
membrane lipids183–187. Furthermore, detailed analysis of the mode of cisplatin binding 
in erythrocytes suggested that cisplatin-membrane interactions were mainly attributed 
to electrostatic forces, followed by hydrogen bonding and coordination to the 
phosphate polar head as a Pt-O-P complex187 which further corroborates the in vitro 
binding observed for cisplatin with specific lipids.  
Platinum(II) complexes have also shown to cause changes in the phase properties of 
certain lipid membranes. In particular, cisplatin-induced changes in the phase 
properties of the membranes are dependent on membrane lipid composition since 
alterations found in lipid extracts187,188 were not evidenced in model membranes189. 
Moreover, the binding to specific lipids may also contribute to the observed effect. In 
fact, reorganization of lipid bilayers by induction of several lamellar phases were 
observed for charged species156, but the same effects were not observed for 
zwitterionic lipids179. Furthermore, cisplatin was also shown to cause weak and 
transient alterations in lipid order in erythrocyte membranes that were transmitted 
inwards from the headgroup to the core of the bilayer, whereas in DPPC membranes it 
caused a rearrangement of the headgroups but did not affect the lipid chains180. 
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Overall, these results suggest that cisplatin interacts with lipid bilayers but its effects 
are complex and dependent on a variety of extrinsic factors including, pH and chloride 
concentration, as well as, membrane composition and other unknown factors. 
Similarly, the importance of the physical state of lipid membranes as a mechanism of 
resistance of cells to cisplatin is controversial and remains to be determined. 
Accumulating evidence suggests that membrane composition determines membrane 
structure and fluidity, which modulate membrane permeability to cisplatin143,190,191. 
Indeed, platinum accumulation is generally higher in sensitive cells and this 
accumulation occurs as early as 10 minutes after exposure, suggesting an active role 
on membrane composition to the permeation143,190,191. Furthermore, cisplatin caused 
alterations in the membrane miscibility in models of cisplatin-sensitive cells but not on 
models cisplatin-resistant cells192. Analogously, cisplatin was able to increase the 
membrane fluidity of sensitive-cells whereas in resistant-cells caused increased 
microviscosity193. On the other hand, modulating the fluidity of membranes of both 
sensitive- and resistance-cells models, resulted in different toxicity of cisplatin on those 
cells143,192,194. Even though the molecular details underlying the contribution of 
membrane lipid composition and fluidity to the mechanisms of resistance are yet not 
fully known, evidence suggests that resistant cells are less fluid than their sensitive 
counterparts173,195,196.     
Understanding drug-membrane interactions may thus create new opportunities to 
target membrane lipid composition and biophysical properties to develop innovative 
strategies to optimize drug efficacy and bypass the mechanisms of drug resistance 
originated by efflux of the drug or the DNA repair mechanisms. It might also guide the 
design of improved cisplatin derivatives and/or other chemotherapeutics and DDS..  
1.12. Dendrimers and lipid membrane interactions 
Dendrimers are in the same size scale of other common biomolecules, such as, 
proteins and nucleic acids, as well as, the thickness of the membrane (Figure 1.8). As 
a result, membranes can accommodate dendrimers in a similar manner to membrane 
proteins or the dendrimer can create holes in the membrane197. These effects have 
shown to be dependent on the dendrimer composition and terminal groups, size and 
concentration, as well as, the properties of the membrane (phase and lipid 
composition). In fact, studies on PAMAM dendrimers evidenced high deleterious 
effects both in model membranes198,199 and cells200,201, including pore formation, 
membrane disruption, destruction of microvilli and hemolysis, particularly when large 
generations of positively charged PAMAM dendrimers were used. To better understand 
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the molecular mechanism underlying the interaction of dendrimers with membranes 
both bench198,199,202 and computational experiments111,117,203 have been performed. 
Results suggest that increasing the generation and concentration of PAMAM 
dendrimers resulted in deleterious effects for the membrane. In DPPC (1,2-Dimyristoyl-
sn-glycero-3-phosphocholine) bilayer stabilized in a mica layer198,199, PAMAM G7 
dendrimers with different terminal groups (amine, carboxylic and acetamide) were able 
to form holes ranging from 15-40 nm in the membrane, but the extent of hole formation 
was smaller for acetamide-terminated dendrimers, which suggests that these groups 
are better accommodated in the membrane. Contrary to G7, amine-terminated PAMAM 
G5 dendrimers did not show the ability to form holes but rather were able to enlarge 
existing defects in the bilayer199. However, substituting the terminal amines with 
acetamide groups abolished these effects, and the dendrimers were intercalated within 
the lipid bilayer instead199. Similarly, amine-terminated PAMAM G3 and G4 showed a 
concentration-dependent incorporation within the lipid membranes with preferential 
absorption at defective edges and lacked the ability to expand defective parts of the 
membrane199,202,204.  
In addition, the simulations showed that an initial strong interaction with the 
headgroups117 is followed by the flattening of the dendrimer to cover a greater area and 
enhance interactions203. However, the flattening process is dependent on the size of 
the dendrimer, as it is energetically unfavorable for higher generations205, and also 
dependent on the fluidity of the membrane, since it was not observed for the gel phase 
lipid bilayer117. This effect was attributed to the capacity of fluid membranes to create a 
pocket to accommodate the dendrimers, promoting a higher number of interactions117. 
However, upon dendrimer-membrane interaction the ordering of the lipid bilayer 
increases comparable to gel conditions due to tilting of the chains206 promoted by the 
hydrophobic parts of the dendrimer117,207. Therefore, in the case of PAMAM G7 these 
have limited flexibility. Thus the mechanism by which they promote pore formation is 
due to extraction of lipids from the bilayer forming lipid vesicles encasing these 
dendrimers 198,199,208. On the other hand, at small generations, PAMAM dendrimers lack 
the ability to form and stabilize these vesicles which may explain the pore formation in 




Figure 1.8 – Dendrimers size scale in comparison to  other biological molecules. 
Dendrimers have the approximate size of small proteins, DNA as well as the lipid bilayer.  
The results observed for model membranes correlate well with the toxicity observed in 
cells. In a similar way to what was observed in model membranes, PAMAM dendrimers 
were found to cause toxicity in a concentration, terminal charge- and generation-
dependent manner210. The mechanistic effect of dendrimers as observed for model 
membranes may also explain the leakage observed for PAMAM dendrimers upon 
interaction with the cell as measured by LDH assay211.  The correlation between in vitro 
and in vivo may however not be straightforward and extrapolations should be done 
conservatively. One particular factor is the difference between in vivo and in vitro 
environments, which may have a key role in the difference of efficacy of the dendrimers 
in the two types of experiments. Indeed, when PAMAM G5 dendrimers were added to a 
cell culture in serum not only did their transfection decrease but also their toxicity, as 
compared to serum free media91. This was attributed to a shielding effect caused by 
proteins which is also expected to occur in vivo. Further studies are therefore required 
to understand the interactions of dendrimers with biological systems so that new drug 
delivery systems can be rationally designed to better meet a desired therapeutic profile. 
1.13. Overview and contextualization of the thesis  
The task of developing new drug delivery systems for anti-cancer drugs requires a 
multidisciplinary approach. Anti-cancer therapies generally suffer from severe side 
effects as a result of non-specific binding to cells. Furthermore, platinum(II) 
compounds, such as, cisplatin have demonstrated limiting therapeutic effects on long 
term treatment due to the arise of resistance mechanism, particularly at cell lipid 
membranes, that are still poorly understood. Consequently, the development of new 
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DDS that address these limitations are of utmost importance. In this regard, this thesis 
describes a proof-of-concept approach starting from the design of fluorescent 
dendrimers as tools to investigate how these behave with lipid membranes and how 
they can impact the delivery of cisplatin. Concomitantly, the interaction of cisplatin with 
lipid model membranes should be used as a guide to further improve the design of 
these dendrimers. The use of computational modelling approaches is therefore critical 
to understand the structure of these dendrimers at the molecular level and how these 
relate to the interactions with both cisplatin and different lipid models. The synthesis of 
these candidates from a bottom up approach also allows a higher control over the 
structure and understanding of the physicochemical properties of these dendrimers, 
which in turn are valuable to validate the computational models. Particularly, it allows 
the creation of a modular synthetic approach where the fluorophore can be easily 
exchangeable so that probes with different properties can be tested. As a result, the 
combined knowledge of each approach should converge to improve the design of 
future DDS.  
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CHAPTER II  




Chapter II – Molecular modeling and dynamics of flu orescence 
PG dendrimers  
The introduction of this chapter is presented as a published review paper that originated from 
this work and is relevant for the discussions in this chapter.  
PAPER 1 (Introduction) – Molecular modeling to stud y 


































































































































































The results of this chapter are presented as a published original papers that originated from 
this work.  
PAPER 2 (Results) – Practical computational toolkit s for 






























PAPER 3 (Results) – Rational design of novel, fluor escent, 
tagged glutamic acid dendrimers with different term inal groups 











Note : Equation 6 should read as:  

































































CHAPTER III: Synthesis of poly-glutamic acid (PG) d endrimers   
3.1. Introduction  
3.1.1. General considerations on dendrimers synthes is 
Despite the tremendous amount of investment in developing new method for synthesis 
of dendrimers, producing novel dendrimers is still a great challenge. Contrary to 
traditional synthesis of polymers where statistical variations of their molecular weight 
are common, dendrimers are synthesized precisely. Therefore, a high degree of 
synthetic control has to be achieved by high-yield and high-selectivity reactions so that 
monodisperse populations can be obtained.  
Because dendrimers can virtually be made of any building blocks (monomers) the 
synthetic route chosen will be dependent on the type of functional groups available in 
the monomer. Regardless of the route of synthesis, dendrimers can be produced 
though a convergent or divergent approach (or a mix method of both) in a step-wise 
manner1–3. In the divergent synthesis approach, the reaction is carried out outward from 
the core in an exponential-like growth. In this approach the core reacts with monomers 
that are generally capped by protecting groups and these are then de-protected to 
generate the intermediary backbone that is used to grow the next generation. The main 
problem associated with this synthetic approach is the possible inconsistencies caused 
by side-reactions and/or incomplete reactions that can lead to defective dendrimers. 
This is particularly relevant at higher generations where a higher number of groups 
have to be conjugated. In order to cope with this challenge, it is common to use excess 
amounts of reagents and longer reactions times which can be highly inefficient. 
Moreover, at higher generations there is a need to perform an increasingly number of 
reactions and the purification becomes increasingly more difficult due to number of 
defective dendrimers with similar biophysical properties. Furthermore, highly selective 
reactions are necessary since every small percentage of unreacted groups have dire 
consequences when growing the dendrimer (i.e. fully incomplete arms that scale up).  
On the contrary, the convergent route requires an initial step of building the dendrons 
(individual branches) or the building blocks (e.g. linear sequence of monomers) that will 
constitute the layer separately before attaching them to the multifunctional core in the 
final step. The major advantage of using this route is the easier purification step since 
the products are very distinct from side-products. Moreover, the lower number of 
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reactions that need to occur at each step minimizes the defects in the final structure. 
However, there are restrictions when using this approach that arise from a potential 
steric hindrance effects at higher generations,  and for very bulky and/or rigid 
monomers4. Additionally, the pre-formed branches may have groups that are 
incompatible with the intended reaction to conjugate them to the core and thus may 
hinder the possibility of using this route.  
Finally, using mixed methods, where both convergent and divergent routes are 
combined, can minimize the problems associated with each individual approach. In this 
approach the number of reactions can be reduced to achieve the desired generation. 
However, not all dendrimer types benefit from this approach or have the functional 
groups necessary for this approach. Ultimately, the route should be selected using a 
case-by-case evaluation.  
Upon continuous increase in dendrimers size, the exterior surface starts to become 
crowded due to the number of monomers that can be found close to each other. This 
results in restriction of the availability of the functional groups to further react. In fact, 
dendrimers grow faster than  their volume and become densely packed which results in 
smaller space necessary to accommodate all additional groups necessary for the next 
layer (sometimes referred as “Malthusian packing paradox”)5,6. The dense packing 
concept of the surface was further explored by de Gennes and Hervet7, which 
introduced a theoretical approach to show the limitation of growth (a finite generation) 
due to steric hindrance effects. For this reason, this effect is often referred to as the “de 
Gennes packing”8. Even though this can be a limiting factor for most dendrimers, it was 
recently reported the synthesis of a dendrimer up to the size of a small virus (∼30 nm)9.  
3.1.2. General considerations on synthesis of pepti de dendrimers  
In regards to peptide dendrimers, both carboxylic acid and amino groups are present in 
the monomers. Because of their nature they are expected to have protein-like behavior 
and thus its reactivity is similar to proteins. As there are many natural and un-natural 
amino acids there are other different synthetic approaches that can then be undertaken 
depending on the side chain groups. Amino acids can be present in the backbone or as 
terminal groups and this dictates the synthetic approach to be taken. Commonly, 
peptide dendrimer syntheses involve the formation of a peptide bond (amide bond 
formation) between the carboxyl and the amine. This approach has been used for 
therapeutic peptide synthesis and a plethora of other small drug molecules10 and thus 
its translation to dendrimers synthesis should be straightforward. Indeed, this type of 
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reaction is commonly employed in the synthesis of PLL dendrimers using N-Boc 
protected lysine derivatives (Figure 3.1). The protecting groups are then removed using 
TFA to release the free amine and continually grow the dendrimer.  
 
Figure 3.1 – Synthesis of PLL dendrimers G0. The core lysine amino acid with the carboxyl group 
capped with a protecting group is reacted with amine-capped branching lysines using the Boc protecting 
group to prevent further reaction of the amines.  
Similarly to lysine, glutamic acid also has 3 functional groups (1 amine and 2 carboxylic 
acid groups) and therefore has inherent branching directionality. Depending on which 
groups are protected, it originates a complex variety of chemistry scaffolds that can be 
further modified. This has resulted in different types of PG dendrimers described in the 
literature, in which linear sequences of glutamic acid or dendrons have been attached 
to different core monomers (naphthoic, adamantine, oxalyl, silsesquioxane, CBZ- and 
porphyrin-glutamic acid), using both convergent and divergent approaches (Figure 
3.2)11–15. However, the reactions necessary for the synthesis of PG dendrimers in this 
work concerns only the reactions between carboxylic acid and amine groups. 
 
Figure 3.2 – Examples of PG dendrimers G0 described i n the literature using different cores and 
different capping groups 11–15. Despite Glu being used to grow the different dendrimers, the use of 
different cores resulted in very different scaffolds. In fact the type of core can have (A-B) mono-, (C) bi- 
and (D) tri-functionality meaning that for the same generation the architecture and size of the dendrimer 
vary. (E): Similarly using a core composed of a di-glutamic acid results in a different final scaffold. 
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3.1.3. Coupling reagents used for peptide synthesis   
As the production of dendrimers requires the reactions to be simple with fewer 
synthetic steps, the reagents should be compatible with the precursors (in terms of 
stability, reactivity and steric constraints) while maintaining minimal racemization and 
having high coupling efficiency.  This stems from the nature of dendrimers synthesis 
where, at each step, multiple similar reactions have to occur simultaneously. 
Additionally, small defects at low generations will have deleterious effects when 
growing larger dendrimers. Peptide dendrimers synthesis can be carried using solid 
phase peptide synthesis (SPPS)16,17 or in liquid phase. SPPS is particularly useful in 
the divergent method since the dendrimer is attached to a solid surface at all times. 
This allows washing off the unreacted reagents as well as side products formed during 
the reaction without compromising the main product. On the other hand, both 
convergent and divergent synthesis can be carried out in liquid phase, but this requires 
the purification of the dendrimer at each step. Nevertheless, in both approaches, the 
amide bond formation is usually carried out by in situ pre-activation of the carboxylic 
acid prior to the addition of the amine. This approach aims to enhance the electrophilic 
nature of the carboxylate groups to make it a better leaving group, and thus moving the 
reaction forward at higher rates, while preventing unwanted side reactions and 
racemization. In this regard, the most common reagents used include acyl halides, acyl 
azides, carbodiimides, uranium salt and acylimizadoles. 
The activation of carboxyl by acyl halides is commonly carried out by using thionyl 
chloride, SOCl2 or oxalyl cholaride
10. In this reaction, the carboxylic acid is treated to 
form the corresponding acyl halide, which is a very reactive derivative since the halide 
is a good leaving group. Therefore, in the presence of amines a nucleophilic reaction 
occurs forming the corresponding amide (Figure 3.3). The problems occurring from 
acyl chlorides are the formation of acidic by-products that can be incompatible with the 
use of acid-sensitive groups, such as Boc-protected groups, and the formation of the 
amine salt rendering it non-nucleophilic. This can be minimized by the use of acyl 
fluoride and/or base10. However, this type of reaction is also commonly prone to 
hydrolysis and racemization and commonly suffers from poor yields.  
Similarly, acyl azides (e.g. sodium azide, diphenylphosphoryl azide, 
dimethylphosphinothioylazide) are also commonly used for coupling. This reagent uses 
two-step activation process in which the methyl esters are converted into hydrazine 
and that is subsequently nitrosated to form the acyl azide. Even though the 
racemization is kept low it can lead to the isocyanate form10 which can be difficult to 
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handle. Furthermore the obtained yield may be lower than in the case of other amide 
coupling reagents10,18. 
 
Figure 3.3 – Mechanism reaction of acyl halides for  amide formation. During the reaction 
there is formation of gases that are extracted and further drive the reaction forward. 
On the other hand, carbodiimides have been one of the most popular activators used 
for peptide synthesis and have also been commonly used for dendrimers synthesis. 
Examples of common carbodiimides include the DCC (N,N'-dicyclohexylcarbodiimide) 
19–21, DIPC (N,N′-Diisopropylcarbodiimide) and the more aqueous soluble version EDC 
(1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide)14,22. Among them, DCC is by far the 
most commonly used and it is highly soluble in several organic solvents but insoluble in 
water. During the reaction, DCC also forms an insoluble urea (dicyclohexylurea) in 
most organic solvents that precipitates and therefore drives the reaction forward. 
However, small amounts of dicyclohexylurea remain in the solution and can be difficult 
to remove. To prevent this, DIPC has been commonly used as an alternative to DCC 
since the formed urea is soluble in organic solvents which can sometimes facilitate the 
purification process. Finally, EDC is a carbodiimide whose urea is soluble in water 
facilitates the purification step on organic solvents (e.g. acidic wash). However, EDC is 
generally associated with lower yields in comparison to DCC18. The mechanism of 
carboxylic activation by carbodiimides involves the formation of an O-acylisourea, 
which can then be substituted by the amine or form the unreacted N-acylurea 
(undesirable) by acyl transfer10 (Figure 3.4). Methods to reduce this unwanted by-
product include carrying out the activation of the carboxyl at low temperature, or 
addition of an intermediary nucleophile such as HOBt (hydroxybenzotriazole), NHS (N-
hydroxysuccinimide) or DMAP (4-dimethylaminopyridine) that compete for the acyl 
transfer. In fact, DCC/NHS is a very common combination of reagents and has been 





Figure 3.4 – Side product of carbodiimides reacting  with carboxyl group resulting in the formation 
of the N-acylurea.  
Uronium salts (HBTU, TBTU, HOBt)14,24 are reagents that have been starting to replace 
the carbodiimides. Similarly to carbodiimides, uronium reagents are also prone to side 
products generation by guanidinylation formation. Therefore, HOBt and HOAt (1-
hydroxy-7-azabenzotriazole) triazoles are commonly used to keep the racemization 
levels low since they form a less reactive intermediate, and therefore lower the 
propensity for racemization. Furthermore, the orientation of the reagents can also have 
a pronounced effect on coupling by promoting chelation/neighbouring effects (e.g HOAt 
chelation with both precursors Figure 3.5). 
 
Figure 3.5 - Neighboring effect of HAOt with the pr ecursors favoring the homing effect. This 
orientates both precursor reagents and facilitates their reaction.   
Finally, acylimidazoles and in particular CDI (carbonyl diimidazole) are another class of 
coupling reagents that can be used in an one-pot syntheses that are commonly used in 
large-scale25. The acylimidazole is formed in situ by pre-activating the carboxyl with 
CDI (not requiring an additional base) followed by addition of the amine (Figure 3.6). 
The major advantage of this reagent is the compatibility with acid salts of amines and 
the by-product is carbon dioxide, making it easier to purify. The presence of a weakly 
acidic moiety has the advantage that the partial protonation of the imidazolide leads to 
an enhanced reaction rate25. 
 
Figure 3.6 – Mechanism of reaction of CDI with carb oxyl to form an amide bond.  
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3.1.4. Related work on PG dendrimer synthesis 
Regardless of the coupling agents used in syntheses, the purification of dendrimers 
remains a difficult task. This is particularly relevant for biomedical applications where 
larger dendrimers have to be synthesized via a higher number of reactions with 
potentially unsatisfactory yield. When comparing the outcome of PG G0 dendrimers 
syntheses carried out from CBZ-glutamic acid with di-ethyl ester using 
DCC/NHS/DMAP to those using HBTU/HOBt as coupling reagents, a higher yield of 
92% was obtained for the latter in comparison to 58% yield for the former24. Moreover, 
it has been observed that these reagents have significantly higher success for lower 
generations and limited success for higher generations. Using divergent approaches, 
glutamic acid diethyl ester was grown from a napthyl-; oxalyl or benzyloxycarbonyl-
protected glutamic acid15,26,27 using DCC as coupling agent and de-protecting the ester 
using NaOH. The benzyloxycarbonyl-PG-ethyl ester G0, G1 and G2 were obtained as 
89%, 84% and 51% yield, respectively15, demonstrating a large loss in yield at higher 
generations. Similar trends in yields were observed in divergent synthesis from a 
porphyrin core (4 branching groups) using different glutamic acid derivatives (carboxyl, 
allyl, ethyl and benzyl), using DCC/pyridine in THF as coupling method. The yields for 
G0 varied from 65-85%, whereas G1 was obtained in 21-42%, and the G2 had an even 
lower yield of 12-16%28. The decrease in yields is particularly noticeable in the 
convergent synthesis. CBZ-PG-ethyl esters were synthesized in a convergent manner 
with HBTU/HOBt to yield G0, G1 and G2 as 92%, 50% and 43% respectively24. As it 
can be observed for the second generation the yield decreases to half, and the same 
was observed for PG-methyl esters, where the convergent approach had a loss in yield 
from 81% to 37% from the increase of one generation27. This effect may be due to 
steric and crowding effects related to the side chain and protecting groups of the 
glutamic acid. When using both glutamic acid and aspartic acid to produce G1 and G2 
dendrimers from an 1,3-adamantane dicarbonyl core, significantly lower yields were 
obtained with aspartic acid, which was attributed to steric effects29. Similar results were 
obtained using a convergent approach with a 1,3,5-benzene tricarbonyl chloride or 1,3-
benzene tricarbonyl chloride as core and DCC/NHS as coupling reagents to generate a 
G2 dendrimer30. In this study, using a tri-functional core instead of a di-functional core 
decreased the yield of the reaction from 52% to 40% showing that steric effects of 
bulky branches hinder further addition.  Finally, the effect of spacing between functional 
groups in the side chain on the yield of higher generation can also be observed on a 
different construct of PG dendrimers. When growing the dendrimer using a di-peptide 
composed of glutamic acids where one of the side chains is capped with methyl ester, 
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it was possible to synthesize a G2/G4 of high molecular weight (5689 g.mol-1) with high 
yields of 91%31. This can be attributed to the larger spacing between branching points, 
which reduces the steric effects. Nevertheless, further reaction to form the next 
generation was not possible due to the steric hindrance that shielded the reaction sites.   
A positive characteristic of PG dendrimers is their versatility to further modification. PG 
G2 were synthesized using a divergent approach from a octa(3-
aminopropyl)silsesquioxane core using glutamic acid di-tert-butyl ester as a branching 
amino acid. Reactions were carried out using HBTU/HOBt/DIPEA in DMF and de-
protection of the capping groups with TFA13,14. These dendrimers were then modified at 
the surface with carbazic acid tert-butyl ester via EDC/HOBt/DIPEA to subsequently 
attach biotin and doxorubicin14. Using a similar approach, linear PG was attached to 
PAMAM G4 where the side chain of the glutamic acid was de-protected and used to 
couple with PEI polymer11. Linear PG has also been attached to PAMAM32–34 by ring-
opening polymerization, using HBr to study their structure and in particular their binding 
capacity to other molecules. Because of their charged nature that can be controlled by 
the solvent or pH, PG dendrimers can form different macromolecular structures. In fact, 
PG-benzyl ester G0 dendrimers attached to an aliphatic octadecanoyl core were able 
to adapt different architectures in response to changes the environment (e.g. ions)35–37. 
3.1.5. Designing fluorescence-based tracking strate gies 
As peptide dendrimers are not expected to have intrinsic fluorescent properties that 
can be observed at physiological pH, it would be beneficial to attach a tag molecule 
with this type of properties. This would allow the direct tracking of dendrimers within the 
biological milieu and enable the study of their biological interactions with other 
biomolecules. The NBD-Cl (7-chloride-4-nitrobenz-2-oxa-1,3-diazole, NBD) was first 
introduced in 1969 as a non-fluorescent and chromogenic pale-yellow compound that 
becomes highly fluorescent once it reacts in the 7-position with amino groups (or 
thiols). This fluorescence is also intensified in environments of low polarity (red shift 
from non-polar to polar environment)38–42. Due to this strong fluorescence properties, 
NBD has been commonly used in bioanalytical chemistry including labelling of amino 
acids, peptides and proteins38,42, lipids43, sugars(glycoproteins, glycolipids and 
lectins)40,44 and other bioactive molecules45, with some derivatives having even 
demonstrated biological activity40,46,47. Synthetically, NBD is particularly useful since it 
is a cheap compound and is considerably stable in aqueous solutions and other 
solvents44. The coupling mechanism in the synthesis of NBD-derivatives is based on 
nucleophilic substitution (e.g. chloride) via a SNAr reaction (Figure 3.7) by the amine 
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(either primary or secondary)44,45. This reaction generally produces high yields (i.e. 50-
100%) but some amines produce very low yields attributed to steric hindrance effects, 
or due to the presence of competing molecules, such as, hydroxyl groups coming from 
solvent44. As a result NBD is a suitable probe to be conjugated to non-fluorescent 
dendrimers and in particular to PG dendrimers since these have available amines to 
react at the core.  
 
Figure 3.7 – Reaction scheme of coupling the NBD to  the amine 47. The nucleophilic nature 
of amines displaces the chloride of NBD.   
In this chapter, the synthesis of PG G4, designed by molecular modelling, was 
attempted. Different coupling reagents (carbodiimides, uronium salts and CDI) were 
tested in different conditions and different purification methods were used. Moreover, 
the step at which NBD coupling should be carried out on the dendrimer backbone was 
evaluated. Finally, different terminal groups were synthesized for attachment to the PG 
dendrimer backbone as well as different cores. Due to the amount of similar 
compounds described in this chapter, their naming is followed by a description number 
referencing the ordering by which they appear in the methods section 3.3, where the 
2D structure and structural analysis of these compounds are also provided.   
3.2 Results and Discussion 
 
3.2.1. Synthesis of PG dendrimers using DCC as coup ling agent 
As described above, syntheses of dendrimers requires a series of repetitive step-by-
step reactions. The decision of using a divergent approach over the convergent 
approach is highly dependent on the dendrimers generation required and the chemical 
constraints of the monomers. Moreover, a mix of both a convergent and divergent 
synthesis could reduce the number of reactions necessary to achieve the G4. In this 
regard, purely on a theoretical reasoning, synthesizing the N-protected-PG G0 with free 
carboxyl groups and the NH2-PG-Ester G1 and combining them together would afford 
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the N-protected-PG-Ester G3 directly. This would be a good compromise between 
synthesizing lower generations (which are expected to produce higher yields and 
easier to purify), while having lower steric hindrance constraints in larger dendrimers as 
well as the number of reactions required (i.e. sets of de-protection and formation of 
new layers). Moreover, having the last step to generate the G4 in this approach would 
be the most optimized approach since the different terminal groups could be added at 
this step. However, as reported in the literature for PG dendrimers, it is expected steric 
hindrance of the G1 when combining with the short side chain of the glutamic 
acid24,29,30. Consequently, combining both NH2-PG-Ester G0 and N-protected PG-OH 
G0 to obtain the N-protected PG-Ester G2 would be a better strategy to pursue as a 
first approach to minimize the number of reactions required (Figure 3.8).  
 
Figure 3.8 – Initial intended synthetic approach to  generate N-protected PG-Ester G2; a) coupling 
reagents (typically DCC/NHS; HBTU/HOBt; CDI); b) basic hydrolysis with NaOH or LiOH; c) acid 
hydrolysis with TFA or concentrated HCl/sulfuric acid; d) Fmoc-removal with piperidine  
In order to use glutamic acid both as the core and as branching monomers, different 
analogues of glutamic acid have to be used. This is necessary to prevent the 
nucleophilic amine of glutamic acid from reacting with itself. Free amines are usually 
protected with CBZ, Fmoc or N-Boc groups in peptide coupling. The protection results 
in loss of nucleophilicity since the nitrogen lone pairs are shared to the carboxy group. 
The use of CBZ-Glutamic acid was reported in the previously published of the PG 
dendrimers synthesis, but showed some problematic lack of compatibility with other 
protecting groups when the de-protection was carried out30. On the other hand, Fmoc 
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and N-Boc are versatile protecting groups that are compatible with ester protection and 
are well-established and extensively studied in peptide synthesis. Furthermore, N-Boc 
has been commonly  used for the production of PG dendrimers31,35–37, where its 
removal can be easily achieved with acidic hydrolysis in high yields. On the other hand, 
Fmoc protecting group provides many advantages such as suitable solubility in organic 
solvents. It is also stable in acidic conditions while being easily removed in the mild 
basic conditions.  
To explore the reactivity of reagents to form the first generation dendrimer, Fmoc-PG-
OEt G0 (4) and two additional intermediates were synthesized (Figure 3.9). Firstly, 
Fmoc-L-glutamic acid 5-tert-butyl ester was pre-activated with DCC/NHS, and upon 
addition of 1 equivalent of glutamic diethyl ester the desired dipeptide Fmoc-Glu(OtBu)-
Glu-OEt (3) was obtained (for more information see method section 3.3). Alternatively, 
Fmoc-L-glutamic acid was reacted with 2 equivalents of DCC/NHS and subsequently 
either purified to obtain the Fmoc-Glu-NHS (1) intermediate, or immediately reacted 
with L-glutamic acid diethyl ester to obtain the first generation Fmoc-PG-OEt G0 (4).  
 
Figure 3.9 – Chemical structure of two synthesized intermediates (Fmoc-GLU-NHS (1) and Fmoc-
GLU(OtBu)-GLU-OEt (2)) and first generation Fmoc-PG-O Et G0 (4) dendrimer 
All reactions were carried out until completion as monitored by thin layer 
chromatography (TLC). Even though all three products were obtained in high yields, 
there were distinctive differences in the outcomes of the different synthetic approaches. 
Fmoc-Glu-NHS (1) was obtained with 65% yield and was subsequently used as the 
precursor to react with 2 equivalents of glutamic acid diethyl ester to form the first 
generation Fmoc-PG-OEt G0 (3) with 97% yield (with urea still present). Alternatively, 
the di-peptide Fmoc-Glu(OtBu)-Glu-OEt (2) was obtained with 98% yield, and was 
subsequently hydrolyzed to remove the tert-butyl-ester in quantitative yield to obtain 
the Fmoc-Glu(OH)-Glu-OEt (3) with the free carboxyl. The latter was then reacted with 
1 equivalent of glutamic acid di-ethyl ester using the DCC/NHS coupling again to obtain 
the dendrimer Fmoc-PG-OEt G0 (4) (yield: 97%). On the other hand, the direct one-pot 
synthesis of Fmoc-PG-OEt G0 (4) by reacting Fmoc-L-glutamic acid with 2 equivalents 
129 
 
of glutamic acid di-ethyl ester via DCC/NHS coupling resulted in 78-89% yield after 
purification. Overall, the direct reaction of Fmoc-PG-OEt G0 (4) was shown to be the 
best approach in terms of overall yield and lower number of synthetic steps. Even 
though the Fmoc-Glu-NHS (1) was an interesting precursor to obtain since it could be 
subsequently used to generate the higher generations (and therefore be synthesized in 
one big batch), it afforded a lower yield in comparison and was prone to hydrolysis 
during handling (new bromocresol active spots on  TLC were observed– data not 
shown). On the other hand, the synthesis of the di-peptide had no benefit in the 
synthesis of the dendrimer but could be an interesting moiety to subsequently be used 
as a terminal group instead. 
Since reactions were carried out with DCC, the N-acylurea (DCU) byproduct was 
formed in all reactions. This urea is almost insoluble in most organic solvents and even 
though it precipitates, it still remains in detectable amounts in most of solvents. 
Moreover, in order to eliminate the unreacted DCC, acetic acid was added to the 
mixture and allowed to react for 1 hour to convert the DCC to DCU. The newly formed 
urea was then filtrated out with but small amounts remained in the solvent. 
Nevertheless, in all cases single spots in the TLC showed that only one product was 
formed (data not shown) and thus no side reaction products derived from the 
isomerization of the DCC (O-acylurea) on the carboxyl groups were expected. This 
result was expected since NHS was used concomitantly.  NHS controls the 
racemization by rapid addition to the DCC activation. Moreover, the reactions were 
carried out in solvents of low dielectric constant (DCM) which accelerates the reaction 
together with the catalytic amounts of DMAP. Additionally, when the reaction was 
carried out without NHS, the yield of the reaction was significantly lower and the TLC 
showed multiple spots below the dendrimer spot.  
The Fmoc-PG-OEt G0 (4) was then purified by several methods including column 
chromatography. For this, different eluents were tested: (a) DCM/THF (3:1 v/v); (b) 
THF/n-hexane (1:2 v/v); (c) ethyl acetate/n-hexane (3:1 v/v); and (d) methyl 
acetate/methanol (95:5 v/v). All eluents were able to separate the urea to a certain 
extent while the ethyl acetate/n-hexane (3:1 v/v) and methyl acetate/methanol (95:5 
v/v) showed better separation from impurities to yield the product as a white solid. The 
1H NMR confirmed the product to be pure (Figure 3.10). Moreover, both trituration from 
methanol with water and crystallization with acetonitrile were also able to purify the 
dendrimer but had significantly lower yields. Low generation PG dendrimers were 
previously shown to be able to crystalize which was attributed to formation of 




Figure 3.10 – 1H NMR of Fmoc-PG-OEt G0 (4) in deuterated chlorofor m as single pure 
product; the esters were used as reference and are in a proportional ratio to the Fmoc groups. 
Under these conditions the amides (7.97, 7.56 and 5.28 ppm) (h, i, g) were visible further 
evidencing the coupling to both sides of glutamic acid and the different microenvironment these 
amines are exposed to. 
As shown in figure 3.10 all peaks in the 1H NMR of the product obtained could be easily 
assigned to the hydrogen atoms of the dendrimer. Moreover, all α-carbons of glutamic 
acid (4.27, 4.59 and 4.66 ppm) and amides (7.97, 7.68 and 5.28 ppm) showed 
distinctive signal.  Furthermore, the ratio of esters correlated to the β and γ carbon 
hydrogens, and the COSY NMR also showed the correct correlation between the CH3 
and CH2 groups of the esters as well as correct correlation of the Fmoc hydrogens 
(data not shown). These results strongly suggested that there was no formation of side 
products and that both carboxyl groups of the core reacted. The distinct nature of the 
peaks has also been observed in other PG dendrimers where it has been attributed to 
the involvement of the amide bonds in intramolecular hydrogen bonding29.  
The Fmoc-PG-OEt (4) was then reacted with piperidine in DMF or DCM to remove the 
Fmoc group and generate the intermediate NH2-PG-OEt (10) to serve as scaffold to 
further grow the dendrimer (Figure 3.8.). The Fmoc removal occurs due to the slightly 
more acidic nature of the hydrogen in the fluorenyl group due to charge stabilization by 
the aromatic rings. This results in the removal of this hydrogen in presence of excess of 
base which subsequently decomposes the carbamate to form the dibenzofulvene 
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intermediate together with carbon dioxide. This reaction then releases the amine 
(Figure 3.11)49. Furthermore, the dibenzofulvene is highly reactive and thus can react 
with the excess of piperidine to form a stable product. 
 
Figure 3.11 – Chemical scheme of Fmoc removal mecha nism. This reaction releases the free amine 
and the fulvene intermediate that subsequently reacts with piperidine to form a stable product 
The Fmoc removal was monitored spectrophotometrically as well as by TLC (ethyl 
acetate/methanol 95:5 v/v) (data not shown). The 209.5 nm pre-reaction peak shifted to 
218 nm and reached a plateau after 2 hours. On the other hand, the 265 nm peak 
shifted to 255 nm after 2 hours and returned to 262 nm after 4 hours. This could 
probably be attributed to de-protection of the fulvene and reaction with the piperidine. 
This is in accordance with the TLC results where after 2 hours two top UV spots were 
observed and after 4 hours only one spot was observed.  
The obtained reaction mixture containing the dendrimer then was purified by silica 
column chromatography using ethyl acetate/methanol (95:5 v/v) as eluent to effectively 
separate the Fmoc-piperidine and the NH2-PG-OEt (10). However a low recovery yield 
was obtained (yield: 50-60%), which could be only slightly increased by doping the 
eluent with TEA to an improved yield of 66%. The first eluted product (rf 0.7 and UV 
positive) was identified to be solely the Fmoc-piperidine by 1H NMR (Figure 3.12), and 
by mass spectrometry with a m/z of 264 Da. This confirmed that all the fulvene 
molecules released during the reaction were converted to a single product that could 
be removed. Also, the 1H NMR spectrum allowed the characterization of the reaction 





Figure 3.12 – 1H NMR of Fmoc-piperidine that is formed as a side p roduct when reacting with the 
fulvene released. Particularly, the Fmoc peaks (7.18-7.63 ppm) (a-d) are at slightly different position to 
those when coupled to the dendrimer.  
The second eluted product (rf 0.5 and reactive to ninhydrin) was obtained as a yellow 
oil which was characterized by 1H NMR (Figure 3.13) and 13C NMR (methods section 
3.3). The 1H NMR showed similar peaks to its precursor but the Fmoc-related peaks 
completely disappeared (around 7 ppm), showing that the product was pure. Moreover, 
the NMR peaks are in agreement to those previously  published for this molecule24. 
The product was also characterized by MS where an m/z of 540.23 Da was found [Na 
+ NH2-PG-OEt G0 (10)].  
In the attempt to improve the yield two additional methods were tested. The first 
method relied on the poor solubility of the Fmoc-piperidine in cold methanol, and thus 
multiple cycles of cold methanol and removal of the precipitate were carried out. 
However, to fully remove the impurity, the yield of recovery of the intended product was 
low (yield: 40%) due to the number of cycles required. The second method followed a 
published protocol based on partition of the Fmoc-piperidine between polar solvents 
(e.g. DMF) and an immiscible hydrocarbon solvent50. This method showed efficient 
transfer of the Fmoc-piperidine to the n-hexane layer phase and improved the yield of 




Figure 3.13 – 1H NMR of NH2-PG-OEt G0 (10) in deuterated methanol; all peaks attributed to the Fmoc 
were completely absent (around 7 ppm and 4 ppm). The free amine hydrogens were also detected at 
around 2.1-2.4 ppm. All other peaks are similar to those found to Fmoc-PG-OEt G0 (4) 
In order to synthesize the G2 directly from two G0, the Fmoc-PG-OEt G0 (4) had to 
also to be hydrolyzed. Ester hydrolysis to form a free carboxyl can be carried out in 
aqueous methanol or THF using both basic or acidic conditions20,51,52. However, basic 
hydrolysis could not be carried out due to the nature of the Fmoc that would be de-
protected concomitantly. Even carrying out the reaction with LiOH in the presence of 
CaCl2, which has been reported to increase the stability of the Fmoc
53, showed limited 
success with the majority of Fmoc undergoing de-protection (data not shown). Thus, 
acidic hydrolysis with concentrated acid under reflux was tested to remove the esters. 
However, due to the harsh conditions of the heating cycle, the dendrimer was found to 
be degraded forming a tar-like precipitate. Analysis of the solution also showed that the 
esters were not completely removed.  
In order to carry out the hydrolysis in milder conditions, the methyl ester derivative of 
the branching glutamic acid was used instead. The reaction to generate the dendrimer 
was similar to the Fmoc-PG-OEt G0 (4) using DCC/NHS, affording the Fmoc-PG-OMe 
G0 (5) in similar yield (88-95%) in pure form (Figure 3.14). Again the NMR peaks were 
easily attributed to each functional group. As observed, the Fmoc (7.24-7.66 ppm and 
4.00-4.27 ppm) and the α (4.14-4.69 ppm), β and δ (1.89-2.38 ppm) carbon hydrogen 
peaks remained similar, whereas the ester is identifiable as group of single peaks at 
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3.57-5.70 ppm. Nevertheless, attempts on hydrolysis under acidic conditions resulted 
in multiple species due to incomplete ester hydrolysis similarly to the Fmoc-PG-OEt G0 
(4) as determined by the NMR (data not shown). As a result, this synthetic route was 
deemed unsuitable since it would be detrimentally for higher generation dendrimers 
where a high number of hydrolyses have to occur. 
 
Figure 3.14 – 1H NMR of Fmoc-PG-OMe G0 (5) in deuterated chloroform ; the protecting ester groups 
were differentiated between 3.5-.3.7 ppm (a) and the amides were clearly observed at 7.89, 7.51 and 5.31 
ppm further evidencing coupling to both sides of the core. All other peaks were similar to Fmoc-PG-OEt G0 
(4) 
In order to prevent the issue of ester hydrolysis being incompatible with the Fmoc 
group, two alternatives were devised: (1) change of the Fmoc to an N-Boc and carry 
out hydrolysis of the esters under basic conditions; and (2) change of the ester (ethyl or 
methyl) to an acid-sensitive ester such as tert-butyl ester. Even though both ethyl and 
methyl esters can be sensitive to acid hydrolysis this process is slow under conditions 
employed for N-Boc removal52. Moreover, the N-Boc is stable to nucleophile reagents 
and thus suitable for ester hydrolysis under basic conditions. It has also been 
previously reported the selective de-protection of the N-Boc in the presence of tert-
butyl esters by concentrated sulfuric acid in t-BuOAc or with MeSO3H in t-BuOAc
54. 
The mechanism of this reaction does not rely on selective de-protection of N-Boc but 
rather on the re-esterification of the carboxylic acid that is formed during the reaction52. 
Even though this was a convenient approach, adding more steps in the same reaction 
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when producing a dendrimer may not be the best approach since it can lead to more 
defects at higher generations. However, theoretically the N-Boc-PG-OtBu G0 could be 
synthesized to produce the NH2-PG-OH G0 using a single de-protection reaction with 
acidic conditions (Figure 3.15).  
 
Figure 3.15 – Theoretical synthesis of NH 2-PG-OH G0 using a single de-protection reaction to 
remove all t-Boc groups with an acid 
 As a result, both PG derivatives above described were synthesized in a similar manner 
to the Fmoc-PG-OEt (4) and Fmoc-PG-OMe (5) using the DCC/NHS coupling method 
(Figure 3.8). Both resulted in similar yield of 97% for N-Boc-PG-OMe G0 (8) and 95% 
for Fmoc-PG-OtBu (6). The N-Boc-PG-OMe G0 (8) was then hydrolyzed under basic 
conditions with either NaOH or LiOH, whereas Fmoc-PG-OtBu G0 (6) was hydrolyzed 
under acidic conditions using TFA (Figure 3.16).  
 
Figure 3.16 – Reaction mechanism of basic hydrolysi s of methyl esters using LiOH and acidic 
hydrolysis N-Boc and tert-butyl esters using TFA 
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When using basic hydrolysis, the hydroxide ions attack the carbon of the ester and 
form a tetrahedral intermediate that collapses to reform the carbonyl resulting in the 
release of the alcohol and generating the free carboxylic acid group (Figure 3.16). On 
the other hand, in acidic conditions, the acid donates the proton to the carbonyl with 
subsequent release of the 2-methylprop-1-ene and the free carboxyl (Figure 3.16). 
Both routes showed complete hydrolysis of the esters in high yields (similar to other 
reported PG dendrimers55) producing the desired free carboxylic acid products in the 
form of N-Boc-PG-OH G0 (9) (1H NMR showed in Figure 3.17) and Fmoc-PG-OH G0 
(7) (1H NMR showed Figure 3.18) to be further used as the core for the PG dendrimers 
G2.  
 
Figure 3.17 – 1H NMR of N-Boc-PG-OH G0 (9) in deuterated methanol; the N-Boc peak at 1.43 ppm 
was used as reference; solvent peaks are still present.  
Since the N-Boc group is resistant to basic conditions the G2 could be formed by the 
conjugation of the N-Boc-PG-OH G0 (9) with the previously synthesized NH2-PG-OEt 
G0 (10) (Figure 3.8). However, because the methyl esters are more suitable since they 
can be hydrolyzed in less harsh conditions, a new intermediate derivative was 
synthesized. To this, the Fmoc-PG-OMe (5) was reacted with piperidine to generate 
the NH2-PG-OMe (11) as an oil (yield: 40-68%). Alternatively, the Fmoc-PG-OtBu G0 
(6) was reacted with piperidine to yield NH2-PG-OtBu G0 (12) (yield: 65-79%), to be 




Figure 3.18 – 1H NMR of Fmoc-PG-OH G0 (7) in deuterated methanol; Fmoc group was used as 
reference and no evidence of hydrolysis of this group was evident in the spectra. 
The synthesis of N-protected-PG-Ester G2 was then attempted using the different 
combinations of the previous synthesized precursors. The first was carried out by 
combining the Fmoc-PG-OH G0 (7) with NH2-PG-OMe G0 (11) by DCC/NHS coupling. 
The second was carried out by combining N-Boc-PG-OH G0 (9) with NH2-PG-OMe 
(11) by DCC/NHS coupling. The TLC for both couplings showed a complex mixture of 
products (data not shown). Multiple close peaks were observed which suggested the 
formation of both mono- and di-substitutions. The reaction was extended to 120 hours 
without change and the analysis by 1H NMR showed a complex mixture of peaks that 
could not be assigned to the G2. The incomplete substitution was probably due to the 
steric hindrance effects. Therefore once one carboxyl is substituted, the G0 may be too 
bulky for the substitution of another G0.  
Consequently, two new synthetic routes to synthesize a G1 were tested and compared. 
Using a convergent approach, NH2-PG-OEt G0 (12) was coupled to Fmoc-L-glutamic 
acid to form the G1. Similarly to the attempted synthesis of the G2, this approach yield 
multiple TLC spots which upon purification of the product yielded the Fmoc-PG-OEt G1 
(13) in 44% yield. On the other hand, using a divergent approach combining the Fmoc-
PG-OH (7) with glutamic acid di-ethyl ester afforded the product with a much higher 
yield (73-88%). These results further corroborated the effects of steric hindrance to limit 
the growth of PG dendrimers. Furthermore, as observed in 1H NMR (Figure 3.19), the 
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isolated product still showed the presence of small amounts of DCU urea. Several 
eluents mixtures in various ratios (ethyl acetate, methanol, diethyl ether, ether) were 
tested for the separation of the DCU but all showed similar rf to the dendrimer by TLC, 
and thus the separation by silica column chromatography was not complete.  
Moreover, running the product through a gradient of water/acetonitrile in a C18 column 
was not able to separate the product and most of it partitioned to the first fraction of 5% 
water in acetonitrile. This suggested that the dendrimer established strong interactions 
with the DCU urea. 
 
Figure 3.19 – 1H NMR of Fmoc-PG-OEt G1 (13) in chloroform; urea was still present in significant 
amounts as it can be observed by the peaks at 1.0-1.7 ppm; comparing to the 1H NMR of the G0, the 
signals were broader due to the exponential growth of signaling by each monomer. However, the Fmoc 
groups were still distinct and in proportional ratio to the ester groups which suggested complete reaction of 
all branches. 
The Fmoc group was subsequently removed using piperidine to afford the NH2-PG-OEt 
G1 (22) as a thick yellow oil. The TLC showed incomplete reaction where the initial 
product was still present even after extension of the the reaction time for 48 hours. The 
product was then purified by flash chromatography from a dry loading to afford the 
product with a low yield of 34%. To further test the availability of the Fmoc group for de-
protection, the N-Boc-PG-OMe G1 (20) analogue was synthesized from reaction of the 
N-Boc-PG-OH (9) with glutamic acid di-methyl ester via DCC/NHS coupling. This 
compound was then reacted with 10 equivalents of TFA in an ice bath to remove the N-
Boc13. A common problem that can arise during the N-Boc de-protection with TFA is 
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the cyclization of the glutamic acid56. To optimize the reaction, the small N-Boc 
glutamic acid was reacted with TFA and cyclization was indeed observed as the 
product did not react with ninhydrin and the integration of the 1H NMR did not match 
both esters (data not shown). However, when carrying out the reaction with N-Boc-PG-
OMe G0 (8) and N-Boc-PG-OMe G1 (20) no cyclization were observed (ninhydrin 
reaction positive). Furthermore, the 1H NMR confirmed the peak corresponding to N-
Boc group completely disappeared (Figure 3.20). In both cases, the products were 
obtained in quantitative yield (91-97%), therefore suggesting that the bulkiness of the 
group in the core is essential for the success of the de-protection reaction.  
 
Figure 3.20 – 1H NMR of NH 2-PG-OMe G0 (11) in deuterated methanol; the N-Boc was not visible 
suggesting complete hydrolysis  
The newly synthesized NH2-PG-OEt G1 (22) was then coupled to Fmoc-L-glutamic 
acid in a convergent manner to form the G2 intermediary. However, as expected 
multiple peaks appeared in the TLC and upon isolation of these products the 1H NMR 
showed multiple complex peaks that indicated a complex mixture of multiple Fmoc and 
esters peaks close to each other together with urea and unknown peaks. Altogether, 
these results suggested that the divergent synthesis may be a more suitable route for 
the synthesis of this type of dendrimers since the bulkiness of the dendrons prevents 
complete substitution of both carboxyl groups of the GLU monomer.  
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Consequently, the divergent approach was further explored. To this, the N-Boc-PG-
OMe G1 (20) was hydrolyzed with LiOH/MeOH/THF/water to obtain the N-Boc-PG-OH 
G1 (21) (Figure 3.21) as an yellow oil with an yield of 38%. Alternatively, the Fmoc-PG-
OtBu G0 (6) was synthesized via DCC/NHS (yield: 96%) and then hydrolyzed to form 
Fmoc-PG-OH G0 (7) in quantitative yield. This was subsequently used to form the G1 
via DCC/NHS to afford the Fmoc-PG-OtBu G1 (15) (yield: 85%). Finally, the later was 
then hydrolyzed with TFA to afford the Fmoc-PG-OH G1 (16) (Figure 3.21) with a yield 
of 55%. These results showed that the de-protection of tert-butyl esters had an 
improved yield in comparison to the methyl esters. However, as observed previously, 
the ability to de-protect the Fmoc is harder than the N-boc.  Nevertheless, to further 
explore the best approach, both compounds were used to synthesize PG G2 
dendrimers.  
   
Figure 3.21 – 2D structure of the Fmoc-PG-OH G1 (16)  (left) and N-Boc-PG-OH G1 (21) (right) 
As a result, Fmoc-PG-OH G1 (16) was reacted with L-glutamic acid di-tert-butyl-ester 
whereas the N-Boc-PG-OH G1 (21) was reacted with L-glutamic acid di-methyl ester 
via DCC/NHS coupling to afford the corresponding G2. However, both products were 
obtained in low yield (5-21%). Moreover, the purification of the G2 showed to be 
particularly difficult since no suitable eluent was found to effectively separate the high 
amounts of urea even at high salt concentrations as well as in acidic conditions on both 
silica column chromatography and C18 column (with varied ratios of water/acetonitrile). 
Moreover, the 1H NMR showed to be extremely complex and high amounts of urea 
peaks were present (e.g. 1H NMR of Fmoc-PG-OtBu G2 (24) in Figure 3.22). In fact, 
due to the high number of repetitive monomers the integration of the signal and 
attribution of the peaks is considerably harder and cannot be done properly to 
determine whether the urea is associated or coupled to the main dendrimer backbone. 
The COSY NMR also displayed a complex signal that did not allow the determination of 




Figure 3.22 – 1H NMR of the Fmoc-PG-OtBu G2 (24) in deuterated chlo roform. The NMR spectra 
started to become very complex. However, high amounts of urea can be observed demonstrating the 
difficulty in purification for the bigger dendrimers.  
Furthermore, even after hydrolysis of the N-Boc-PG-OMe G2 (24) with LiOH, the DCC 
remained in the water phase after washings with organic solvents. Therefore, it was not 
possible to ascertain whether or not the DCC was linked or complexed to the 
dendrimer. Nonetheless, it is plausible that these form a stable complex (Figure 3.23) 
between the carboxylic acid and the urea group and when in the ester form, the PG 
may work as a host molecule for the DCC/DCU. On the other hand, because there are 
a higher number of terminal groups the reaction may be slower for the substitution of 
the NHS and thus leading to the side product. This is also evidenced by the fact that 
even at high salt concentrations there was no evident reduction of the DCU. 
Nevertheless, the yield of recovery was extremely low (~11%) and thus not suitable as 
a method for further growth of the dendrimer. 
Previous studies of PG dendrimers have described high yield for the G0 (around 65-
92%)15,28 and G1 (58-92%)15,24 which drop drastically for the G2 (33-51%)15,24,29. One 
reason for lower yields at higher generations may be due to the crowding effect 
resulting in steric hindrance. This could be observed when comparing glutamic acid 
and aspartic acid as building blocks for dendrimers using a convergent method where 
aspartic acid based dendrimers had a yield of 10% for G2, whereas this was slightly 
higher (33%) for PG dendrimers29.  This can also occur in the core as observed for 
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benzene tricarbonyl or dicarbonyl cores, where 40 and 50% yield was obtained 
respectively. In the convergent approach, the N-protected group has to be removed. In 
the case of N-benzyloxycarbonyl groups this could be removed with high yields with 
iodotrimethylsilane for G0 (94%)  but not for G1 where the slow cleavage allowed the 
ester degradation and thus Pd-C/H2 had to be used, which afforded a good yield 
(73%)15. Therefore, taking into account the results obtained in this work together with 
the ones reported in the literature, the synthesis of higher generations PG dendrimers 
should be carried out by divergent synthesis. As a result, given that DCC is a bulky 
reagent and it is difficult to remove, different coupling reagents were tested to ascertain 
the ability to improve the yield and purification of PG dendrimers. 
 
Figure 3.23 – Possible complex between urea the carb oxylic groups of the PG dendrimer 
3.2.2. Synthesis of PG dendrimers using alternative  coupling agents  
The Fmoc-PG-OtBu G0 (6) was chosen as a reference to study the ability of different 
coupling reagents to afford the PG dendrimers with high yield and ease of purification. 
These reagents included: (a) DCC; (b) DIPC; (c) EDC; and (d) CDI. Results for the 
synthesis of this dendrimer are displayed in table 3.1. It can be observed that different 
coupling reagents resulted in varied yield of recovery. Even though some reactions had 
lower yield they are comparatively similar to the others previously described since 
these reagents (EDC and CDI) can be easily removed by aqueous washings.  
Similarly to the results obtained with DCC coupling, the DIPC coupling produced higher 
yields in the presence of NHS. However, contrary to the DCC, the urea of DIPC did not 
precipitate. In order to remove it, column chromatography had to be carried out for 
purification. On the other hand, using the water soluble carbodiimide EDC showed a 
significantly drop in the yield. However, the purification was much easier since all side 
products and precursors can be extracted to the aqueous layer under acidic conditions. 
Nevertheless, the major consensus on using this reagent is that it can result in lower 
yields in comparison to other reagents35. This comparatively lower yield was also 
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observed in the synthesis of both Fmoc-PG-OEt G0 (4) and N-Boc-PG-OMe (8), where 
a yield in the range of 44-60% was achieved. This is in contrast with the work carried 
out with EDC for other PG dendrimers where high yields were attained57. Again, the 
limited spacing between both carboxyl groups in the same GLU may contribute to this 
issue, since in these dendrimers di-glutamic acid (instead of a single GLU) were used 
as monomers for branching. Thus, when single GLU are used, it is possible that after 
one of the carboxylic acid groups reacted with EDC, the side chain of the latter may 
interfere by forming a salt bridge with the other carboxylic acid in the other side chain of 
the GLU, thus slowing the reaction.  
Table 3.1 – Yield obtained for Fmoc-PG-OtBu G0 (6) re action using different coupling reagents  
Coupling reagents Yield (% expected mass) 
DCC/NHS 96%* 




Notes: * urea present; ** after column purification; DCC: N,N'-Dicyclohexylcarbodiimide; NHS: N-
hydroxysuccinimide; DIPC: N,N′-Diisopropylcarbodiimide; HOBt: Hydroxybenzotriazole; CDI: 1,1'-
Carbonyldiimidazole 
 
Finally, CDI was also tested as coupling reagent. CDI, similarly to EDC, offers a 
valuable benefit for amide formation since the work up is easily carried out by washing 
of the organic phase with acidic solutions and phase separation. Moreover, with the 
use of glutamic acid ester hydrochloride monomers, the acid protonates the remaining 
CDI, promoting its precipitation in solution. As observed in table 3.1., CDI afforded the 
small dendrimers in high yield. Moreover, the dendrimer was obtained with minimal 
loss in the purification process and no side products were obtained after purification. 
Consequently, this reagent was chosen to carry out further synthesis of PG 
dendrimers.  
To this, the Fmoc-PG-OtBu G0 (6) was then hydrolysed using TFA to afford a viscous 
yellow oil in quantitative yield. The obtained Fmoc-PG-OH G0 (7) was then pre-
activated with CDI and coupled with L-glutamic acid di-tert-butyl ester to afford the 
Fmoc-PG-OtBu G1 (15) with a yield of 62-80%. The 1H NMR (Figure 3.24) showed that 
the dendrimer was obtained pure, and the integration of peaks correlated with the 





Figure 3.24 – 1H NMR of Fmoc-PG-OtBu G1 (15). The NMR showed the Fmoc group signal between 
7.29-7.66 ppm and around 4.26-4.51 ppm similarly to the previous PG dendrimers. Solvent peaks were 
still present.  
Because tert-butyl esters are bulky, a different type of coupling reagent was also 
tested. HATU (Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium) and 
HBTU (Hexafluorophosphate Benzotriazole Tetramethyl Uronium) are generally potent 
coupling reagents that have high success for bulky amino acids. In fact, the 
combination of HATU/DIPEA has previously been used in the synthesis of tryptophan-
terminated dendrimers with tert-butyl esters55. Therefore, these reagents were first 
tested on their ability to synthesize Fmoc-PG-OEt G0 (4) and Fmoc-PG-OMe G0 (5) 
since they are cheaper derivatives of glutamic acid. These reagents showed the ability 
to produce these dendrimers in highly pure forms with minimal purification steps (yield 
70-92%). However, when using these reagents in the synthesis of Fmoc-PG-OMe G1 
(14), the NMR showed a mixture of multiple Fmoc peaks including the ones previously 
determined to correspond  to fulvene peaks. However, whether the coupling reagents 
were responsible for acting as a base for de-protection of the Fmoc or the product was 
degraded during handling was not determined.  
Therefore, the previously obtained Fmoc-PG-OtBu G1 (15) was then hydrolysed using 
TFA and extracted to an organic solvent to obtain the Fmoc-PG-OH G1 (16) as a 
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dense orange oil (yield 56-72%). The 1H NMR (Figure 3.25) showed complete removal 
of tert-butyl esters as observed by the disappearance of the 1.40 ppm peak. 
 
Figure 3.25 – 1H NMR of Fmoc-PG-OH G1 (16) in deuterated methanol; solvent peaks were still 
present; the tert-butyl ester groups were not present at 1.40 ppm indicating that the hydrolysis was 
complete.  
Continuing the synthesis cycle, the Fmoc-PG-OH G1 (16) was then activated with CDI 
for 24 hours. Following the reaction by TLC, it was possible to observe a multitude of 
peaks arising from the origin point (data not shown). After 24 hours, no change in the 
peaks was observed even after adding more CDI and thus the L-glutamic di-tert-butyl 
ester was added and the reaction was allowed to continue for 7 days. After purification, 
the Fmoc-PG-OtBu G2 (17) was obtained as a sticky white plastic-like product with a 
very low yield of 5%. This low yield is expected as the tert-butyl esters are very bulky 
and thus may restrict the coupling on both sides of the glutamic acid. Nevertheless, the 
obtained dendrimer was then subjected to hydrolysis with TFA to yield the Fmoc-PG-
OH G2 (18) as a very dense turquoise oil (yield 11%) that showed low solubility in 
methanol. The analysis of the 1H NMR (Figure 3.26) showed some impurities around 
1.05-1.35 pm which can be expected due to the multitude in carboxyl groups that may 
establish complexes with impurities present in solvents. It is also noticeable that the 
color of the oil obtained for G0, G1 and G2 varied from yellow, orange and turquoise 
respectively. Furthermore, at this point, very small yields were obtained probably due to 
the amount of acid that has to be used in the hydrolysis reaction, which probably 
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degraded the dendrimer. Nevertheless, the small amounts of Fmoc-PG-OH G2 (18) 
obtained were activated with CDI and coupled to the tert-butyl derivative but very small 
amounts of a product were obtained (even the precipitate of CDI was analyzed to 
determine if the dendrimer had been precipitated). Because the amounts were low and 
the signals were weak and very broad it was not possible to assign the peaks to the 
NMR.   
 
Figure 3.26 – 1H NMR of Fmoc-PG-OH G2 (18) in deuterated mthanol. The tert-butyl ester groups were 
not present at 1.40 ppm showing that the hydrolysis was complete.  
Due to the bulkiness of the tert-butyl esters and the previously described difficulties of 
removing the Fmoc at higher generations, a different alternative was explored that 
would facilitate the integration of the NBD at this point. Despite the limited success at 
ester removal via basic hydrolysis for methyl esters, the fact that these are compatible 
with N-Boc and are less bulky, suggested that higher generations could be easier to 
synthesize. As a result, the N-Boc-PG-OMe G0 (8) was synthesized using CDI, 
HBTU/HOBt/DIPEA58 or HATU/HBTU/DIPEA as coupling agents and all reactions were 
obtained in high yields (86-99%). Again, the product was obtained by washing the 
organic solvent with aqueous solutions and afforded the dendrimer as a pure product 
(Figure 3.27). The amides displayed distinct peaks (7.17, 7.51 and 5.00 ppm) in 
deuterated methanol and all three α-carbon hydrogens had distinct signals (4.69, 4.60 




Figure 3.27 – 1H NMR N-Boc-PG-OMe G0 (8) in deuterated methanol. The 3 amides and 3 α-
carbon hydrogens can be observed as distinct signals.  
The N-Boc-PG-OMe G0 (8) was then hydrolyzed with LiOH/THF/MeOH/water to afford 
the N-Boc-PG-OH (9) as a sticky yellow oil (yield: 65-86%) and subsequently reacted 
with L-glutamic acid di-methyl ester via CDI coupling to generate the N-Boc-PG-OMe 
G1 (20) as a yellow oil (Yield: 50%). This product was then hydrolyzed again to yield a 
dense yellow oil with poor yield (yield: 38%). The next generation was then obtained 
via HBTU/HOBt/DIPEA coupling to obtain the N-Boc-PG-OMe G2 (24) with an 
improved yield of 45%, which was similar to the one reported in the literature for similar 
PG dendrimers and reagents24. However, when analyzing the 1H NMR (Figure 3.28) 
the assignment of peaks was not in agreement to the ones reported for similar 
dendrimers using an adamantane core29, as well as the peaks observed for the N-Boc-
PG-OMe G0 (8). The disparity in the obtained 1H NMR concerns the number of α-
carbon hydrogens present, where only a broad peak at 4.44 ppm can be observed 
(Figure 3.28). Also, a shift of the N-Boc to 0.770 ppm was observed but this could have 
been due to N-Boc being buried inside the dendrimer. Using the methyl groups at 3.61-
3.70 ppm as a reference (accounting for 48 hydrogens) and assuming that the α-
carbon hydrogens shifted, the integration of all peaks between 1.22 and 2.70 account 
for the possible missing α-carbons hydrogens as well as the internal β and γ carbon 
hydrogens. Given this is a reasonable assumption, the product was obtained pure. 
Therefore, further analysis including 13C NMR and MS should be conducted to 
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determine the purity of the compound or whether it is a degraded product.  Because 
the overall yield to obtain the G2 was low taking into consideration both coupling and 
de-protection reactions, new synthetic alternatives should be considered. This could be 
carried by using solid phase synthesis to facilitate the purification process of by altering 
the scaffold of PG dendrimers.  
 
Figure 3.28 – 1H NMR N-Boc-PG-OMe G2 (24) in deuterated chloroform;  the N-Boc at 0.770 ppm as 
well as the methyl groups at 3.610 ppm were used as  reference. 
3.2.3. Attachment of NBD to the core of PG dendrime rs  
Coupling of GLU and PG dendrimers to NBD was concomitantly studied in order to 
ascertain at which step it would benefit its coupling. Based on the experimental results 
of Fmoc removal, and on literature data regarding the convergent synthesis of PG 
dendrimers24, even for  the synthesis of G1, the yield of the reaction was expected to 
be lower. This suggests that the amine of the core may be unavailable to react. The 
coupling of various fluorophores such as dansyl, rhodamine, nitrobenzoxadiazole and 
phthalamine are generally carried out by coupling to an amine59. In particular, several 
different amino acids have been coupled to NBD using different conditions including 
different solvent (methanol, ethanol and ethanol/sodium acetate, DCM, DMF 
acetonitrile, methanol:water), different bases (potassium acetate, sodium hydrogen 
carbonate, triethylamine, Na2B4O7, K2CO3) and different temperatures (from room 
temperature to 80oC) and for different extensions of time (5 min to 48h)38–41,43,44,60. 
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Common side products observed when coupling amino acids to NBD is the substitution 
by hydroxyls present in the solvent resulting in impurities such as NBD-OH43 and NBD-
O-CH3
41.  
Therefore the applicability of NBD to PG dendrimers was studied using different 
derivatives of GLU (L-glutamic acid, L-glutamic di-ethyl ester, L-glutamic di-methyl 
ester and L-glutamic di-tert-butyl ester; Figure 3.29) in different conditions (varying both 
bases and solvents) to optimize the coupling reaction.  
   
Figure 3.29 – Reaction scheme of the different obta ined products tested to optimize GLU coupling 
to NBD  
Table 3.2 outlines all conditions tested for the coupling reaction. A common feature 
observed across all reactions was that the reaction started with a light orange color that 
evolves to a darker color of blue, brown, red and black tones. The difference in tones 
was dependent not only on the GLU derivative but also on the impurities formed. All 
reactions were followed by TLC (ethyl acetate/hexane (1:1 v/v)) and were terminated 
once the GLU spot did not test positive to ninhydrin. The results showed clear trends 
that both DMF and acetonitrile were the favorable solvents and that DIPEA and 
Cs2CO3 were the better bases. In fact, when using carbonate bases a clear trend of 
increasing yield was observed. For example the glutamic acid di-ethyl ester reaction 
with NBD had a yield of 50%, 73% and 88% when using Na2CO3, K2CO3 and Cs2CO3 
respectively. This is in line with previous reports of high yield reactions for conjugation 
of NBD to putrescine, tri-Boc-spermine or N-Boc-piperazine using Cs2CO3 as base in 
acetonitrile. Furthermore, the yield was increased with tert-butyl and methyl esters 
suggesting that the type of ester may contribute to the reaction. On the other hand, 
using strong bases, such as KOH, or methanol as solvent was detrimental for the 
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reaction. This was due to the formation of the side products as a consequence of direct 
reaction with NBD (Figure 3.30)43,61.   
Table 3.2 – Different conditions tested for couplin g of NBD to different glutamic acid derivatives; R 1 
and R2 denote the carboxyl portion of glutamic acid; 
R1; R2 group  Solvent  Base Yield / %  
Carboxyl 
 
DMF K2CO3 0% 
DCM  DIPEA 40% 
Acetonitrile  DIPEA  51% 
Ethyl ester 
MeOH Na2CO3 16% 
MeOH TEA 15% 
Acetonitrile TEA 98% 
DMF Na2CO3 50% 
DMF TEA 53% 
DMF KOH 27% 
DMF K2CO3 71% 
DMF 80oC K2CO3 73% 
DMF  Cs2CO3 88% 
Acetonitrile K2CO3 73% 
DCM  K2CO3 71% 
Methyl ester 
DMF DIPEA 96% 
DMF K2CO3 88% 
DMF Cs2CO3 92% 
t-butyl 
Acetonitrile Cs2CO3 82% 
Acetonitrile DIPEA 92% 
DCM  Cs2CO3 97% 
DCM K2CO3 88% 
DMF 80oC Cs2CO3 90% 
DMF Cs2CO3 97% 
DMF DIPEA 98% 
 
The pure NBD-GLU-OMe (26) and NBD-GLU-OtBu (27) (Figure 3.31) were then used 
to study the effects of acid and basic hydrolysis on these compounds. For this purpose, 
basic hydrolysis of methyl esters was carried out with LiOH/THF/Water, and acidic 
hydrolysis of tert-butyl esters was carried out with TFA. The basic hydrolysis showed 
multiple NBD peaks on the TLC and the hydrolysis was incomplete. Among the 
obtained products the common NBD-OH peaks were found on the 1H NMR. Similarly, 
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the TFA reaction produced several NBD peaks on the TLC, and the 1H NMR showed 
significant shift on the α-carbon hydrogen, which could be caused by the probable 
cyclization of the glutamic acid (data not shown).  
 
Figure 3.30 – 1H NMR of a side product from the reaction of glutam ic acid with NBD where the 
methanol directly substitute the chloride.  
Extending the NBD coupling to PG dendrimers, the fluorophore was reacted with NH2-
PG-OEt G0 (10), NH2-PG-OMe G0 (11) and NH2-PG-OtBu G0 (12) in DMF with 
Cs2CO3 or DIPEA, and the conjugates were obtained with a yield of 65%, 68% and 
44%, respectively. Similarly to the results obtained in the convergent synthesis 
approach, the bulkier derivative resulted in lower yield. Again, these results suggest 
that steric hindrance prevents the orthogonal attack of the amine to the NBD. 
The NBD-PG-OMe G0 (30) was then hydrolyzed with LiOH in THF/MeOH/water to 
afford the NBD-PG-OH G0 (31) as dark colored oil with a yield of 53%. However, the 
TLC showed that both precursors and the NBD-OH impurity were still present. On the 
other hand, the NBD-PG-OtBu G0 (32) was hydrolyzed with TFA and recovered with a 
yield of 35%. The 1H NMR showed multiple peaks for the dendrimer and NBD, which 
could be related to polymerization. It is therefore possible that the conversion of the 
secondary amine to a quaternary one may result in the release of NBD. However, no 
further experiments were carried to elucidate these low yields. The NBD-PG-OH G0 
(31) obtained from both hydrolysis was then activated with HBTU/HOBt/DIPEA and 
coupled to L-glutamic acid di-tert-butyl ester to afford the NBD-PG-OtBu G1 (33) (yield 
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of 55%). The TLC however showed multiple colored spots which suggested that NBD 
is not stable under the experimental conditions.  
 
Figure 3.31 – 1H NMR of NBD-GLU-OtBu (27) in deuterated chloroform  
3.2.4. Derivatization reactions of the core amine 
Because secondary amines can still be reactive (e.g. react with CDI62), the 
transformation of the amine of GLU was further studied. In order to test the viability of 
using a secondary amine to couple NBD, L-proline methyl ester was first used to 
optimize the reaction. The latter was coupled to the NBD using DIPEA or Cs2CO3 as 
base and afforded the NBD-proline-OMe (44) with a yield of 59% and 37% 
respectively. This suggested that secondary amines are still able to couple to NBD and 
therefore the modification of GLU amine should be a viable strategy. Alkylation of 
amines is widely used and this approach has been previously reported for the 
synthesis NBD-tri-Boc-spermine60. However, alkylation reactions can sometimes also 
methylate carboxylic acids63 or even the α-carbons64 depending on the type of strong 
base (LDA, methyl iodide (MeI)) used. Nevertheless, this is not problematic for the PG 
dendrimers since the core is restricted from the external environment, and these 
alterations are not expected to impact the overall structure (i.e. branching). As a result, 
mono-methylation of GLU was carried using different bases (Cs2CO3, LDA or NaH) in 
DMF as previously reported in the literature65,66. The direct alkylation with alkyl halides 
is a common practice for the formation of secondary amines but it is limited due to the 
possible over-alkylation that creates a mixture of primary, secondary and tertiary 
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amines as well as quaternary salts67. Both the starting amine and the product amine 
are nucleophiles and consequently it will be alkylated a second time when competing 
with the starting material. To this, the addition of an inorganic base in a polar aprotic 
solvent (DMF, DMSO, MeCN) is commonly used to prevent the overalkylation. In fact, 
Cs2CO3 has shown to not only promote mono-N-alkylations but also to suppress 
overalkylations, favoring secondary amine formation over tertiary amines67. However, 
performing the reaction in these conditions afforded the N-alkyl-GLU-OMe (36) and N-
alkyl-GLU-OH (37) in very low yields of around 10-34%. Subsequently, using the N-
alkyl-GLU-OMe (36) to further react with NBD-Cl in the presence of Cs2CO3 resulted in 
a TLC with multiple NBD peaks suggesting that the conversion of the amine promoted 
the formation of NBD side products (possibly due to slower reaction rate). Therefore, 
as an alternative, the NBD-GLU-OtBu (27) previously synthesized was reacted with 
MeI in the presence of Cs2CO3 to afford the N-alkyl-NBD-GLU-OtBu (40) (Figure 3.32). 
Again the TLC showed multiple spots of NBD and the desired product was obtained by 
preparative TLC in low yields. However, contrary to the previously observed cyclization 
of glutamic acid after TFA hydrolysis, the N-alkyl-NBD-GLU-OH (41) was obtained pure 
as a salt (Figure 3.33). On the other hand, when alkaline hydrolysis68 was used for the 
N-alkyl-NBD-GLU-OMe (39) it resulted in removal of the NBD, which limits this 
synthetic route.  
 
Figure 3.32 – 1H NMR of N-alkyl-NBD-GLU-OtBu (40) in deuterated ch loroform. The NBD peaks have 
a ratio of 1:1 to the α-carbon hydrogens and 1:2 ratio to the β and γ carbon hydrogens. Solvent peaks are 




Figure 3.33 – 1H NMR of N-alkyl-NBD-GLU-OH (41) in deuterated meth anol. The 1.39 ppm single peak 
corresponds to the alkyl group in a ratio of 1:3 of NBD to Alkyl. Solvent peaks are still present   
To further explore other amine modifications to use GLU-NBD as the core, the N-Boc-
glutamic acid was alternatively used since the amine is not primary but rather in 
resonance with the carbonyl. In this strategy, the alkylation of the amine69–71 would be 
followed by subsequently hydrolysis of the N-Boc and the secondary amine would then 
react with the NBD to afford the tertiary amine. It was previously reported that selective 
N-methylation of Boc-protected valine using MeI in the presence of NaH occurred 
because the carboxylate was protected by chelation with Na+ ions72. Moreover, based 
on previous reports, the use K2CO3 should not methylate the N-Boc amine
73. 
Therefore, to test this approach, methylation of the amine was tested with Cs2CO3. As 
a base, Cs2CO3 has shown advantages over bases in terms of yield and reaction time. 
In particular this base is advantageous when reactions are too sensitive towards strong 
bases or reactions that required a balanced base, stronger than other carbonates but 
weaker than hydroxides or alkoxides74. However, carrying the reactions with Cs2CO3 it 
was observed that the reaction did not progress. This may be due to the fact that the 
base is not strong enough to deprotonate the NH group as previously reported72. 
Therefore, NaH was used alternatively as base since in combination with MeI in DMF it 
has been reported to be able to methylate N-boc protected amines70.However, when 
tested with GLU, NaH only afforded the N-Boc-alkyl-GLU (38) in low yield of 10-15%. 
Furthermore, using NaH to directly conjugate the N-Boc-glutamic acid to NBD resulted 
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in multiple products (but not the desired product) and cyclization of the product was 
observed (data not shown) which is in accordance with previous reports75.  
Finally, formation of a sulfonamide76 of glutamic acid di-methyl ester was alternatively 
synthesized using NaH to afford the N-sulfonamide-GLU-OMe (43) (Figure 3.34). 
Sulfonamides can be obtained by the classical SN2 or acyl substitution displacements 
and are commonly used in drugs77,78. The product was obtained as a yellow oil with an 
improved yield of 32%. However, further attempts of reaction of this intermediate with 
NBD failed and therefore novel methods have to be attempted.  
 
Figure 3.34 – 1H NMR of N-Sulfonamide-GLU-OMe (43) in chloroform. The singlet peak at 2.88 ppm 
corresponds to the CH3 of the sulfonamide group and the amide group can be observed at 4.98 ppm. 
Overall, different core glutamic acid derivatives have the potential to be synthesized but 
the conditions need to be optimized since very low yields were obtained. In particular 
the N-alkyl-NBD-GLU-OH (41) could be a starting point to further grow the dendrimer. 
On the other hand, the N-sulfonamide-GLU-OMe (43) could also potentially be used 





2.2.5. Synthesis of different PG terminal groups   
As with other macromolecules and drug delivery systems only a portion of them 
reaches the intended tissues and most of it just accumulates in non-targeted areas. 
Being able to among other things, modulate the ability to cross cellular barriers, toxicity 
and elimination is also important alongside bioactivity. In this regard, dendrimers are 
valuable scaffolds due to the ease of functionalization of the terminal groups. Different 
terminal groups can determine cell viability even if made of amino acids, which can be 
attributed to conformation and charge distribution at the surface79. From the molecular 
modelling studies carried out earlier in this work for the PG dendrimers (Chapter 2), 
tryptophan and lysine were chosen to be present at the surface. However, these two 
reagents were not available at the time these experiments were performed and thus 
two other alternative reagents with similar chemistry were used. Therefore, instead of 
tryptophan, phenylalanine was chosen to optimize the reactions since it was the most 
similar in structure. As a result, small branches were synthesized to study if the 
reactions used for PG dendrimer could be applied to synthesize the terminal groups 
(Figure 3.35 and 3.36). However, it should be noted that even though the reactions 
between these branches on the PG G2 dendrimer would directly afford the desired G4, 
due to the previous results in the synthesis of PG dendrimers this was highly unlike to 
occur due to steric hindrance and therefore suitable strategies should be developed in 
order to accomplish this route.  
The L-phenylalanine methyl ester hydrochloride was reacted with Fmoc-glutamic acid 
using CDI as the coupling reagent to afford the Fmoc-glu-(phenylalanine)2 (47) as a 
white plastic-like product and with a similar yield (89%) to that obtained for the other G0 
dendrimers. Contrary to similar reactions with PG dendrimers, this reaction took more 
time to full completion and even after 12 hours the mono-substitution was still 
evidenced by TLC and therefore the reaction as extended for 24 hours. The product 
was then purified and the Fmoc was removed with piperidine affording the NH2-GLU-
(Fmoc)2 (45) as a white solid (Yield: 69%). Therefore, these results suggest that the 
conditions developed to PG dendrimers can also be applied for the synthesis of this 




Figure 3.35 – Structure of the hydrophobic terminal group synthesized as a small branch that 
would be coupled to the PG dendrimer. 
To further explore different types of terminal groups, Fmoc-ethylamine was coupled to 
N-Boc glutamic acid using the CDI coupling. The product of this reaction, N-Boc-GLU-
(Fmoc)2 (44), was obtained in considerably high yield (98%) since it precipitated in the 
solvent, and therefore could easily be recovered. Similarly to the Fmoc-GLU-
(phenylalanine)2 (47) the reaction took longer than the reactions for PG dendrimer. The 
product was however found to be insoluble in methanol, acetone, acetonitrile and 
hexane and soluble in DMSO and DMF. Therefore, the N-Boc was subsequently 
removed with TFA in DMF to afford the NH2-GLU-(Fmoc)2 (48) as a salt in quantitative 
yield. Theoretically, this branch would then be attached at the surface, and then de-
protected with piperidine to release the two amines. However, this compound would not 
be suitable since it is most likely to produce an insoluble polymer (due to the amount of 
terminal groups in the PG G3 dendrimer). Therefore, if this dendrimer were to be 
synthesized a different derivate and method (e.g. SPPS) would have to be explored.  
 
Figure 3.36 – 2D structure of the positive derivati ve to attach to the PG backbone 
Finally, a smaller terminal group that would present zwitterionic properties once de-
protected was tested. To this, Fmoc-glutamic acid 5-tert-butyl ester was reacted with 
ethylamine using the CDI coupling to afford the N-Boc-GLU(OtBu)-ethylamine (48) 
(Figure 3.37). This reaction was carried out by statistical selectivity. In this type of 
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reaction, the N-Boc-Glu(OtBu)(OH) was first activated with 1 equivalent of CDI. Once 
the reaction was finished, as monitored by TLC, this compound was slowly added to a 
solution with 20 equivalents of ethane-1,3-diamine. Because only small amounts are 
added at each time there is a higher amount of diamine precursors and therefore the 
monosubstitution is more likely to take place. However, under the conditions tested, the 
di-substitution still occurred in high amounts and therefore the desired product was only 
obtained with low yield (20%).  
 

















3.3 Materials and Methods 
 
All reactions were conducted under an inert atmosphere at room temperature unless 
otherwise specified. All solvents were purchased from common chemical suppliers and 
utilized as received without further purification. 
3.3.1 Materials 
L-glutamic acid diethyl ester hydrochloride (GLU-OEt), N,N,N′,N′-Tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), 1-Hydroxybenzotriazole 
hydrate (HOBt), 1-Hydroxy-7-azabenzotriazole (HOAt), N-[(Dimethylamino)-1H-1,2,3-
triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-
oxide (HATU), Triethylamine (TEA), N,N-diisopropylethylamine (DIPEA), 
(dimethylamino)pyridine (DMAP), dicyclohexylcarbodiimide (DCC), 
diisopropylcarbodiimide (DIPC), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
(EDC), Bromocresol, 4-chloro-7-nitrobenzofurazan (NBD-Cl), dichloromethane (DCM), 
tetrahydrofuran (THF), methanol (MeOH), ethanol (EtOH), dimethylformamide (DMF), 
hexane, cyclohexane, diethyl ether, ethyl acetate, acetone, acetonitrile (ACN), dimethyl 
sulfoxide (DMSO), n-butanol, isopropanol, ninhydrin, silica gel 60 (50-70 mesh). From 
Bachem it was acquired Fmoc-L-glutamic acid (Fmoc-Glu(OH)). From Nova Biochem 
was acquired glutamic acid di-tert-butyl ester hydrochloride (Glu-(OBoc)) were all 
acquired from Sigma-Aldrich. N-Hydroxysuccinimide was acquired from AlfaAesar. 
1H and 13C NMR spectrum were recorded in deuterated solvent (chloroform, methanol, 
water, dimethylsulfoxide) using a Bruker Avance system 400 MHz with ultrashield 
Bruker magnet and Broadband probe or in a 500 MHz Oxford magnet and QNP 
cryoprobe. Tetramethylsilane (TMS) was used as internal standard in organic 
deuterated chloroform. All NMR data was analysed using SpinWorks 4 and chemical 
shifts are expressed in parts per million (ppm). Peaks are described as follows: singlet 
(s), doublet (d), triplet (t), quartet (q), multiplet (m) and for undistinguished peaks 
classified as broad (br) 
Liquid chromatography-mass spectrometry (LC/MS) was used to determine the mass 
spectra and compound purity using a Shimadzu LC/MS 2020 (pump: Shimadzu LC-
20AD; autosampler: Shimadzu-SIL20AC HT); detector: Shimadzu-SPD-20A between 
220-254 nm). The nebulizing gas flow was set to 1.5 L/min and the system was fitted in 
a Xterra MS C18 column from Waters with a flow rate set to 1 mL/min with a mobile 
phase of water and acetonitrile both spiked with 0.1% formic acid.   
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Thin Layer Chromatography (TLC) was carried out in TLC silica gel 60 F254 Analytical 
Chromatography. Staining solutions included: PMA, crystal iodine, bromocresol, 
ninhydrin. 
3.3.2 Synthesis  
Fmoc-GLU-NHS (1);  
IUPAC: (S)-bis(2,5-dioxopyrrolidin-1-yl) 2-((((9H-f lupren-9-yl) methoxy)carbonyl) 
amino)pentanedioate 
Fmoc-glutamic acid (0.2M) was suspended in DCM and 
mixed with 2.1 equivalents of NHS and 2.1 equivalents 
of DCC for 1 hour at 0oC. The reaction mixture was 
then allowed to warm to room temperature for another 2 
hours. The white crystalline precipitate composed of the 
DCC urea (DCU) was then removed by filtration and the reaction mixture was then 
washed with water and brine and dried with anhydrous MgSO4. The organic layer was 
evaporated under vacuum on a rotary evaporator to give a white solid (Yield: 65%). 
Rf 0.5 on TLC (methanol:ethyl acetate 95:5 v/v). 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 7.69 (d, 2H, Fmoc CH), 7.53 (d, 2H, Fmoc 
CH), 7.32 (t, 2H, Fmoc CH), 7.26 (t, 2H, Fmoc CH), 4.37 (br, 2H, Fmoc CH2), 4.16 (br, 
2H, Fmoc CH + αC CH), 3.14 (br, 1H, CH2), 2.75 (br, 8H, NHS CH2), 2.57 (br, 1H, 
CH2), 2.38 (br, 1H, CH2), 2.28 (br, 1H, CH2). 
Fmoc-GLU(OtBu)-GLU-OEt (2);  
IUPAC: (S)-diethyl 2-((S)-2-((((9H-fluoren-9-yl)met hoxy) carbonyl)amino)-5-(tert-
butoxy)-5-oxopentanamido)pentanedioate 
Fmoc-GLU(OtBu)(OH) (0.2M) was dissolved in DCM and 
2.1 equivalents of NHS and 2.1 equivalents of DCC were 
added to react for 30 min at 0oC. A mixture of glutamic 
acid diethyl ester (2.2 eq.) and TEA (2.2 eq.) pre-
activated in situ in ice-cold DCM was then slowly added. 
The reaction was carried out at 0oC for 45 minutes after which was allowed to warm to 
room temperature and stirred for 24 hours. The mixture was filtered to remove the 
DCU, and the filtrated DCM was washed with citric acid, water and brine. The organic 
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layer was then dried over anhydrous MgSO4 and evaporated to afford a white solid 
(Yield: 98% in presence of DCU). 
Rf 0.7 on TLC (methanol:ethyl acetate 95:5 v/v). 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.00 (d, 1H, NH), 7.67 (d, 2H, Fmoc CH), 
7.51 (d, 2H, Fmoc CH), 7.32 (t, 2H, Fmoc CH), 7.23 (t, 2H, Fmoc CH), 6.31 (d, 1H, 
NH), 5.30 (br, 1H, αC), 4.50 (br, 1H, αC), 4.46 (br, 1H, Fmoc CH), 4.2 (m, 2H, Fmoc 
CH2), 4.10 (m, 4, Ester CH2), 2.63 (m, 4H, CH2), 2.10-2.00 (m, 4H, CH2), 1.40-1.28 (m, 
15H, CH3) 
Fmoc-GLU(OH)-GLU-OEt (3); 
IUPAC: (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)a mino)-5-(((S)-1,5-diethoxy 1,5-
dioxopentan-2-yl)amino)-5-oxopentanoic acid 
Ten equivalents of TFA were added dropwise to a 
solution of Fmoc-GLU(OtBu)-GLU-OEt (2) in DCM in ice 
for a period of 1 hour. The reaction mixture was then 
stirred for another 2 hours and monitored using TLC. 
After two hours TLC showed complete disappearance of 
the initial spot and the appearance of a UV spot that was reactive towards bromocresol 
(yellow color). The solvent was then removed under vacuum and co-evaporated 
several cycles with a mixture of THF and ethyl acetate to give a crystalline white solid 
(in quantitate yield) that was used without further purification or analysis.  
Fmoc-PG-OEt G0 (4);  
IUPAC: (2S, 2’S)-tetraethyl 2,2’(((S)-2-((((9H-fluo ren-9-yl)methoxy)carbonyl)amino) 
pentanedioyl)bis(azanediyl)dipentanedioate 
(A) DCC coupling:  Fmoc-glutamic acid (0.2-0.3M) 
was suspended in ice-cold DCM in a round-bottom 
flask flushed with nitrogen and pre-activated for 30 
minutes with DCC (2.05-2.5 eq) in the presence of 
NHS or HOBt (2.05-2.5 eq) and catalytic amounts of 
DMAP. Significant amounts of crystalline urea precipitate formed composed of DCU. 
Glutamic acid diethyl ester hydrochloride was neutralized in situ to generate the free 
amine with TEA or DIPEA in ice-cold DCM and was then added dropwise to the 
previous mixture and allowed to react for 45 minutes before warming to room 
temperature and left stirring overnight. The precipitate composed of DCU was filtered 
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out and glacial acetic acid was added to the reaction mixture to decompose the 
unreacted DCC for 1 hour. The remaining newly precipitated DCU was then filtered and 
the solvent was replaced with ethyl acetate and washed with cold 0.1M HCl (or 0.1M 
sulfuric acid or 10% critic acid), ice cold water, ice cold 5% bicarbonate and brine,  
dried over MgSO4 or NaSO4 and concentrated under vacuum in a rotary evaporator to 
give a transparent solid (Yield: 88-98%). Further purification included short silica gel 
column chromatography with chloroform:methanol (92:8 or 95:5 v/v), ethyl 
acetate:methanol (95:5) or THF:n-hexane (1:2 v/v), trituration from cold ethanol or 
methanol upon addition of water or crystallization using cold acetonitrile. Cold ethyl 
ether was added to remove small amounts of impurities which were then removed by 
centrifugation at 2000 rpm. Alternatively, using the same protocol, Fmoc-GLU(OH)-
GLU-OEt (3) was used as the core molecule to react with 1.1 eq. of DCC and 1.1 eq. of 
NHS and 1.1 eq. of glutamic acid diethyl ester to yield the Fmoc-PG-OEt G0 (Yield: 
92%). 
(B) DIPC coupling:  Similar to DCC coupling, the reaction was carried out with 2.5 eq. 
of DIPC instead of DCC. After 12 hours stirring at room temperature, glacial acetic was 
added to the reaction mixture and stirred for 1 hour. The reaction mixture was then 
washed with 0.1 HCl, water, 5% NaHCO3 and brine and dried over MgSO4. The solvent 
was then evaporated and the product was purified through a silica gel column 
chromatography using ethyl acetate:methanol (95:5) as eluent (Yield: 80%).  
(C) EDC coupling:  This reaction was carried out according to previous protocols69. 
The Fmoc-glutamic acid (0.15-0.2 M) was mixed with HOBt (2.1- 2.5 eq.) or NHS (2.1-
2.5 eq.) in DMF or DCM at 0oC, and cold EDC (2.1-2.5 eq) was then added to the 
mixture. After stirring for 30 min, glutamic acid diethyl ester (2.1-2.5 eq) generated in 
situ with DIPEA or HOBt was added to the reaction mixture and the reaction was 
carried out for 24h-48h at room temperature. The solvent was then removed under 
vacuum on a rotary evaporator and the product was dissolved in ethyl acetate and 
washed with aqueous HCl (0.1M), water and brine. The organic phase was then 
removed in vacuum to give a white solid (Yield: 44-60%) and no further purification was 
performed. 
(C) HATU coupling:  Fmoc-glutamic acid (0.2M) in a round-bottom flask flushed with 
argon was reacted with 2.05 of HATU in anhydrous DMF for 1 hour at 0oC. Excess of 
glutamic acid diethyl ester hydrochloride (2.2-3 eq) was then slowly added dropwise 
and the solution became yellow. The reaction mixture was stirred for 10 minutes after 
which DIPEA (2.2-10 eq) was added dropwise under argon. The reaction mixture was 
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then allowed to react at 0oC for 45 minutes, warm up to room temperature and stirred 
for 8 hours. The DMF was then removed and the product was re-dissolved in 
chloroform or ethyl acetate and washed with 10% citric acid, saturated NaHCO3, water 
and brine. The organic phase was then dried over MgSO4 and the solvent was 
removed under vacuum to afford a white solid (Yield: 70-75%).  
Rf 0.7 in THF/n-hexane (1:4 v/v); 0.8 in ethyl acetate:methanol 95:5 or 90:10 v/v)  
1H NMR (CDCl3, 400MHz, 300K) δ(ppm):1.07-1.26 (12H, m, CH2CH3), 1.75-2.44 
(12H,m, CHCH2CH2), 3.94-4.19 (10H, m, CH2CH3 and CHCH2CH2 and CH-CH2-O), 
4.59 (2H, q, CH-CH2-O),  4.66 (2H, CHCH2CH2), 5.28 (1H, d, NH), 7.241 (2H, t, Ar), 
7.32 (2H, t, Ar), 7.51 (2H, d, Ar), 7.59 (1H, d, NH), 7.68 (2H, d, Ar), 7.97 (1H, d, NH). 
13C NMR (CDCl3): δH (400 MHz); 14.01(CH2CH3), 14.13(CH2CH3), 14.20(CH2CH3), 
26.67(CH2), 26.82(CH2), 29.35 (CH2), 30.42 (CH2), 30.59(CH2), 32.15(CH2), 
47.11(Ar-CH), 51.58(CH), 51.62(CH), 53.53(CH), 60.56(CH2CH3), 60.70(CH2CH3), 
62.28(CH2CH3), 62.27(CH2CH3), 67.04(R-CH2), 76.85(CHCl3, solvent), 120.21(ArC), 
125.00(ArC), 127.0(ArC), 127.70(ArC), 141.22(ArC), 143.89(R-CH2-O-CO), 143.9 (R-
CH2-O-CO), 172.43(CO), 172.46(CO), 172.62(CO), 173.88(CO), 174.03 (CO). 
C38H49N3O12
 requires 739.80 g.mol-1; MS found MH+ 740.35 MW; M-Na+ 762.78 MW  
Fmoc-PG-OMe G0 (5);  
IUPAC: (2S, 2’S)-tetramethyl 2,2’(((S)-2-((((9H-flu oren-9-yl)methoxy)carbonyl) 
amino)pentanedioyl)bis(azanediyl)dipentanedioate 
(A) DCC coupling:  Similar procedure was followed 
as that used for Fmoc-PG-OEt G0 (4) by using the 
DCC/NHS/DMAP coupling method and by using the 
glutamic di-methyl ester hydrochloride for adding the 
branching layer. Yield: 88-95%. 
(B) HATU or HBTU coupling:  Similar procedure to a ppreviously published protocol 
was used13,80. Briefly, Fmoc-glutamic acid (0.2-2M) was activated with HBTU (2.1 eq) 
or HATU (2.1 eq) and HOBt (2.2 eq) and DIPEA (4 eq) in anhydrous DCM, DMF or 
DMA for 30 min to 1 h at 0oC or room temperature followed by addition of the glutamic 
acid dimethyl ester hydrochloride (2.2 eq). After 10 minutes the reaction was allowed to 
warm to RT and reacted for 8 hours. The solvent was then evaporated and the product 
was re-dissolved in ethyl ester and washed with 10% citric acid, water, NaHCO3 and 
brine. The organic phase was dried over MgSO4 and the solvent removed under 
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reduced-pressure evaporation. Further purification was carried out by recrystallization 
in acetonitrile (Yield: 88-92%). 
(C) CDI coupling:  Fmoc-glutamic acid (0.2-0.3M) was mixed with 2.05-2.5 eq. of CDI 
in dry THF or dry DCM under argon for 3 hours before adding 2.15 eq. of glutamic acid 
di-methyl ester over a period of 30 min. The reaction was then stirred for 24 hours at 
room temperature. Additional CDI or glutamic acid di-methyl ester was added as 
required by monitoring the reaction by TLC. The solvent was then evaporated and the 
product re-dissolved in ethyl ester and washed with 10% critic acid, water, NaHCO3 
and brine. The organic phase was then dried over MgSO4 and the solvent evaporated 
under vacuum to afford a white crystaline plastic-like solid (Yield 97%). 
Rf 0.7 in THF/n-hexane (1:4 v/v); 0.8 in ethyl acetate:methanol 95:5 or 90:10 v/v).  
The product may be further purified by flash chromatography (eluent: ethyl acetate: 
hexane 3:1 v/v or chloroform:methanol 95:5) if required. 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 7.89 (d, 1H, NH), 7.67 (d, 2H, Fmoc CH), 
7.50 (d, 3H, Fmoc CH + NH), 7.33 (t, 2H, Fmoc CH), 7.24 (t, 2H, Fmoc, CH), 5.31 (d, 
1H, NH), 4.69-4.59 (m, 2H, αC), 4.2 (m, 2H, Fmoc CH2), 4.13 (m, 2H, Fmoc CH), 4.01 
(m, 1H, αC), 3.70-3.50 (s, 12H, Ester CH3), 2.39-1.87 (m, 12H, CH2) 
Fmoc-PG-OtBu G0 (6);  
IUPAC: (2S, 2’S)-tetra- tert-butyl 2,2’(((S)-2-((((9H-fluoren-9-yl)methoxy)carb onyl) 
amino)pentanedioyl)bis(azanediyl)dipentanedioate 
Reactions were carried out following a protocol 
similar to Fmoc-PG-OMe G0 synthesis (5) using the 
DCC/NHS (Yield: 96%), DIPC/NHS (Yield: 80%), 
EDC/HOBt (Yield: 55%) or CDI (Yield: 88-90%) as 
coupling agents. The glutamic acid di-tert-butyl 
ester hydrochloride was used as the branching unit 
for generation growth. The product was obtained as a white solid. Alternatively, the 
reaction was carried out in benzene for the CDI coupling (Yield: 85%). 
Rf 0.7 in ethyl acetate:methanol (95:5 v/v) 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.07 (d, 1H, NH), 7.68 (d, 2H, Fmoc CH), 
7.59 (d, 3H, Fmoc CH + NH), 7.33 (t, 2H, Fmoc CH), 7.21 (t, 2H, Fmoc, CH), 5.28 (d, 
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1H, NH), 4.55-4.28 (m, 6H, 3xαC, Fmoc CH2, Fmoc CH), 2.5-1.9 (m, 12H, CH2), 1.36-
1.30 (m, 36H, Ester CH3) 
13C NMR (CDCl3, 400MHz, 300K) δ(ppm): 172.65 (CO) 171.79 (CO) 169.70 (CO) 
143.82 (CO), 141.24 (CO), 127.75 (CO), 126.89 (R-CH2-O-CO), 125.30 (ArC), 120.02 
(ArC), 83.10 (ArC), 80.77 (ArC), 52.19 (R-CH2), 51.80 (CH), 47.28 (R-CH), 33.79 (CH), 
32.19 (CH), 31.82 (CH2), 31.60 (CH2), 28.0 (CHCH3) 27.04 (CH2), 25.69 (CH2), 25.48 
(CH2), 24.84 (CH2)   
Fmoc-PG-OH G0 (7);  
IUPAC: (2S, 2’S)-2,2’(((S)-2-((((9H-fluoren-9-yl)me thoxy) carbonyl)amino) 
pentanedioyl)bis(azanediyl)dipentanedioic acid 
(A) Acid hydrolysis of ethyl and methyl esters:  
Fmoc-PG-OEt G0 (4) or Fmoc-PG-OMe G0 (5) was 
refluxed with HCl, TFA or H2SO4 (10 eq. per ester) 
aqueous solutions in minimum acetone or ethanol for 
8-16 hours. The reaction was followed by TLC with the 
disappearance of the precursor spot to give a new UV 
spot (bromocresol active: yellow) at the origin (ethyl 
acetate:methanol 95:5 v/v). The solution was then 
cooled down and the compounds were extracted with ethyl acetate or DCM from the 
acidic aqueous layer to yield on average 40% of the expected mass. 
(B) Acid hydrolysis of tert-butyl esters:  De-protection of Fmoc-PG-OtBu G0 (6) was 
carried out with 4-10 eq. of TFA per ester in TFA:DCM (1:1 v/v) or TFA:DMF (1:1 v/v) 
ice-bath and reacted for 8-24 hours (the reaction slowly became pale yellow). The 
reaction was followed by TLC for the disappearance of the precursor dendrimer spot 
but no eluent was found to differentiate partial hydrolysis of the esters. The reaction 
mixture was concentrated by repeated co-distillation with DCM and ethyl acetate or 
toluene to give a viscous yellow oil with white crystalline solid (TFA salt form) 
(quantitative yield).  
When necessary further purification was carried out by re-dissolution of the product in a 
mixture of ethyl acetate:water (1:1 v/v) and addition of sodium hydrogen carbonate or 
HCl with vigorous stirring following by recovery with ethyl acetate. The organic phase 
was then dried with MgSO4 and the solvent removed under vacuum. A dense oil was 
recovered (Yield: 56%). 
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Rf 0.5 in 100% ethyl acetate when protonated, and at origin when deprotonated. 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 7.70 (d, 2H, Fmoc), 7.66 (t, 2H, Fmoc), 
7.38 (t, 2H Fmoc), 72.93 (t, 2H, Fmoc), 4.52-4.22 (m, 6H, Fmoc CH2, CH and 3xαC), 
1.91-2.39 (m, 12H, CH2).   
13C NMR (CD3COD, 400MHz, 300K) δ(ppm): 172.59 (CO), 172.57 (CO), 171.93 (CO), 
143.92 (CO), 141.42 (CO), 127.58 (CO), 126.99 (R-CH2-O-CO), 125.15 (ArC), 119.96 
(ArC), 62.26 (ArC), 60.71 (ArC), 51.77 (ArC), 51.70 (ArC) 47.08 (R-CH2), 32.10 (CH), 
30.68 (CH), 30.36 (CH), 29.43 (CH), 26.80 (CH2), 26.63 (CH2), 14.17 (CH2). 14.11 
(CH2), 14.03 (CH2) 
C30H33N3O12 requires 627.59 g.mol
-1; found M+H 628 g.mol-1 + M+Na+ 650.3 g.mol-1  
N-Boc-PG-OMe G0 (8);  
IUPAC: (2S, 2’S)-tetramethyl 2,2’-(((S)-2-(( tert-butoxycarbonyl)amino) 
pentanedioyl)bis(azanediyl)dipentanedioate 
(A) N-Boc-Glutamic acid was used as the core and a 
similar method to the synthesis of Fmoc-PG-OMe G0 
(5) using HBTU/HOBt/DIPEA or HOAT/HBTU/DIPEA 
in DMF was employed. For both coupling reagent 
systems the reaction was carried out for 12 hours 
after which the solvent was evaporated and the 
product was re-dissolved in ethyl acetate and washed 
with cold 10% citric acid (TLC showed no degradation of N-Boc), water, NaHCO3 and 
brine. The organic layer was then dried over MgSO4 and the solvent evaporated to give 
a crystalline white solid (Yield: 86-88% (for HBTU) and 84-99% (for HOAT).  
(B) The N-Boc-Glutamic acid was coupled with glutamic acid di-methyl ester 
hydrochloride by CDI coupling in a similar methodology for the Fmoc-PG-OMe G0 (5) 
to afford a crystalline white solid (Yield: 86-88%) 
Rf 0.5 (chloroform), 0.7 (chloroforom:methanol 90:10 v/v), 0.7 (ethyl acetate), 0.8 (ethyl 
acetate:hexane 1:1 v/v)  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 7.72 (br, 1H, NH), 5.0 (br, 1H, NH), 4.69 
(m, 1H, αC), 4.60 (m, 1H, αC), 3.91 (br, 1H, αC), 3.70-3.61 (s, 12H, Ester CH3), 1.79-
2.40 (m, 12H, CH2), 1.36 (s, 9H, N-boc CH3)     
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N-Boc-PG-OH G0 (9);  
IUPAC: (2S, 2’S)-2,2-(((S)-2-(( tert-butoxycarbonyl)amino)pentanedioyl) 
bis(azanediyl)dipentanedioic acid 
(A) Basic ester hydrolysis with NaOH:  N-Boc-
PG-OMe G0 (8) (0.01M) was refluxed with NaOH 
(10 eq. per ester) in methanol or THF at RT or at 
50oC for 6-12 hours26. The solution was then 
cooled down t room temperature, neutralized with 
HOAc and concentrated under vacuum. 
Alternatively, methanol was removed under vacuum and acidified with ice-cold 5% HCl 
or 10% citric acid to pH 3 and extracted to ethyl acetate followed by evaporation to 
dryness to obtain a sticky yellow oil (Yield: 70-80%). 
(B) Basic ester hydrolysis with LiOH:  Alternatively, hydrolysis of N-Boc-PG-OMe G0 
(8) was carried out with LiOH-H2O (2-10 eq. per ester) in THF:Ethanol (1:5) or 
water:THF (1:1) for 12-48 hours at room temperature. The aqueous layer was then 
acidified with 10% citric acid or 5% HCl or acetic acid to pH 3-5, diluted in brine and 
extracted with ethyl acetate or DCM70. The organic layer was then dried over MgSO4 or 
Na2SO4 and evaporated under vacuum to give a sticky yellow oil (Yield: 65-86%).  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.44-4.53 (m, 2H, 2x αC), 3.99 (t, 1H, αC), 
2.44-1.95 (m, 12H, CH2), 1.43 (s, 9H, N-boc CH3).   
C20H31N3O12 requires 505.47 g/mol; MS found M
+ 505.25 g/mol 
NH2-PG-OEt G0 (10);  
IUPAC: (2S, 2’S)-tetraethyl 2,2’(((S)-2-aminopentan edioyl) bis(azanediyl)) 
dipentanedioate;  
Fmoc-PG-OEt G0 (4) was dissolved in either DMF or 
DCM with varied amounts of piperidine (20-50% v/v; 5-
10 eq). The reaction was followed by UV and TLC and 
was completed after 2 hours. The solvent was then 
evaporated to afford a yellow oil with white solid 
precipitated in it. The oil was re-dissolved in ethyl 
acetate and washed with saturated NaHCO3 and brine. The organic layer was then 
evaporated and the residue was suspended in cold methanol or acetonitrile to remove 
most of the precipitate (Fmoc-piperidine) for several cycles.  
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When necessary column chromatography was carried out using ethyl acetate:methanol 
(95:5 or 80:20 v/v) or ethyl acetate:hexane (3:1 v/v) in the presence of trimethylamine 
(Yield 50-66%). Alternatively, the purification of the product was carried out by 
dissolving it in DMF and vigorous stir with n-hexane. Once phases separated, the DMF 
layer was washed 2x with n-hexane and evaporated under vacuum (Yield: 78%).  
Rf 0.5 (dendrimer) in ethyl acetate:methanol (95:5 v/v) that was active to ninhydrin 
(purple color) and bromocresol (blue color). Other TLC spot was found at 0.9 (Fmoc-
piperidine). Similar TLC spots were found with chloroform:methanol (92:8). Rf 0.2 
(dendrimer) in ethyl acetate:hexane (95:5). 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.72-4.62 (m, 2H, 2x αC), 4.22-4.05 (m, 
9H, Ester CH2 + 1x αC), 2.54-1.83 (m, 14H, CH2 + NH2), 1.27 (m, 12H, Ester CH3)  
13C NMR (CD3COD, 400MHz, 300K) δ(ppm): 174.30, 173.31, 170.12, 65.54, 61.75, 
55.17, 53.18, 34.85, 32.26, 31.27, 30.87, 27.48, 26.69, 26.09, 14.53 
NH2-PG-OMe G0 (11);  
IUPAC: (2S, 2’S)-tetramethyl 2,2’(((S)-2-aminopenta nedioyl)bis(azanediyl)) 
dipentanedioate 
(A) Fmoc removal with piperidine: Fmoc-PG-OMe G0 (5) 
was reacted with piperidine in a similar protocol used for 
NH2-PG-OEt G0 (10) to generate a yellow oil that was 
chromatographed with 5% methanol in ethyl acetate spiked 
with or without triethylamine (Yield: 40-68%).  
(B) N-Boc removal with TFA:  N-Boc-PG-OMe G0 (8) was dissolved in cold DCM 
(Alternatively DCM:methanol 10:1). TFA (10 eq) in equal volume to DCM was added at 
0oC dropwise over a period of 30 min. The reaction was then allowed to warm up to 
room temperature and stirred for 8-12 hours where the reaction mixture turned pale 
yellow. The solvent was then removed under vacuum in co-distillation with ethyl 
acetate, THF or toluene for several cycles. For further purification the residue was 
stirred vigorously with ethyl acetate or DCM and saturated NaHCO3 (alternatively ice 
cold NaOH aqueous solution61). Once phase separation the organic layer was washed 
with brine, dried over MgSO4 and concentrated under vacuum to afford a yellow oil 
(Yield: 80-91%).  
Rf 0.5 (dendrimer) in ethyl acetate:methanol (95:5 v/v) that was active to ninhydrin 
(purple color) and bromocresol (blue color); and 0.9 (Fmoc-piperidine).   
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1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.61 (m, 1H, αC), 4.49 (m, 1H, αC), 3.99 
(t, 1H, αC), 3.78-3.71 (s, 12H, CH3), 2.58-2.02 (m, 14H, CH2 + NH2) 
NH2-PG-OtBu G0 (12);  
IUPAC name (2S, 2’S)-tetra- tert-butyl 2,2’(((S)-2-aminopentanedioyl)bis 
(azanediyl))dipentanedioate 
Using Fmoc-PG-tBu G0 (6), the Fmoc removal was carried 
out by following the standard protocol used for NH2-PG-OEt 
G0 (10) using piperidine (4 eq) as base. The purification was 
carried out by diluting the oil in DMF and extracting the 
impurities with n-hexane or c-hexane following by 
evaporation of DMF. The product was then further washed 
with petroleum ether which did not solubilize the product but removed further impurities 
to afford a yellow oil (Yield: 65-79%) 
Rf 0.6 (dendrimer) in ethyl acetate:methanol (95:5 v/v) that was active to ninhydrin 
(purple color) and bromocresol (blue color) and rf 0.9 (Fmoc-piperidine). 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.46 (q, 1H, αC), 4.38 (q, 1H, αC), 3.16 (t, 
1H, αC), 1.72-2.50 (m, 14H, CH2 + NH2), 1.49 (m, 36H, Ester CH3)  
Fmoc-PG-OEt G1 (13);  
IUPAC: (3S,8S,11S,16S,21S)-tetraethyl 11-((((9H-flu oren-9-yl)methoxy) 
carbonyl)amino)8,16-bis(((S)-1,5-diethoxy-1,5-dioxo pentan-2-yl)carbamoyl)-
5,10,14,19-tetraoxo-4,9,15,20-tetraazatricosane-1,3 ,21,23-tetracarboxylate 
(A) Convergent synthesis:  Similar to the synthesis of 
Fmoc-PG-OEt G0 (4), Fmoc-glutamic acid was pre-
activated with DCC/NHS/DMAP for 30 min followed by 
the addition of NH2-PG-OEt (10) (2.5 eq) with equimolar 
amounts of TEA. The reaction was carried out for 80 
hours. The precipitate was filtered out and acetic acid 
was added for 1 hour to react with unreacted DCC. The remaining urea was filtered out 
and the reaction mixture was washed with HCl 0.1M, water, 5% NaHCO3 and brine. 
The organic solvent was then reduced under vacuum and the product was purified by 
silica column chromatography using chloroform:methanol (92:8) to give a white plastic 
solid (Yield: 44%). 
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(B) Divergent synthesis:  Fmoc-PG-OH G0 (7) was pre-activated with DCC (6 
eq.)/NHS (6 eq.)/DMAP(cat.) for 4 hours in a similar protocol to Fmoc-PG-OEt G0 (4), 
followed by addition of glutamic acid diethyl ester hydrochloride (10 eq.) with equimolar 
amounts of TEA. The reaction was stirred for 80 hours and standard purification was 
carried out to yield a white plastic solid. Further purification was carried out by silica 
column chromatography using hexane:ethyl acetate (7:3 v/v) (Yield: 73-88%).  
Rf 0.8 in ethyl acetate:methanol (95:5 v/v), acetone and hexane:ethyl acetate (7:3 v/v) 
and rf 0.7 in ethyl acetate 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 7.67 (d, 2H, Fmoc CH), 7.63 (d, 2H, Fmoc 
CH), 7.50 (d, 1H, 2x NH), 7.30 (t, 2H, Fmoc CH), 7.25 (t, 2H, Fmoc CH), 6.70 (d, 2H, 
NH), 6.55 (d, 2H, NH), 6.24 (d, 2H, NH) 4.47 (m, 3H, 3x αC), 4.13-3.94 (m, 23H, Fmoc 
CHCH2, Ester CH2 + 4x αC), 2.43-2.04 (br, 28H, CH2), 1.19 (m, 24, Ester CH3)  
Fmoc-PG-OMe G1 (14); 




The Fmoc-G0-OH (7) was activated with 
HATU/HOBt/DIPEA (4.2-5 eq) followed by addition of 
5-8 eq. of glutamic acid di-methyl ester formed in situ 
with DIPEA. The product was purified by washing the 
recovered organic phase with citric acid, water, 
NaHCO3 and brine. 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm):The NMR showed a complex mixture 
composed of Fmoc-PG-OMe G1 (14), Fmoc- de-protected PG-OMe G1 as well as the 








Fmoc-PG-tBu G1 (15);  




(A) The Fmoc-PG-OH (7) was pre-activated with 
DCC/NHS/DMAP (similarly to Fmoc-PG-OEt (13)). 
Glutamic acid di-tert-butyl ester hydrochloride (2.05-2.1 
eq.) with equimolar amount of DIPEA was then added. 
The product was purified by washing the organic phase 
with citric acid, water, NaHCO3 and brine and dried over 
MgSO4. (Yield: 85%). 
(B) Alternatively, Fmoc-PG-OH (7) was pre-activated with CDI for 4 hours followed by 
addition of glutamic acid di-tert-butyl ester hydrochloride (4.05-5 eq.) and the reaction 
was carried out for 72 hours at room temperature. The solvent was removed and the 
product re-dissolved in ethyl acetate and washed with 10% citric acid, water, 5% 
NaHCO3 and brine and dried over MgSO4. The organic phase was then removed and 
cold chloroform was added to filter impurities leaving a white solid (Yield: 62-80%) 
When necessary the product was further purified by preparative TLC (ethyl 
acetate:methanol 95:5 v/v) 
Rf 0.85 in ethyl acetate:methanol (95:5 v/v), acetone, rf 0.6 hexane:ethyl acetate (7:3 
v/v) and rf 0.7 on ethyl acetate 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.28-8.23 (d, 2H, 2x NH), 7.83 (d, 1H, NH), 
7.63 (d, 4H, Fmoc CH), 7.53 (d, 1H, NH), 7.42 (m, 1H, NH), 7.30 (t, 2H, Fmoc CH), 
7.24(t, 2H, Fmoc CH), 5.19 (d, 1H, NH), 4.67 (m, 2H, 2x αC), 4.5 (m, 2H, 2x αC), 4.36 
(t, 1H, Fmoc CH), 4.18 (m, 3H, Fmoc CH2 + αC), 3.99 (m, 1H, αC), 3.79 (m, 1H, αC), 











Fmoc-PG-tBu G1 (15) was dissolved in ice-cold DCM, 
and cold TFA (10 eq. per ester) was slowly added and 
the reaction was carried out for 12h. The organic 
solvent was then co-distilled with ethyl acetate multiple 
times and the obtained product was recovered as a 
dense orange oil.  When necessary the product was 
further purified by re-dissolution in water and acidification to pH 2-3 and extraction to 
ethyl acetate. (Yield: 56-72%).  
Rf at origin in ethyl acetate:methanol (5:95 v/v) that was active to PMA and 
bromocresol (yellow) 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 7.80 (d, 2H, Fmoc CH), 7.70 (d, 2H, Fmoc 
CH), 7.39 (t, 2H, Fmoc CH), 7.33 (t, 2H, Fmoc CH), 4.63-4.25 (m, 9H, Fmoc CH and 
CH2 + 6 αC), 3.45 (m, 1H, αC), 2.45-1.93 (m, 28H, CH2).     
C50H61N7O24 requires 1144.05 g/mol and MS found M
+ 1144.40 g/mol 
Fmoc-PG-OtBu G2 (17); 
IUPAC: (3S,8S,13S,16S,21S,26S,31S)-tetra- tert-butyl 11-((((9H-fluoren-9-yl13,21-
bis(((6S,9S,14S)-6,14-bis(methoxycarbonyl)-3,8,12,1 7-tetraoxo-2,18-dioxa-7,13-
diazanonadecan-9-yl)carbamoyl)-8,26-bis(((S)-1,5-di -tert-buthoxy-1,5 dioxopentan 
-2-yl)carbamoyl)-5,10,15,19,24,29-hexaoxo-4,9,14,20 ,25,30-hexaazatritriacontane-
1,3,31,33-tetracarboxylate 
Fmoc-PG-OH G1 (16) was pre-activated with CDI (10 
eq.) for 24 hours followed by addition of glutamic acid 
tert-butyl ester hydrochloride (12 eq.) and the reaction 
was allowed to stir for 7 days. The purification was 
carried out similarly to Fmoc-PG-OtBu G1 (15) and the 




1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 7.635 (br, 1H, Fmoc), 7.50 (br, 1H, Fmoc), 
7.28 (br, 1H, Fmoc), 7.19 (br, 1H, Fmoc), 6.62 (d, 4H Fmoc), 4.42-4.10 (m, 9H, Fmoc 
CH + CH2, 6x αC), 3.67-3.41 (m, 9H, 9x αC), 2.40-1.58 (m, 56H, CH2), 1.374 (m, 144H, 
Ester CH3).   
Fmoc-PG-OH G2 (18);  





The hydrolysis of tert-butyl esters of Fmoc-PG-
OtBu G2 (17) was carried out in a similar manner 
to that of Fmoc-PG-OH G1 (16) using TFA (20 
eq). The solvent was then removed in co-
distillation and no further purification was carried 
out.  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm):7.69 (d, 2H, Fmoc), 7.58 (br, 2H, Fmoc), 
7.27 (t, 2H, Fmoc), 7.23 (t, 2H, Fmoc), 4.38-3.86 (m, 18H, Fmoc CH2,CH and 15x αC), 
2.29-1.052 (m, 64H, CH2). 
Fmoc-PG-OtBu G3 (19);  
IUPAC: Not shown for clarity 
Structure:  Not shown for clarity; The structure is composed of Fmoc linked to a central 
GLU as the core and 2, 4, 8 GLU for each layer followed by 16 GLU-OtBu as terminal 
groups (Fmoc-GLU-GLU2-GLU4-GLU8-GLU16-OtBu) 
The synthesis of Fmoc-PG-tBu G3 (19) was carried out similarly to the synthesis of 
Fmoc-PG-OtBu G2 (17). However after washing the organic phase a very small 
amount of product was recovered. 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): too complex to directly assign the correct 





N-Boc-PG-OMe G1 (20); 
IUPAC: (3S,8S,11S,16S,21S)-tetramethyl 11-(( tert-butoxycarbonyl)amino)-8-16-
bis(((S)-1,5-dimethoxy-1,5-dioxopentan-2-yl)carbamo yl)-5,10,14,19-tetraoxo-
4,9,15,20-tetraazatricosane-1,3,21,23-tetracarboxyl ate 
Synthesis was carried out similarly to N-Boc-PG-OMe 
G0 (5) using CDI as the coupling agent. The product 
was washed with water and 5% NaHCO3 and then 
purified on a short silica gel column with 
cyclohexane/AcOET (8:2) to obtain a yellow oil (Yield: 
50%). 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 4.87-4.78 (m, 4H, αC), 4.14-4.09 (br, 2H, 
αC), 3.70-3.56 (s, 24H, Ester CH3), 2.40-1.90 (m, 28H, CH2), 1.32 (s, 9H, N-Boc CH3) 




N-Boc-PG-OMe G1 (20) was hydrolyzed with 
LiOH (10 eq. per ester) in a mixture of 
water:THF 1:1 for 24 hours at room 
temperature. The aqueous layer was then 
acidified with 10% citric acid to pH 3, diluted in 
brine and extracted with ethyl acetate or ether 
to yield a yellow oil (recovered mass: 38%) 
MS confirmed the presence of the product in small amounts and the 1H NMR showed 








NH2-PG-OEt G1 (22);  
IUPAC: (3S,8S,11S,16S,21S)-tetraethyl 11-amino-8,16 -bis(((S)-1,5-diethoxy-1,5-
dioxopentan-2-yl)carbamoyl)-5,10,14,19-tetraoxo-4,9 ,15,20-tetraazatricosane-
1,3,21,23-tetracarboxylate 
Fmoc-PG-OEt G1 (13) was mixed with 50% 
piperidine in DMF and stirred for 8 hours. The 
solvent was evaporated and the product was 
then dissolved in minimum methanol, mixed 
with silica and dried followed by purification by 
flash chromatography from a dry loading 
using ethyl acetate as eluent (Yield: 34%). 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.52-4.45 (m, 4H, αC), 4.22-4.12 (m, 16, 
Ester CH2), 4.05 (t, 1H, αC), 3.75 (m, 1H, αC), 2.43-1.86 (m, 28H, CH2), 1.26 (m, 24H, 
Ester CH3). 
NH2-PG-OMe G1 (23);  
IUPAC: (3S,8S,11S,16S,21S)-tetramethyl 11-amino-8,1 6-bis(((S)-1,5-dimethoxy-
1,5-dioxopentan-2-yl)carbamoyl)-5,10,14,19-tetraoxo -4,9,15,20-tetraazatricosane-
1,3,21,23-tetracarboxylate  
(A) Fmoc-removal:  Fmoc-PG-OMe G1 
(14) was reacted with 50% piperidine in 
DMF for 12 hours. The solvent was 
evaporated and the product was then 
purified through a preparative TLC with 
methanol:ethyl acetate (5:95 v/v). The 
product was re-dissolved in ethyl acetate 
and washed with saturated NaHCO3 and brine, and the organic phase was evaporated 
to yield a yellow gel (Yield: 65-78%). Alternatively, the DMF phase was washed with n-
hexane or cyclohexane and the DMF was then evaporated.   
(B) N-Boc  removal:  The N-Boc-PG-OMe G1 (20) was dissolved in cold DCM, and 
TFA (10 eq.) were slowly added under inert atmosphere. The reaction was stirred for 
12 hours and the DCM was co-distilled multiple times with ethyl acetate and THF. 
Rf 0.6 in methanol:ethyl acetate (5:95 v/v) with 1% TEA.  
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1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.23-4.12 (m, 4H, αC), 3.47 (t, 1H, αC), 
3.30 (m, 1H, αC), 2.96-2.85 (m, 24, Ester CH3), 1.92-1.43 (m, 28H, CH2), 1.26 (m, 24H, 
Ester CH3). 
N-Boc-PG-OMe G2 (24);  





N-Boc-PG-OH G1 (21) was pre-activated with 
HBTU/HOBt/DIPEA (8.5 eq.) for 24 hours before 
adding glutamic acid di-methyl ester (10 eq.) 
formed in situ with DIPEA. The reaction was 
stirred for 10 days. The product was then 
recovered by washing the product with 10% citric 
acid, water and brine and the organic phase was 
evaporated to obtain the product as a yellow oil (Yield 45%).    
Rf 0.6 on THF/n-hexane. 
1H NMR of the product recovered did not match the desired product but a possible 
partial degraded dendrimer. 
NBD-GLU-OEt (25);  
IUPAC: (S)-diethyl-2-((7-nitrobenzo[c][1,2,5]oxadia zol-4-yl)amino)pentanedioate 
L-glutamic acid diethyl ester hydrochloride (0.2M-0.6M) was 
dissolved in dry dichloromethane, chloroform:methanol (1:1 
v/v), DMF or acetonitrile in a presence of a base (1-4 eq. of 
TEA, DIPEA, Na2CO3, K2CO3 or Cs2CO3). The mixture was 
stirred for 30 min at room temperature and then mixed with 
NBD-Cl dissolved in the same solvent. The reaction mixture 
was then stirred for 2-12 hours protected from light at room temperature, 60oC (for 
DMF) or 80oC ( for ACN) after which the reaction turned into a dark brown color. The 
solvent was then evaporated and the product re-dissolved with ethyl acetate and 
washed with HCl 0.1M, water and dried over MgSO4. The solvent was then removed by 
rotary evaporation the and crude product was obtained as a dark solid. 
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Rf 0.7 in chloroform:methanol (7:3 v/v) colored orange/brown 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.40 (d, 1H, NBD), 7.59 (d, 1H, NBD), 7.02 
(br, 0.5H, αC) 6.19 (d, 1H, NH), 4.47 (br, 0.5H, αC), 4.27-4.03 (m, 4H, Ester CH2), 
2.58-2.28 (m, 4H, CH2), 1.24-1.14 (m, 6H, Ester CH3). 
C20H23NO4 requires 357.2 g.mol
-1; MS found M+H+ 358.2 g.mol-1 and M+Na+ 380.2 
g.mol-1. 
NBD-GLU-OMe (26);  
IUPAC: (S)-dimethyl 2-((7-nitrobenzo[c][1,2,5]oxadi azol-4-yl)amino)pentanedioate 
L-Glutamic acid di-methyl ester hydrochloride was coupled to 
NBD-Cl similarly to the NBD-GLU-OEt (25). The reaction was 
tested in different solvents including DCM, DMF, THF, MeOH 
and acetonitrile. Different bases (TEA, DIPEA, Na2CO3, 
K2CO3 or Cs2CO3) with different ratios and different 
temperatures (0oC, 25oC and 40oC) were also tested. 
Alternatively the NBD-Cl was added at 0oC and then refluxed at 48oC (acetonitrile) or 
80oC (DMF). The reaction turned from a light orange to a dark brown colour.  
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.50 (d, 2H, NBD), 7.67 (d, 2H, NBD), 6.28 
(d, 2H, NH), 4.14 (t, 1H, αC), 3.72-3.87 (s, 6H, Ester CH3), 2.70-2.22 (m, 4H, CH2)  
C13H14N4O7 requires 338.09 g.mol
-1; MS found M+ 338.01 g.mol-1 
NBD-GLU-OtBu (27);  
IUPAC: (S)-di- tert-butyl 2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)ami no) 
pentanedioate 
L-glutamic acid di-tert-butyl ester was coupled to NBD-Cl 
similarly to the NBD-GLU-OEt (25) and NBD-GLU-OMe (26) 
using DCM or acetonitrile as solvents and using DIPEA or 
Cs2CO3 as base at room temperature. 
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.40 (d, 1H, NBD), 6.1 
(d, 1H, NBD), 4.36 (b, 1H, αC), 2.41 (m, 2H, CH2) 2.21 (m, 2H, 
CH2), 1.47-1.28 (s, 18H, Ester CH3)  
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13C NMR (CD3COD) δ: 171.24, 168.46, 143.38, 142.78, 141.79, 135.09, 142.08, 82.71, 
80.52, 79.95, 55.26, 29.80, 27.21, 25.63. 
C19H26N4O7 requires 422.43 g.mol
-1; MS found M+H 423.00 g.mol-1 
NBD-GLU-OH (28);  
IUPAC: (S)-2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl )amino)pentanedioic acid 
(A) Direct coupling: L-Glutamic acid was reacted with 
NBD-Cl in acetonitrile using TEA or DIPEA as base similar 
the synthesis of NBD-GLU-OEt (25). The solvent was then 
evaporated and re-dissolved in an aqueous solution of HCl 
and extracted to ethyl acetate. The organic phase was 
reduced under vacuum to obtain a dark colored oil (Yield: 
54%).  
(B) From basic hydrolysis:  NBD-GLU-OEt (25) or NBD-GLU-OMe (26) were 
hydrolyzed using LiOH (10 eq./ester)/THF/Water. The reaction was stirred for 8 hours 
and then washed with ethyl acetate. The aqueous solution was then acidified with HCl 
0.1M and extracted to ethyl acetate. The organic phase was then dried over MgSO4 
and evaporated under vacuum to obtain a dark colored oil (yield: 30%) 
(C) From acidic hydrolysis:  NBD-GLU-OtBu was mixed with TFA (10 eq./ester) in 
DCM. The reaction was stirred for 8 hours and then extracted with ethyl acetate. The 
organic phase was then dried over MgSO4 and evaporated under vacuum to obtain a 
dark colored oil (Yield: 78%).  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm):8.49 (d, 1H, NBD), 6.65 (d, 1H, NBD), 4.00 
(q, 1H, αC), 1.89 (t, 2H, CH2) 1.12 (q, 2H, CH2) 
NBD-PG-OEt G0 (29);  
IUPAC: (2S,2'S)-tetraethyl 2,2'-(((S)-2-((7-nitrobe nzo[c][1,2,5]oxadiazol-4-yl) 
amino)pentanedioyl)bis(azanediyl))dipentanedioate 
The NH2-PG-OEt G0 (10) was mixed with 
different bases (NaHCO3, K2CO3, TEA, 
DIPEA) in different solvents (DMF, ACN, 
MeOH, EtOH) and reacted for 4-12h at 
room temperature or at 40-70oC. The 
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solvent was then reduced under vacuum and re-dissolved in ethyl acetate and washed 
with HCl 0.1M, NaHCO3, water and brine. The organic phase was then dried with 
MgSO4 and evaporated under vacuum to obtain a dark colored solid (Yield: 60-65%). 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 8.40 (d, 1H, NBD), 8.34 (d, 1H, NH), 6.79 
(d, 1H, NH), 6.23 (d, 1H, NBD), 4.76 (m, 1H, αC), 4.56 (m, 1H, αC), 4.19-4.01 (m, 13H, 
Ester CH2 + αC), 2.46-1.91 (m, 12H, CH2), 1.28-1.18 (m, 12H, CH3) 
C29H40N6O13 requires 680.66 g.mol
-1; MS found M+H 681.45 g.mol-1 
NBD-PG-OMe G0 (30);  
IUPAC: (2S,2'S)-tetramethyl 2,2'-(((S)-2-((7-nitrob enzo[c][1,2,5]oxadiazol-4-yl) 
amino)pentanedioyl)bis(azanediyl))dipentanedioate 
The NH2-PG-OMe G0 (11) was reacted with NBD-Cl 
similarly to NBD-PG-OEt G0 (29) to obtain a dark 
colored solid after purification (Yield: 68%). 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 8.40 (d, 
1H, NBD), 6.18 (d, 1H, NBD), 5.78 (m, 1H, NH), 4.51 
(m, 1H, αC), 4.37 (m, 1H, αC), 3.67-3.55 (s, 12H, 
Ester CH3), 2.78-2.46 (m, 12H, CH2), 1.28-1.18 (m, 12H, CH3) 
NBD-PG-OH G0 (31);  
IUPAC: (2S,2’S)-2,2’-(((S)-2-((7-nitrobenzo[c][1,2, 5]oxadiazol-4-yl)amino) 
pentanedioyl)bis(azanediyl))dipentanedioic acid 
NBD-PG-OMe G0 (30) was hydrolyzed with 
LiOH/THF/MeOH for 12 hours. The product was 
then acidified and extracted to ethyl acetate to 
obtain a dark colored oil (yield: 53%). 
 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm):8.63 (d, 1H, NBD), 6.76 (d, 1H, NBD), 






NBD-PG-OtBu G0 (32);  
IUPAC: (2S,2S’)-tetra- tert-butyl 2,2’-(((S)-2-((7-nitrobenzo[c][1,2,5]oxadiaz ol-4-
yl)amino)pentanedioyl)bis(azanediyl))dipentanedioat e 
NBD-GLU-OH (28) was pre-activated with CDI for 
30 min before adding glutamic acid di-tert-butyl 
ester (2.05-2.2 eq). The solvent was evaporated 
and the product was purified by preparative TLC 
using ethyl acetate as eluent (Yield: 44-67%).  
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.58-8.34 (d, 1H, NBD), 6.15 (d, 1H, NBD), 
4.9 (d, 1H,NH) 4.35-4.22 (br, 2H, αC), 4.04 (q, 1H, αC), 2.93-2.08 (m, 12H, CH2), 1.44-
1.26 (m, 36H, Ester CH3)  
C37H56N6O13 requires 792.39 g.mol
-1; MS found M+ 792.66 g.mol-1 
NBD-PG-OtBu G1 (33);  
IUPAC: (3S,8S,11S,16S,21S)-tetra- tert-butyl 8,16-bis(((S)-1,5-di-tert-butoxy-1,5-
dioxopentan-2-yl)carbamoyl)-11-((7-nitrobenzo[c][1, 2,5]oxadiazol-4-yl)amino)-
5,10,14,19-tetraoxo-4,9,15,20-tetraazatricosane-1,3 ,21,23-tetracarboxylate 
NBD-PG-OH G0 (31) was pre-activated with 
HBTU/HOBt/DIPEA in DMF for 2 hours. 
Glutamic acid di-tert-butyl ester (6 eq) was 
then added to the reaction mixture and stirred 
for 72 hours. The solvent was evaporated and 
the product was re-dissolved in ethyl acetate 
and washed with citric acid, water, NaHCO3 
and brine. The organic phase was then evaporated to obtain a dark colored plastic 
solid (Yield: 55%).  
1H NMR (CDCl3, 400MHz, 300K) δ(ppm): 8.41 (d, 2H, NBD), 6.17 (d, 2H, NBD), 4.98 







NBD-PG-OtBu G3 (34);  
IUPAC: Not shown for clarity 
Structure:  Not shown for clarity; the core is composed of NBD linked to GLU, followed 
by 2, 4 and 8 GLU for each layer and 16 GLU-OtBu as terminal monomers (NBD-GLU-
GLU2-GLU4-GLU8-GLU16-OtBu) 
Fmoc-PG-OtBu (19) was mixed with piperidine in DMF and the reaction was carried out 
at room temperature for 7 days after which NBD was added and reacted for another 7 
days. The product was then isolated from a preparative TLC to obtain the color spot 
that did not match the same Rf as NBD-Cl or NBD-OH (Yield: not determined due to 
small amounts) 
1H NMR showed that even after preparative TLC the product is impure and it was too 
complex to assign correctly the peaks and integration. Two duplet at 7.65 and 6.60 
suggests the presence of NBD (possibly complexed) and it was in an integration ratio 
compatible with a possible PG-OBtu G3. 
N-Boc-NBD-GLU-OH (35);  
IUPAC: (S)-2-((tert-butoxycarbonyl)(7-nitrobenzo[c] [1,2,5]oxadizol-4-yl)amino) 
pentanedioic acid 
N-Boc glutamic acid was mixed with DMAP in THF. NBD-Cl 
was then added to the previous solution and stirred for 24 
hours. The solvent was evaporated and the product was 
then re-dissolved in citric acid and extracted to ethyl 
acetate (Yield: 33%). 
1H NMR: complex NMR with multiple products (multiple 
NBD species). Peak at 5.96 (d, 1H) indicates the presence of NBD attach to glutamic 
acid with a ratio of ~1:9 to a singlet at 1.35 (possibly n-Boc); 2.29 ppm (m, 2H, CH2), 







N-alkyl-GLU-OMe (36);  
IUPAC: (S)-dimethyl 2-(methylamino)pentanedioate 
(A) Glutamic acid di-ethyl ester hydrochloride (0.2 M) was 
dissolved in DMF or acetonitrile with Cs2CO3 and MeI at room 
temperature or 90oC81–83. The reaction was carried out with 
vigorous stirring for 24 hours. The solvent was then evaporated 
and the product re-dissolved in ethyl acetate and washed with water and brine. The 
organic solvent was then removed under vacuum to obtain a yellow oil.    
(B) L-Glutamic acid di-methyl ester (0.1M) was dissolved in THF and treated by slow 
addition of LDA (1.1-2 eq) at -78oC for 2 hour followed by addition of methyl iodide (10 
eq). The reaction was allowed to warm to room temperature and was stirred for 24 
hours under argon. The reaction mixture was then diluted in DCM and washed with 
water.  
(C) L-Glutamic acid di-methyl ester hydrochloride (0.1M) was added dropwise to a 
suspension of a sodium hydride (0.4 M 60 wt% dispersion in mineral oil or alternatively 
washed with hexanes) in DMF at 0oC under inert atmosphere. Methyl iodide (10 eq.) 
was then added and stirred for 4 hours. Once the reaction was completed (as indicated 
by TLC), the mixture was stirred at room temperature for 30 min84,85. The reaction was 
quenched by addition of ice and the resulting mixture was diluted with ethyl acetate and 
washed with hexane followed by washing with brine and dried over MgSO4. The 
organic phase was then evaporated under vacuum.  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 5.98 (q, 1H, αC), 4.77-4.62 (s, 6H, Ester 
CH3), 4.26 (t, 2H, CH2), 3.98 (m, 1H, CH2), 3.73 (m, 1H, CH2), 3.14 (s, 3H, N-CH3). 
N-alkyl-GLU-OH (37) ; 
IUPAC: (S)-dimethyl 2-(methylamino)pentanedioate 
Sodium hydride was slowly added to a round bottom flask 
containing L-glutamic acid and MeI in ice cold THF. The 
reaction was then allowed to warm up to room temperature, 
and stirred for 12 hours. Ethyl acetate was then added, and 
the organic phase was washed with NaHCO3 (sat). Yield: 34% 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 5.74 (m, 1H, αC), 3.53 (s, 3H, N-CH3), 




IUPAC: dimethyl 2-(( tert-butoxycarbonyl)(methyl)amino)pentanedioate 
N-Boc glutamic acid was mixed with MeI (10 eq) in ice cold 
THF. Sodium hydride was slowly added and the reaction 
was allowed to warm to room temperature and stirred for 24 
hours. Ethyl acetate was added and the organic phase was washed with 10% citric 
acid, water and brine.  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.96 (br, 1H, CH), 3.72-3.60 (s, 6H, CH3), 
3.22 (t, 2H, CH2), 2.95 (m, 1H, CH2), 2.71 (m, 1H, CH2), 2.65 (s, 9H, N-Boc CH3), 2.10 
(s, 3H, CH3), 1.70 (m, 1H, NH) 
N-alkyl-NBD-GLU-OMe (39);  
IUPAC: (S)-dimethyl 2-(methyl(7-nitrobenzo[c][1,2,5 ]oxadiazol-4-yl)amino) 
pentanedioate 
N-alkyl-Glu-OMe (36) was reacted with NBD-Cl (1.5 eq) using 
DIPEA (1.5 eq) or Cs2CO3 (1.5 eq) as base in DCM. The 
reaction was carried out at room temperature for 18 hours. The 
solvent was then evaporated and the product was purified by 
preparative TLC using methanol:ethyl acetate (5:95) as eluent. 
Rf 0.8 in methanol:ethyl acetate (5:95) 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 8.4 (d, 1H, NBD), 6.20 (d, 1H, NBD), 4.53 
(q, 1H, CH), 3.76 (s, 3H, CH3), 3.67 (s, 3H, CH3), 2.50 (m, 2H, CH2), 2.24 (m, 2H, CH2), 
1.46 (s, 3H, CH3)  
N-alkyl-NBD-GLU-OtBu (40);  
IUPAC: (S)-di- tert-butyl 2-(methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino) 
pentanedioate 
NBD-GLU-OtBu (27) was reacted with MeI and DIPEA in THF for 
12 hours at room temperature or with Cs2CO3 in DCM or DMF. 
Ethyl acetate was then added and the reaction was washed with 
water, NaHCO3 (sat) and brine. The organic phase was then 
evaporated and the product was purified by preparative TLC 
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using methanol:ethyl acetate (5:95) as eluent. 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 8.40 (d, 1H, NBD), 6.19 (d, 1H, NBD), 
4.37 (br, 1H, CH), 2.38 (m, 2H, CH2), 2.19 (m, 2H, CH2), 1.45-1.34 (s, 21H, Ester CH3 + 
N-CH3).  
N-alkyl-NBD-GLU-OH (41);  
IUPAC: (S)-2-(methyl(7-nitrobenzo[c][1,2,5]oxadiazo l-4-yl)amino)pentanedioic 
acid 
TFA (10 eq.) was slowly added to N-alkyl-NBD-GLU-OtBu (40) 
in dry ice cold DCM. The reaction was allowed to warm up to 
room temperature and was stirred for 8 hours. The solvent was 
then co-distilled with ethyl acetate and THF to obtain a yellow 
oil (Yield: 98%).  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 8.40 (d, 1H, NBD), 6.32 (d, 1H, NBD), 
4.26 (t, 1H, CH), 2.38-2.00 (m, 4H, CH2), 1.88 (s, 3H, N-CH3).  
NBD-proline-OMe (42);  
IUPAC: (S)-methyl 1-(7-nitrobenzo[c][1,2,5]oxadiazo l-4-yl)pyrrolidine-2-
carboxylate 
L-proline was mixed with DIPEA or Cs2CO3 in acetonitrile or 
THF, and NBD-Cl was then added in equimolar amounts at 
room temperature. The solvent was removed, and the product 
was re-dissolved in ethyl acetate and washed with water and 
brine and dried over MgSO4. The organic phase was then 
evaporated under vacuum to obtain a dark orange plastic. 
(Yield: 59% (DIPEA), 37% (Cs2CO3)) 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 8.39 (d, 1H, NBD), 6.04 (br, 1H, NBD), 








IUPAC: (S)-dimethyl 2-(methylsulfonamido)pentanedio ate 
L-glutamic acid di-ethyl ester was mixed with sulfonyl chloride 
(1.02 eq) in THF at room temperature (or alternatively at 40oC). 
DIPEA (2.1 eq) or NaH was slowly added over a period of 20 min 
and the reaction was stirred for 12 hours. The solvent was then 
evaporated under vacuum and re-dissolved in ethyl acetate and 
washed with 10% citric acid, water and brine (Yield: 13%).   
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.98 (d, 1H, NH), 4.11 (m, 1H, CH), 3.73 
(s, 3H, Ester CH3), 3.62 (s, 3H, Ester), 2.88 (s, 3H, SO2CH3), 2.44 (m, 2H, CH2), 2.16 
(m, 1H, CH2), 1.89 (m, 1H, CH2) 
N-Boc-GLU-(Fmoc) 2 (44); 
IUPAC: (S)- tert-butyl-(1,19-di(9H-fluoren-9-yl)-3,8,12,17-tetraoxo -2,18-dioxa-
4,7,13,16-tetraazanonadecan-9-yl)carbamate  
N-Boc-glutamic acid was pre-activated with CDI (2.05 eq.) 
in THF for 30 min. Fmoc-Ethylenediamine hydrochloride 
was then added (2.05 eq.) and the reaction was stirred for 
12 hours at room temperature. The precipitated product 
was then filtered and washed with water and 10% citric 
acid to obtain a white solid (yield: 97%). 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 7.88 (d, 4H, Fmoc), 7.83 (br, 2H, NH), 
7.69 (d, 4H, Fmoc), 7.42 (t, 4H, Fmoc), 7.32 (t, 4H, Fmoc), 7.27 (br, 2H, NH), 6.78 (d, 
1H, NH), 4.28-4.21 (m, 6H, Fmoc CH2 + CH), 3.05 (m, 8H, N-CH2), 2.09 (t, 2H, CH2), 
1.84-1.70 (m, 2H, CH2), 1.37 (s, 9H, CH3)  
NH2-GLU-(Fmoc) 2 (45);  
IUPAC: (S)-bis-((9H-fluoren-9-yl)methyl) (((2-amino pentanedioyl) 
bis(azanediyl))bis(ethane-2,1-diyl))dicarbamate 
N-Boc-GLU-(Fmoc)2 (44) was mixed with TFA (10 eq.) in ice 
cold DCM and stirred for 8 hours. The solvent was co-




1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 8.42 (t, 1H, NH), 8.11 (br, 3H, NH), 7.91 (t, 
1H, NH), 7.82 (d, 4H, Fmoc), 7.61 (d, 4H, Fmoc), 7.36 (t, 4H, Fmoc), 7.23 (t, 5H, Fmoc 
+ NH), 4.21-4.11 (m, 6H, Fmoc CH2+CH), 3.64 (br, 1H, CH), 3.15-2.93 (m, 8H, N-CH2), 
2.10 (t, 2H, CH2), 1.85 (m, 2H, CH2).  
Fmoc-GLU-(phenylalanine) 2 (46); 
IUPAC: (2S,2’S)-dimethyl 2,2’-(((S)-2-((((9H-fluore n-9-yl)methoxy)carbonyl)amino) 
pentanedioyl)bis(azanediyl))bis(3-phenylpropanoate)  
Fmoc-glutamic acid was pre-activated with CDI (2.05 
eq) in THF for 30 min. L-phenylalanine methyl ester 
hydrochloride (2.1 eq) was then added and the reaction 
was stirred for 12 hours at room temperature. The 
precipitated residue was filtered and washed with water 
and brine to obtain a white solid (yield: 98%). 
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 7.68 (d, 3H, Fmoc + NH), 7.50 (d, 2H, 
Fmoc), 7.31 (t, 2H, Fmoc), 7.22-7.13 (12H, Fmoc + Aromatics), 5.29 (d, 1H, NH), 4.80 
(br, 2H, CH), 4.26-4.10 (br, 4H, Fmoc CH2 + CH, CH), 3.69 (s, 6H, Ester CH3), 2.99-
2.82 (m, 4H, CH2), 2.20-2.07 (m, 3H, CH2), 1.80 (m, 1H, CH2) 
Fmoc-GLU-(phenylalanine) 2 (47);  
IUPAC: (2S,2’S)-dimethyl 2,2’-(((S)-2-aminopentaned ioyl)bis(azanediyl))bis(3-
phenylpropanoate) 
Fmoc-GLU-(phenylalanine)2 (46) was mixed with 
piperidine (2 eq) in DMF at room temperature and 
stirred for 8 hours. The solvent was then evaporated 
under vacuum, and the product was purified by 
preparative TLC using ethyl acetate as eluent to obtain a white solid (yield: 69%) 
Rf 0.8 in ethyl acetate  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 7.29-7.12 (m, 10H, Aromatics), 6.39 (d, 
NH), 4.76 (m, 1H, CH), 3.97 (t, 1H, CH), 3.81 (t, 1H, CH), 3.16-2.94 (m, 4H, CH2), 2.50 






IUPAC: (S)- tert-butyl 5-((2-aminoethyl)amino-4-((tert-butoxycarbon yl)amino)-5-
oxopentanoate 
The synthesis was performed similarly to a 
previous published method69. Briefly, to a 
vigorously stirred solution of ethane-1,3-diamine 
(10 eq) in DCM at room temperature was added a 
solution of N-Boc-Glu(OtBu)(OH) previously 
activated with CDI (1 eq.) in DCM over a period of 
5 hours. The resulting solution was stirred for 24h at room temperature and then 
concentrated in vacuum. The obtained oil was then partitioned between DCM and 
Na2CO3 and concentrated under vacuum to obtain an yellow oil.  
1H NMR (CD3COD, 400MHz, 300K) δ(ppm): 4.33 (t, 2H, CH2), 3.97 (br, CH), 2.47 (t, 
2H, CH2), 2.35-2.23 (m, CH2), 2.06 (m, CH2), 1.86 (m, CH2), 1.45-1.40 (s, CH3) 
3.4. Conclusions 
 
This chapter describes the attempts of synthesizing the PG dendrimers candidates 
provided by molecular modelling. Different coupling reagents commonly employed in 
the synthesis of peptides were used for the synthesis of these dendrimers. Despite 
reactions carried out with DCC afforded the desired products in high synthetic yields for 
low generation, the side product urea that was formed was difficult to remove for higher 
generations. In fact, it was not possible to determine whether the urea was complexed 
or directly attached to the structure backbone for dendrimers higher than G1. 
Alternatively, other coupling agents were tested and, similar to DCC, showed high 
yields for low generations dendrimers and low yields for the higher generations. 
Moreover, some reagents such as uranium salts showed to be incompatible with 
certain derivatives of GLU. Furthermore, it was observed that the interplay between the 
core protecting group and the protecting groups of the branching monomers was 
important to carry these reactions. In fact, reagents that would not de-protect the 
protecting groups of the core at low generations resulted in de-protection at higher 
generations attributed to the increased reaction times. As a result, different core 
derivatives of GLU with different amine protecting groups were tested. Finally, the CDI 
coupling reagents provided a suitable alternative as coupling reagents. This reagent 
was able to afford the desired products in high yields and was easy to remove. 
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However, the synthesis of dendrimers of generation beyond G2 was not viable due to a 
combination of attached impurities and low yields. The overall trend of the results 
indicates that the side-chain of GLU may be too short and crowding effects may create 
severe steric hindrance. This is further supported by the literature. Therefore, 
alternative methods should be explored in the future such as the use of SPPS or other 
potent and selective coupling agents together with other glutamic acid derivatives. 
Alternatively, new modelling structures could benefit from the limited reactivity 
observed in this work and new branching alternatives could be tested that facilitated 
the synthesis and minimize the crowding effects. Nevertheless, the optimized reactions 
used for PG dendrimers successfully translated to the synthesis of the terminal groups. 
However, issues related with the physicochemical properties (too lipophilic) of the 
monomers issues resulted in limited solubility which would be incompatible with 
dendrimer growth. Therefore, new alternatives for protecting groups should be tested. 
Alternatively, this chapter described the coupling of NBD to the core. The attachment of 
NBD to the GLU was successful under various conditions but not for PG dendrimers. 
This effect was attributed to steric effects. Therefore alternative modifications to the 
NBD-GLU core were tested to prevent the secondary amine from further react when 
growing the PG dendrimers. Both alkylation and sulfonamide showed promising results 
and should be further explored in the future. However, even though selective alkylation 
was achieved it was obtained in low yield and further optimization is required. 
Nevertheless, the use of these modified cores could be used to further grow the 
dendrimers and would allow better tracking of the desired product as well as provide 
information regarding the surrounding environments during reaction by measuring the 
fluorescence properties of NBD. Overall, the results herein described open 
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The introduction of this chapter is presented as an unpublished review manuscript that 
originated from this work and is relevant for the discussion of this chapter (ready for 
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Cisplatin and other platinum(II) analogues are widely used in clinical practice as anti-
cancer drugs for a wide range of tumours. The primary mechanism by which they exert 
their action is through the formation of adducts with genomic DNA. However, multiple 
cellular targets by platinum(II) complexes have been described. In addition, the early 
events occurring at the plasma membrane, i.e., platinum-membrane interactions, seem 
to be involved in the uptake, cytotoxicity and cell-resistance to cisplatin. In fact, plasma 
membrane influences signalling events and perturbation of membrane organization and 
fluidity by cisplatin has shown to promote apoptotic pathways. This review discusses 
the sequence of events caused by lipid-platinum interactions, with emphasis on the 
mechanisms that lead to changes in the biophysical properties of the membranes (e.g. 
fluidity and permeability), and how these correlate with sensitivity and resistance 







Cisplatin (cis‐diamminedichloridoplatinum(II)) is a widely used chemotherapeutic drug 
to treat various types of cancers, including testicular, bladder, ovarian, breast, head 
and neck, and small and non-small cell lung cancers. Despite its effectiveness, 
cisplatin still displays significant side effects and mechanisms of resistance by cancer 
cells are widely reported. Therefore, combination therapies and innovative cisplatin-
based therapies have been pursued to improve its clinical use. These range from the 
development of more effective and less toxic cisplatin analogues, to the use of drug 
carriers that deliver cisplatin in a more controlled way1. Progress in this area is, 
however, dependent on the understanding of the mechanisms underlying cisplatin and 
other platinum(II) complexes action, toxicity and induced resistance. The primary target 
of cisplatin is the genomic DNA. Once inside the cell, cisplatin becomes activated and 
forms adducts with DNA, preventing further DNA replication that culminates in cell 
death2. Nonetheless, other mechanisms not dependent of DNA replication have been 
implicated in cisplatin cytotoxicity, including oxidative stress, modulation of calcium 
signaling and activation of various stress signaling cascades (reviewed in2).  
Besides its effects at the intracellular level, it is now recognized that cisplatin-induced 
cytotoxic events might start at the level of the plasma membrane (PM), where it directly 
interacts with proteins and lipids, causing alterations in membrane structure and 
biophysical properties3,4. Such alterations are likely to impact cell signaling events that 
result in cancer cell death. However, it may also have implications in the activation of 
mechanisms that lead to cancer cell resistance or those associated with side effects. In 
this review, we summarize the current knowledge on cisplatin-membrane interactions 
obtained from studies performed both in artificial membrane systems and living cells, 
and critically address how these interactions influence cell response to cisplatin. 
2. General considerations on the physicochemical pr operties of 
cisplatin and analogues  
Several platinum(II) complexes have been explored for their antitumor activity, 
commonly attributed to platination of nucleic acids. Among them, cisplatin has been the 
most studied but suffers from severe limiting side effects that have prompted second 
generation platinum(II) complexes. Cisplatin is a squared planar platinum(II) complex 
composed by a central metal atom coordinated with two chlorides and two ammonia 
molecules in a cis configuration (Figure 1). Even though the amines are relatively inert, 
the two chlorides are relatively labile ligands that are prone to nucleophilic substitution. 
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In fact, cisplatin in solution exists as an equilibrium of different neutral or positively 
charged “aquated” species (Figure 2)5,6. The equilibrium of these species is dependent 
on the pH, temperature and chloride concentration. It is generally accepted that in the 
blood, where a relatively high concentration of chloride is present, the equilibrium 
minimizes the formation of positively charged species. However, inside cells, where the 
chloride concentration is much lower, these forms are promoted. Cisplatin aquated 
form is much more reactive at forming coordinated intra- and inter-strand cross-links 
with DNA that cancerous cells cannot repair6. Despite the higher reactivity, the low 
chloride concentration inside the cells is however not the limiting factor to cisplatin 
cytotoxicity or resistance behavior since platinum accumulation and DNA platination 
was found to be similar in different cells lines with varied concentrations of chloride7.  
 
Figure 1 – Molecular chemical structure of several platinum(II) compounds studied for interaction with  lipid 
membranes 
Due to the inherent cytotoxicity problems associated with cisplatin, several analogues 
have been synthesized8 and have been tested for clinical use based on the balance 
between binding to nucleic acids, stability, water solubility, acceptable levels of toxicity 
and increased spectrum of activity. These modifications have been generally carried by 
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chelation with anionic groups (e.g. carboplatin and oxaliplatin) or alterations to the 
amine (e.g oxaliplatin) as can be observed in figure 1. Furthermore, other substantial 
modifications to platinum(II) complexes have been tested including the addition of 
aliphatic chains (e.g. miriplatin)9 or using a trans-configuration and positive charge as in 
the case of BBR3464 and BBR357110,11. These changes in platinum(II) complexes 
ultimately result in variations in size and spatial configurations that affect their 
permeation, hydrolysis and reactivity rate, as well as, impact on cells-resistance 
mechanisms12. Moreover, the different analogues form adducts with the DNA that are 
different from one another. For example, the formed adducts can be more hydrophobic 
or bulkier (e.g. oxaliplatin) and thus contribute to increased DNA synthesis inhibition. 
Overall these factors result in clinical differences as exemplified by carboplatin, which 
has shown lower kidney and nervous system toxicity compared to cisplatin13.   
 
Figure 2 – Cisplatin equilibrium in aqueous medium where it exchanges chloride with hydroxyls and wate r to 
form the so called aquated species  
Besides DNA as their primary target, cisplatin and its analogues have shown to have 
multiple off targeting interactions. Off target effects were early evidenced in patients 
where cisplatin caused hemolysis14, and the mechanisms of resistance that arise after 
prolonged exposure. It has been proposed that the labile chemistry of platinum(II) 
complexes is responsible for the associated off target effects, where chemical 
transformations lead to a dynamic cascade of cellular events . In particular, cisplatin 
has high affinity for N and S donors. Thus, covalent Pt-S complexes with proteins are 
relatively stable and can only be reverted by other strong nucleophiles or otherwise 
render an irreversible bond15. Therefore, even before cisplatin reaches the cells 
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membranes it encounters many obstacles. This is clearly observed by its high protein 
binding (>95%) and biological terminal half-life (60-90 hours)16.  
Upon reaching the cell, cisplatin and its analogues can also interact with a variety of 
biomolecules including membrane proteins, small molecules harbored at the surface of 
the bilayer as well as lipids. This interaction will affect its cellular uptake and efflux, and 
ultimately its bioactivity and toxicity. Hence, it is of uppermost importance to 
understand the fundamental interactions of platinum(II) complexes at biological 
interfaces, so that the mechanisms of toxicity can be understood and novel complexes 
can be designed. In particular, there has been an effort to understand the mechanisms 
by which cisplatin enters cells since its uptake is not fully understood15. Moreover, 
understanding the mechanisms leading to drug efflux and/or decreased intracellular 
accumulation is pivotal, since they determine drug efficacy and are associated to drug 
resistance mechanisms. Below we present a brief summary of the mechanisms 
involved in cisplatin uptake and efflux and the importance of cellular membranes for 
them.  
3. Brief overview on cellular uptake and resistance  mechanisms 
The entry of cisplatin in cells is a complex process6. Upon contact with the PM, cisplatin 
and its analogues need to cross the phospholipid bilayer to reach its primary 
intracellular target. In this regard, evidence suggests that the major mechanisms 
involved in cisplatin uptake are through passive diffusion and through facilitated 
transporters in particular organic cation transporters, such as, copper transporters 
(Ctr1)17. Transmembrane passive diffusion is a process that depends on both the size 
and hydrophilic/hydrophobic nature of the molecule. Cisplatin has a small size and no 
net charge and thus it is expected to enter via passive diffusion, even if low due to its 
hydrophilic nature. Indeed, studies in model membranes confirm the ability of cisplatin 
to cross the bilayer through passive diffusion18–20. Studies in cells also showed that 
cisplatin can be taken up by passive diffusion mechanisms since its accumulation by 
concentration gradient up to its saturation point was not the rate limiting factor18–20. 
Moreover, cisplatin structural analogues did not inhibit platinum accumulation inside 
cells. In addition, when cell transporters were inhibited (e.g. by temperature) there was 
still intracellular platinum accumulation to a certain extent21. Evidence further showed 
that cisplatin diffusion in DOPC membranes was much slower at low chloride 
concentrations22, further highlighting the importance of neutral charge of cisplatin in its 
diffusion. Finally, other platinum(II) complexes have showed higher diffusion rate due to 
their more hydrophobic nature23.  
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The permeation of drugs through the membrane also depends on its composition. 
Biological membranes are commonly perceived as entities displaying lateral 
organization into compositionally and functionally distinct domains. The biophysical 
properties of these domains are different and affect the interaction of drugs with 
membranes. It is thus not surprising that drug affinity for those domains can be different 
due to the packing density and free volume within those domains. The membrane 
fluidity has therefore a critical role in drug diffusion since the larger interior volume of 
membranes in the liquid-crystalline phase is more prone to accommodate molecules. 
On the other hand, the insertion of molecules into the lipid bilayer or the existence of 
specific interactions with lipids may cause changes in membrane structure and lateral 
organization. This can affect protein insertion and/or conformation within the 
membrane, which can be translated into changes in cell signaling and other 
membrane-associated cellular processes. Moreover, a variety of external factors (e.g. 
pH, concentration of ions) can influence membrane composition and fluidity that might 
result in a higher or lower uptake of platinum(II) complexes. In fact, several studies 
have shown that cisplatin accumulation and passive permeation into the cells could be 
modulated by a number of different factors including pH, osmolality, temperature, 
Na+K+ ATPase, docosohexaenoic acid, digitonin, genistein, halenaquinone and 
ouabain18,24–26. Furthermore, the different platinum(II) complexes are expected to have 
different metabolisms, and the resultant metabolites will interact differently with the lipid 
bilayer. As an example, the metabolism of oxaliplatin results in the formation of 
products that have shown greater cellular uptake while being more toxic than the 
precursor27–29.  
There is also several resistance mechanisms associated with treatment of cisplatin that 
result in reduced binding of the drug to the DNA. These include the ability of cells to 
repair cisplatin-induced damage, as well as increase of pro-survival events that detoxify 
the platinum (e.g. increase production of molecules with sulfhydryl groups such 
proteins, glutathione or metallothionins)30–32. Recently, the reduced intracellular 
accumulation of cisplatin has also been suggested to be a major factor for resistance. 
Cisplatin can trigger degradation of its transporter at the membrane interface resulting 
in lower influx rate33,34. Moreover, increased expression of MRP1 and MRP4 
transporters results in reduced accumulation of cisplatin and oxaplatin35. Similarly 
TMEM205 protein was found to be overexpressed in resistant cells and when 
transfected into sensitive KB-3-1 cells it conferred resistance to cisplatin by 
approximately 2.5 fold36. In addition, other studies have suggested that the lipid 
membrane composition may also play a crucial role in the intracellular accumulation of 
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cisplatin and thus contribute to lower platinum accumulation. It was shown that the 
overall membrane permeability of resistant cells is lower compared to sensitive cells25, 
thus resulting in a reduced intracellular cisplatin accumulation. However, whether this 
effect is due to changes in lipid composition is not fully understood37.  
In summary, the composition and biophysical properties of cellular membranes 
significantly affects cisplatin uptake. In addition, several intrinsic and extrinsic factors 
may modulate the features of biological membranes and thus influence cisplatin-
membrane interactions. Therefore, it is highly desirable to understand how these 
interactions occur prior to binding to nucleic acid so that new improvements can be 
carried in future platinum(II) analogues and/or delivery systems.  
4. Cisplatin interaction with lipid membranes  
4.1. Mechanistic interaction of cisplatin with lipids  
Despite the binding of cisplatin to phospholipids is in order of magnitude lower 
compared to proteins, it has been shown to still be relevant in cells15. In this regard, 
both the type of lipids in the membrane and the surrounding aqueous environment 
influence cisplatin-membrane interactions. This is supported by studies showing that 
binding of cisplatin to large unilamellar vesicles (LUV) composed of neutral lipids 
(DOPC, DOPE, SM) was negligible but significant in the presence of anionic charged 
lipids, such as, DOPA, DOPS, DOPG, phosphatidylinositol and cardiolipin5. The 
binding to these lipids was also found to be stronger in chloride free buffers. This 
suggests that the formation of aquated species of opposing charge is the factor 
determining the binding to anionic lipids38. On the other hand, direct observation of 
erythrocytes exposed to cisplatin showed evident changes in their shape suggesting 
that cisplatin affect the erythrocyte membrane structure39. Cisplatin was also directly 
observed by electron microscopy to be aggregated at the surface with extensions 
across the cell membrane of ovarian carcinoma cell line40. In addition, studies 
performed in rat human cell membranes suggested binding of cisplatin to cell 
membranes26 and lipid-cisplatin specific interactions, particularly in the lipid chain, were 
also detected in cells using Raman-spectroscopy 41–43. Altogether, these results 
indicate that cisplatin interacts with membrane lipids and may contribute to its action. 
Therefore, mechanistic studies that aim to understand the interactions that result from 
binding (charge-charge interactions) or coordination to the head groups and whether 




Several studies have been carried out to provide further insights into this issue, 
particularly, studies that take advantage of artificial membranes, where specific 
interactions can be more clearly investigated. Since model membranes correlate well 
with what is observed in cells, the specific molecular interactions with lipids can be 
used to correlate with cellular data. In this regard, NMR studies on platinum-lipid 
interactions have shown that cisplatin lowered the motion of lipids attributed to lipid-
protein interactions43,44. Upon interaction with DPPC LUV, cisplatin altered the pre-
transition of gel phase to ripple phase but not the main transition temperature of the gel 
to the fluid phase. This was attributed to rearrangement of the head groups with 
complexation of cisplatin to two phosphate headgroups, that did not cause alterations 
on the lipid chains (Figure 3)45. Similar results were observed for the cationic aquated 
species of cisplatin in DPPC LUV, where strong alterations in the headgroups 
consistent with gauche to trans transformation in the glycerol moiety were 
observed15,46. Additionally, these changes recovered slowly, in a process that started 
from the headgroups and extended to the interior of the membrane15,43. Despite the 
conformational changes on the lipid bilayer, no significant changes in the fluidity of the 
membrane were observed as measured by changes in fluorescence anisotropy of DPH 
and generalized polarization (GP) values for Laurdan in DMPC LUV39. However, this 
effect may be related to membrane composition. Indeed, evidence of phase alterations 
in the pig lipid extract bilayer were observed, consistent with the co-existence of at 
least 3 lipid phases, including a non-lamellar hexagonal II phase43,44. However, these 
alterations were not observed in model LUV composed of a mixture of 
phosphatidylcholine/cholesterol/PEG-DSPE (51:44:5) 47, showing the specificity of 
membrane lipid composition in cisplatin-mediated effects.  
 
Figure 3 – Interaction of cisplatin with DOPS and w ith two DPPC lipids. In the DPPC interaction it was  observed 
further changes in the glycerol group changing the common gauche configurations to a trans configuration. 
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Cisplatin interaction with the serine group of phospholipids (e.g. phosphatidylserine 
(PS)) has also been extensively studied. It was observed that cisplatin inserted into the 
inner monolayer of human erythrocytes and induced stomatocytic shape changes39, 
most likely due to the formation of cisplatin-PS complex39,48. PS is a negatively charged 
phospholipid that is mostly located in the inner leaflet of the PM of non-cancer cells. 
This lipid is crucial in many cellular events as it interacts with proteins anchoring them 
to the inner monolayer of the PM49. However, cancer cells present an increased level of 
PS in their external leaflet of the PM50,51. Thus, an increased level of this lipid on the 
external leaflet of the PM could promote changes on its surface charge and lipid 
packing, changing membrane biophysical properties and consequently its functioning 
and response to chemotherapy. In addition, PS influences the activity of enzymes 
including the Na+/K+-ATPase52 a transporter that has been reported to be involved in 
the uptake of cisplatin18,53. 
NMR studies suggest that cationic aquated cisplatin establishes an electrostatic 
interaction with PS, causing its reorganization54. This results in changes in the lipid 
bilayer, including the formation several lamellar phases54. Other studies showed that 
cisplatin induces structural perturbations in model membranes containing DAPS, but 
not in those composed of zwitterionic lipids39. Moreover, contrary to cisplatin-DPPC 
interaction, it was observed that the phosphate group was not responsible for platinum 
coordination to POPS but rather it formed a complex with both the carboxyl and amine 
group of the serine head group (Figure 2) that was stabilized by the phosphate group38. 
Together this evidence shows that lipid headgroup structure has a major role 
determining cisplatin-membrane interaction.  
In fact, the headgroups of lipids determine the hydrophilic/hydrophobic balance at the 
surface of the bilayer and have major influence on the conformation, transition from gel 
to liquid crystalline phase, hydration levels, as well as, penetration of water, ions and 
small molecules55,56. Even small alterations in the headgroup of phospholipids, such as, 
addition of an extra methyl in the glycerol moiety results in conformational changes of 
lipid bilayers57. Thus, coordination of cisplatin to serine groups of phospholipids is 
expected to result in changes to accommodate the platinum complex. It should 
however be stressed that platinum-PS complex formation is not always observed. In 
fact, the platinum-PS complex has not been detected in some cancer cells and in intact 
erythrocytes48,58. This has been attributed to the fact that cisplatin can react with other 
cellular components and not be available to coordinate with PS. Moreover, the 
membrane permeability was shown to be an important factor for the formation of 
platinum-PS complex. Indeed, in aged erythrocytes and in cells exposed to digitonin 
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where the membrane permeability was increased, the platinum-PS complex was 
detected48. 
Further insight into the interactions of platinum(II) compounds with lipid bilayers was 
obtained from other cisplatin analogues (Figure 1). As expected, the positively charged 
BBR3464 and BBR3571 exhibited higher levels of cellular uptake compared to cisplatin 
due to their enhanced hydrophobic nature. In addition, they were shown to interact not 
only with the phosphate groups but also with the core of the bilayer26. These analogues 
were shown to coordinate with DPPG, DPPA and DPPS and cause changes in the pre-
transition temperature of these lipids, but not of DPPE and DPPC. These interactions 
occurred rapidly within 20 minutes likely due to electrostatic and hydrogen interactions, 
followed by slower formation of platinum-lipid complexes as observed by 31P NMR26. 
Other analogues (Figure 1, complex (2) and complex (3)) were shown to cause phase 
changes consistent with hexagonal phase formation upon interaction with DMPC 
membranes59. The effect of structural modifications of the platinum complexes on their 
interactions with lipid membranes was further explored by comparing complex (2) and 
(3) with cisplatin. While cisplatin induced significant ordering of the alkyl chains with 
decrease in the area per lipid molecule and membrane elasticity, complex (2) only 
showed a small effect in the ordering59. Moreover, both complex (2) and (3) partitioned 
to the interior of the membrane whereas cisplatin accumulated at the surface59. It can 
therefore be concluded that the mechanisms underlying cisplatin and analogues-
membrane interactions depend both on the platinum(II) complex structure particularly, 
hydrophobic moieties, and membrane lipid composition. This interplay will influence the 
type of interactions (e.g electrostatic, covalent, etc.) and the depth at which these 
occur. Moreover, they will influence the organization, structure and properties of the 
membrane. Thus, it is fundamental that future studies integrate lipid interactions as a 
strategy to improve the toxicity profile of cisplatin. 
The membrane fluidity is also determined by its lipid composition and the interactions 
established between lipids and proteins. In this regard, several platinum(II) complexes 
were shown to increase the transition temperatures of human erythrocytes membrane, 
resulting in 1.4-3.5% increase in lipid membranes order15. In ascites cancer cells the 
lateral diffusion of phospholipids was also lower after treatment with a platinum(II) 
complex15, consistent with a cisplatin-induced decrease in membrane fluidity. The type 
and amount of aquated species, as well as, the anionic lipids appeared to be 
responsible for this effect. Indeed, platinum(II) complexes were able to increase the Tm 
of anionic (DPPG) but not zwitterionic (DPPC) phospholipids, indicating that the charge 
of the lipid head group also influences the interaction and the resultant cisplatin-
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induced effects. Such electrostatic interactions established between platinum(II) and 
phospholipids are likely to be responsible for the more rigid and less fluid membrane5. 
This is further supported by studies showing that the influence of ions in the aqueous 
environment (e.g. Ca2+, Mn2+, Mg2+. Cu2+, Zn2) altered the fluidity of the membrane by 
interacting with phosphates (e.g. electrostatic complexation) which in turn resulted in 
higher encapsulation of cisplatin into LUV (since the permeation was slower)60,61. 
These results seem to indicate a connection between the ability of platinum (II) 
complexes to establish electrostatic interactions in model membranes and decreased 
membrane fluidity induced by complexation with the headgroups. However, in 
biological membranes this interaction becomes much more complex, as it will be 
discussed in the next section. 
Besides changes in membrane fluidity it was also reported that cisplatin might create 
small conducting defects in the inner hydrocarbon core. Such defects increase ion 
passage, as shown by ion conducting studies in a phospholipid mix of egg yolk in 
presence of cisplatin6. These results also correlated well with in vitro studies in 
epithelial cells where a drop of 89% on the TEER was observed 24h upon addition of 
cisplatin62.   
Overall literature data highlight that cisplatin interacts with lipid bilayers but its effect 
are complex and dependent on a variety of extrinsic factors including pH and chloride 
concentration, as well as, membrane composition and other unknown factors61,63–65. In 
fact, the importance of the physical state of membranes for the mechanisms of cisplatin 
and other platinum(II) complexes interaction remains to be determined. It is likely that 
differences in membrane composition can lead to structural differences that in turn 
affect the permeability of cisplatin. Ultimately, understanding how drug-membrane 
interactions occur creates new opportunities to develop novel innovative drug 
development strategies. In particular tacking issues related to the bypass of 
mechanisms of drug resistance originated by efflux or the repair mechanism can further 
guide the development of newly improved platinum(II) complexes or DDS. 
4.2. Cell signaling modulation by cisplatin interac tion with cell membrane 
Cell signaling events are often dependent on membrane organization and structure. 
For instance, activation of apoptotic cascades has been related to changes on 
membrane biophysical properties fundamental for receptor clustering66. Since cisplatin 
is able to induce alterations in the fluidity of the membrane it is not unlikely that this 
drug might modulate signaling events upon its interaction with the membrane. In fact, 
relevant therapeutic concentration of cisplatin was shown to cause a transient increase 
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in membrane fluidity that persisted for 4h4. These changes on membrane fluidity were 
accompanied by the formation of large CD95 aggregates and the redistribution of 
CD95, together with the DISC-forming molecules FADD and procaspase-8 into PM lipid 
rafts4,67. The CD95 aggregates were found to be promoted by a rapid and transient 
activation of acid sphingomyelinase (aSMase)4, which occurred in response to a 
decrease in intracellular pH mediated by cisplatin via inhibition of NHE1 (Na+/H+ 
membrane exchanger-1)67,68. Interestingly, the activation of this signaling pathway 
correlated with the formation of ceramides that occur at the external leaflet of the PM 
due to aSMase-mediated sphingomyelin hydrolysis4,67,69. This is supported by previous 
studies showing that ceramide domains are important for the clustering of CD95 at the 
cell surface and subsequent amplification of CD95 signaling4,66,67,70. Increased aSMase 
activity with concomitant upregulation of FAS was also recently described71 in ovarian 
carcinoma A2780 cell line suggesting a common mode of action for cisplatin when 
used in the treatment of different cancer cells. It should however be stressed that the 
observed increase in membrane fluidity induced by cisplatin is biophysically not 
compatible with the formation of ceramide enriched domains since these are expected 
to be highly ordered72,73 and therefore cause a decrease in membrane fluidity, as 
already reported for live cells73. Therefore, changes in membrane fluidity observed in 
these cells upon treatment with cisplatin might derive from other factors, not related to 
ceramide formation. 
Other studies also suggested that cisplatin-induced membrane fluidification was 
implicated in activation of Fas death receptor pathway that in turn resulted in rapid and 
transient re-organization of F-actin microfilaments74. This is in agreement with the 
observation that cisplatin-induced damage to F-actin in proximal tubular cells occurred 
prior to changes in nuclear morphology75. Furthermore, F-actin damage may cause an 
increased monolayer permeability76. These observations are also in accordance with a 
work showing that cisplatin is able to induce permeabilization of the PM of T24 
cells5,38,77. The importance of cisplatin interaction with actin was further shown in 
human ovarian cancer cells where F-actin was indeed considerably remodeled by 
cisplatin, causing changes in cellular nano-mechanics and increasing cell stiffness78. 
This is of major importance since the polymerization of actin monomer (G-actin) and 
depolymerization of filamentous actin (F-actin) represent fundamental molecular 
processes critically involved in cell motility, morphology, transport, cytokinesis and 
intracellular signalling79,80. Therefore, cisplatin interference with actin might impair 
these activities increasing the toxic effects induced at the PM level.  
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However, literature data is controversial regarding the mechanisms by which cisplatin 
modulates cellular structural features. In accordance, it was shown that cisplatin 
induces changes in PS120 fibroblasts membrane morphologic features with the 
appearance of noticeable villosities and long protrusions but no changes were 
observed in cell stiffness or actin cytoskeleton structure81. This suggests that cisplatin 
has a direct effect on the bilayer and not on actin. It should however be stressed that 
different studies use different cell lines75,78,81, different cisplatin concentrations75,81 and 
different methods of analysis75,81 that might all contribute to the observed differences. 
In fact, it was already shown that the time required for cisplatin-induced cytoskeleton 
remodeling and loss of F-actin was concentration dependent75. 
Altogether, these studies suggest that cisplatin-induced changes on membrane 
biophysical properties and cytoskeleton structure might underlie the clustering of death 
receptors and activation of apoptotic cascades. These events occur upstream of 
platinum-DNA adduct formation and are likely to be the early steps contributing to 
cisplatin cytotoxicity.  
 
4.3. Resistance to cisplatin induced by changes on membrane 
biophysical properties and sphingolipid metabolism 
A large fraction of human malignancies rapidly becomes (or intrinsically is) insensitive 
to the cytotoxic effects of cisplatin30,31. Many studies have tried to elucidate the process 
responsible for the resistance to cisplatin treatment to overcome it and improve the 
success of the therapeutic regimen 30,31. The complexity of the multiple factors involved 
is however a major obstacle for the development of an effective strategy to overcome 
resistance. Besides, all the proposed targets are non-specific for cancer cells which 
further increase this challenge. 
Conversely, PM biophysical properties of cancer cells are known to be different from 
the ones of their non-cancerous counterpart82,83. Since cisplatin cytotoxicity starts at the 
PM level as discussed above, cancer cells PM could represent a good target not only 
for developing a specific and directed therapy but also for improvement of cisplatin 
mode of action. To this end, it is important to understand the differences between 
sensitive and resistant cells to cisplatin.  
Cisplatin-resistant ovarian cancer cell lines present a significantly higher cell stiffness 
compared to their cisplatin-sensitive counterparts78,84. Furthermore, an increase in 
sensitive cells stiffness was observed after cisplatin treatment whereas no alterations 
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were observed for resistant cells78. This is also in agreement with the studies showing 
that cisplatin-induced changes in the transition temperature of the membranes were 
directly correlated with the degree of cisplatin resistance. Indeed, no significant 
changes were observed when resistant cells were treated with cisplatin compared to 
cisplatin-sensitive cells or cells with intermediate sensitivity to cisplatin61,85,86. 
Furthermore, modulating the fluidity of the membrane also resulted in different 
response to cisplatin. In models of cells of intermediary sensitivity to cisplatin, 
increasing its fluidity of the membrane with isopropanol resulted in an additive effect of 
increased fluidity upon addition of cisplatin. On the contrary, decreasing the fluidity of 
these cells with menthol, canceled the effect of increased fluidity by addition of 
cisplatin85. This result also correlated with the toxicity of cisplatin on those cells. When 
isopropanol was added to those cells, cisplatin treatment resulted in more cell death 
compared to cisplatin treatment alone. On the contrary, adding menthol to those cells 
resulted in lower toxicity by cisplatin85.  
However, literature evidence is controversial regarding the overall effect of membrane 
fluidity as a mechanism of resistance to cisplatin. Despite similar lipid composition, 
human lung adenocarcinoma A549 cisplatin-resistance cells showed to have more fluid 
membranes compared to sensitive cells but the latter became even more sensitive 
after increasing the fluidity of the membrane with heptadecanoic acid37,61. On the 
contrary, A549 sensitive cells showed to have more fluid membranes and significant 
altered lipid composition compared to A549/DDP cisplatin-resistance cells61,86  which 
could be attributed to shorter unsaturated fatty acids which are known to decrease lipid 
packing and alter lateral diffusion87,88. Cisplatin itself also affected the membrane 
fluidity of these cells over time by increasing membrane fluidity and membrane 
microviscosity in sensitive and resistant cells, respectively89.Similarly, cisplatin-resistant 
breast cancer MCF-7/S cells had an increased content of cholesterol and SM 
suggesting a decrease in membrane fluidity compared to cisplatin-sensitive MCF-7/CP 
cells90. 
In addition, cisplatin resistant ovarian cancer cells were shown to present a highly 
organized actin architecture with a more robust actin cytoskeleton and stress fibers 
compared to cisplatin sensitive cells78,84. A highly dense F-actin network could thus 
create a barrier preventing cisplatin uptake and conferring resistance or inefficacy of 
the drug, for instance by influencing cell membrane biophysical properties, including 
membrane fluidity78,84. Moreover, the membrane potential of human epidermal KCP-20 
carcinoma cells resistant to cisplatin was found to be hyperpolarized compared to the 
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low level resistant KB-CP.5 and sensitive KB-3-1 cell line from where they were 
originated, due to an increased expression of K+ channels on their PM37.  
Finally, as mentioned above, it has been described that cisplatin cytotoxic mechanism 
comprises the activation of aSMase4,67,71. However, the activation of this pathway also 
seems to be dependent on cell sensitivity to cisplatin71. Accordingly, while aSMase 
pathway is activated in ovarian carcinoma A2780 cell line the same is not observed for 
the cisplatin-resistant counterpart A2780/C30 cell line71. Even 24h after treatment no 
alterations were observed in the levels of FAS, FASL, BCL2, CASPASE-3 and -9 
transcripts corroborating the resistant state of the cells to cisplatin71. These results 
evidence the importance of aSMase activation and consequent changes on PM 
biophysical properties in the mechanism underlying cisplatin-induced cell death. 
Moreover, it also highlights that a dysregulation of sphingolipids metabolism on 
resistant cancer cells can be implicated in the development of such resistance, as 
already describe for other therapeutic regimens91. 
In fact, sphingolipids are ubiquitous components of eukaryotic cell membranes known 
to be involved in a variety of cellular processes including proliferation, growth, 
differentiation, apoptosis and membrane structure92–94. Dysregulation of their 
metabolism is evident in various pathological conditions including cancer91,95–97. 
Formation of ceramide in response to a variety of stimuli is typically a hallmark for the 
activation of cell death pathways98,99. Accordingly, it is not surprising that cells treated 
with cisplatin show elevation in ceramide levels. Indeed, elevation in C16-, C18- and C-
20 ceramide species was observed in BKM sensitive cells to cisplatin100. However, no 
changes in ceramide levels were observed in DKO cisplatin-resistant cells100, 
suggesting that these cells developed mechanisms to prevent ceramide-induced cell 
death. In addition to changes in the ceramide pathway, cisplatin-resistant cells tend to 
overexpress glucosylceramide synthase101,102, and have higher levels of 
glycosphingolipids with longer carbohydrate chains and α-hydroxy fatty acids103. The 
distribution of the α-hydroxy groups of fatty acids in the hydrogen bonding region of the 
lipid bilayer, will influence membrane structure and interaction with intrinsic proteins103. 
These changes might contribute to impairment in signaling cascades including those 
leading to cell death. Such observations placed sphingolipid metabolism in the 
spotlight, as one of the target pathways for the development of therapeutic strategies to 
treat cancer disease. Accordingly, studies using different cancer cell lines have already 
shown that modulating the level of certain SLs and specific enzymes from sphingolipid 
metabolism is a good strategy to increase cells sensitivity to cisplatin19,97,101,104,105, but 
also to other anticancer drugs106–109. 
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As suggested above, the observed differences on membrane biophysical properties 
and actin structure of cisplatin-resistant cells could be the direct cause of resistance 
due to changes on membrane structure and consequent impairment of receptors 
clustering and intracellular signaling that could lead to a decreased apoptotic response 
to cisplatin in resistant cells. The passive diffusion and intracellular accumulation of 
cisplatin could also be reduced by an increase in lipid membrane packing, limiting its 
cytotoxic effect as observed for the confluence-dependent resistance phenomenon88. 
However, these differences could also have an indirect contribution by promoting 
changes on the structure and/or function of transmembrane proteins, impairing their 
functioning and, altering their binding and/or response to cisplatin. For instance, it is 
known that P-glycoprotein has greater affinity to substrates when the lipid bilayer is in 
the gel phase than in the fluid phase110. Moreover, protein kinase C migrates to PM 
when activated by cisplatin111. Alterations on the membrane composition and properties 
could alter protein kinase C binding to the PM and hence its activity and cell sensitivity 
to cisplatin action. Finally, cisplatin destabilizes membrane anchoring of actin filaments, 
leading to rearrangement of filamentous actin network and overall loss of cellular 
processes69. 
Overall, the evidence presented herein suggests that sphingolipid metabolism and 
membrane biophysical properties are two interconnected factors that determine 
cisplatin-induced cell death and/or development of cisplatin-resistance mechanisms. 
5. Innovative cisplatin-based therapeutic strategie s 
There has been a tremendous effort in designing new platinum(II) based drugs or to 
develop and improve new delivery strategies to target tumors. Because platinum(II) 
complex have inherent clinical problems, it has been extensively studied the use of 
drug delivery systems to modulate their toxicity. There have been several types of drug 
delivery systems tested but, generally, they are used to circumvent solubility problems, 
modulate release rates, avoid resistance mechanism and avoid non-tumor 
tissues112,113.  These types of drug delivery have been extensively tested and are 
outside of the scope of this review. However, honorable mentions have to be given to 
liposomes since they provide interesting information regarding platinum(II) complexes 
interaction with lipids. Liposomes have been commonly used for platinum formulations 
such as SPI-077 and Lipoplatin for cisplatin and Lipoxal for oxaliplatin114. These lipidic 
nanoparticles protect cisplatin from the outside biomolecules that would normally react 
with platinum(II) complexes and then fuse with cells releasing its contents. 
Interestingly, cisplatin in a lipid suspension of MLVs with equimolar amounts of 
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dioleoyl-phosphatidylserine (PS) and dioleoyl-phosphatidylcholine (PC) showed to be 
more cytotoxic than cisplatin or cisplatin mixed with the lipids115.  
Another interesting case from the use of liposomes has been the combination with 
NDDP (Bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II)) and miriplatin (Figure 
1.1). In particular, miriplatin is a phospholipid dicarboxylic acid platinum complex that 
has been developed for the hepatocellular carcinoma. Both these complexes are highly 
insoluble and thus liposomes offer an alternative for their use. However, in the case of 
NDDP the lipid composition of the liposome was shown to determine its biological 
activity and toxicity. In fact, using liposomes composed of DMPC, DMPG:DMPC (7:3 
and 3:7) as well as DMPG, it was observed that the presence of DMPG was essential 
for NDDP activity. These studies demonstrated that NDDP was inactive, and the 
reaction intermediate between DMPG and NDDP was the active product9,116–118. 
Interestingly, even though miriplatin has similar structure to NDDP, it is active on its 
own and not requiring DMPG. Nevertheless, the loading capacity of different liposomes 
to miriplatin was shown to be higher for DMPC, DMPG and DPPC in comparison to 
HSPC, DPPG and DSPG9.  
Also worth mentioning are the delivery system that take advantage of sphingolipids119–
123 or modulate sphingolipid metabolism124, as a synergistic strategy to enhance 
cisplatin-induced cell death. Examples of such strategies include reports of drug 
delivery systems that combine both the effect of the encapsulated anti-cancer drug with 
the effects of sphingomyelin or ceramide to increase the intracellular levels of ceramide 
and enhance the apoptosis, even in resistance cell lines. In general, the use of 
liposomes in this strategy has shown significant transport of the drug across the 
plasma membranes with enhanced accumulation of ceramide levels that lead to 
increased sensitivity to the cytotoxic effects of the drug119–123. However, to the best of 
our knowledge, the combination with SL-based drug delivery systems has not been 
studied for platinum(II) based drugs and thus further research is needed.  
6. Conclusions 
The clinical use of platinum(II) complexes and in particular cisplatin has been limited 
due to side effects and resistance mechanisms that arise on continuous treatment. 
These effects are not limited to changes in the primary target of cisplatin, such as, 
enhanced DNA repair mechanisms but rather due to a multitude of other molecular 
targets, such as, lipids. Platinum(II) complexes interact directly with lipids and induce 
phase changes that are dependent on plasma membrane lipid composition and other 
external factors. However, these interactions are complex and not fully understood. 
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The design of novel platinum(II) chemotherapeutics should therefore account for these 
interactions and its consequences on platinum accumulation and efficacy in cells. 
Therefore, new modifications in the platinum(II) complexes should not only confer 
stability to reaction with other cell components (e.g. steric hindrance on the ZD0473) 
but also focus on permeation through resistant cells. The increased knowledge 
regarding cisplatin-lipid interaction should therefore contribute to a better 
understanding of the anti-tumor activity and how to overcome the mechanisms that 
determine resistance. 
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The results of this chapter are presented as an unpublished original manuscript ready 
for submission.  
PAPER 5 (Results) - Effect of cisplatin and its cationic analogue in th e 
phase behavior and integrity of model lipid bilayer s 
 
Abstract 
Increasing evidence suggests a critical role of lipids in both the mechanisms of toxicity 
and resistance of cells to platinum(II) complexes. In particular, cisplatin and other 
analogues were shown to interact with lipids and transiently promote lipid phase 
changes both in the bulk membranes and in specific membrane domains, such as, the 
lipid rafts. However, these processes are complex and not fully understood. In this 
work, cisplatin and its cationic species formed at pH 7 in low chloride concentrations 
were tested for their ability to induce phase changes in model membranes with different 
lipid composition. To this end, fluorescent probes that partition to different lipid phases 
were used to report on the fluidity of the membrane and a leakage assay was 
performed to evaluate the integrity of these vesicles. The results showed that 
platinum(II) complexes induced only small decrease in membrane fluidity at high 
infestation concentrations, preferentially in membranes containing gel phase, such as, 
DPPC and ceramide-enriched membranes. Moreover, at high concentration 
platinum(II) complexes were prone to compromise the permeability of the membranes 
without inducing its collapse or aggregation.  
Keywords : cisplatin, aquated cisplatin, membrane fluidity, membrane permeability, gel 







Cisplatin (cis-diaminedichloroplatinum(II)) is a widely used anti-cancer drug in clinical 
practice in a variety of tumors1. Inside cells, genomic DNA is the primary cellular target 
of cisplatin and other platinum(II) complexes with which they form cross-linked 
adducts2. However, growing evidence suggests that other non-DNA targets have an 
important role in cisplatin’s cytotoxic action3. In fact, one of the major limitations 
associated with platinum(II) complexes are the mechanisms of resistance in cells that 
are not dependent on DNA adduct formation and includes reduction of platinum 
accumulation inside the cell4–6. These resistance mechanisms are multifactorial and still 
largely unknown.  
In this regard, membrane lipids were shown to be involved in both the mechanisms of 
cytotoxicity and resistance. Before reaching its primary target, cisplatin needs to cross 
the plasma membrane, which can occur via passive diffusion and receptor-mediated 
uptake (e.g. organic cation transporters)3,7. The passive diffusion depends on the 
surrounding environment, including chloride concentration and pH, which influences 
the formation of “aquated” platinum species (AqCis). These have different 
physicochemical properties and thus interact differently with lipids and lipid 
membranes8. Furthermore, the membrane lipid composition and permeability were 
linked to the resistance mechanisms of cells to platinum(II) compounds4–6, and 
membrane modulators, such as digitonin, were shown to increase the absorption of 
platinum complexes into cells9. Cisplatin is also able to directly interact with 
phospholipids headgroups and further induce lipid phase changes, including non-
lamellar phases (e.g. hexagonal II phase10). The binding of platinum complexes to the 
head group of lipids was also shown to induce structural changes at deeper sites of the 
lipid membrane7,11, but these effects were transient and recoverable within a few 
hours7,12. On the other hand, whether complexation is relevant for cisplatin mode of 
action is still not fully understood12.  
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Finally, the molecular response regarding lipid metabolism was also linked to the 
toxicity of cisplatin in cells via activation of apoptotic pathways. Evidence suggests that 
activation of death signaling pathways might involve the lipid raft domains13. Indeed, 
cisplatin was shown to induce ceramide (Cer) formation in lipid rafts via acid 
sphingomyelinase (aSMase) activation. This resulted in the clustering of Fas receptor 
and activation of apoptosis14, with a concomitant increase in membrane fluidity. 
However, membrane enrichment in Cer commonly results in increased membrane 
order15,16, suggesting that mechanisms other than Cer formation might be responsible 
for the observed increased fluidity. Furthermore, other studies showed that cisplatin i) 
reduces the fluidity of erythrocytes and model membranes7, ii)  elevates the transition 
temperature and order of the aliphatic chains, and iii) increases the thickness of the 
bilayer17. Therefore, contradictory data are present in the literature regarding how 
cisplatin affects the biophysical properties of the membranes, and whether these 
effects may be linked to its mechanisms of action. 
To gain further insight into this subject, the impact of cisplatin and AqCis in the fluidity 
of lipid model bilayers containing different lipid composition, and thus different 
biophysical properties, was evaluated, as well as its contribution to the permeability of 
these membranes. A better understanding on these factors should provide context 
regarding the lipid membrane interactions that lead to apoptosis and the potential 
mechanisms of resistance by changes in cell lipid composition. 
2. Materials and methods 
2.1. Materials  
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-
glycero-3-phosphocholine), C16Cer (C16 ceramide, N-palmitoyl-D-erythro-
sphingosine), C24:1Cer (C24:1 Ceramide, N-nervonoyl-D-erythro-sphingosine), SM 
(sphingomyelin, from egg, chicken), POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
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L-serine) were obtained from Avanti Polar Lipids, Inc, (Alabaster, AL, U.S.A.). DPH 
(1,6-diphenyl-1,3,4-hexatriene), TMA-DPH (1-(4-(trimethylamino)phenyl)-6-phenylhexa-
1,3,5-triene), t-PnA (trans-parinaric acid) and CF (5(6)-carboxyfluorescein) were 
obtained from Molecular Probes/Invitrogen (Eugene). Chol (Cholesterol) and Triton X-
100 (TX-100) were obtained from Sigma-Aldrich (St. Louis, MO, U.S.A.). All other 
chemicals were analytical grade from Merck and Fluka (St Louis, MO, U.S.A.) and 
were used without further purification.  
The concentration of lipids stock solutions as well as lipids recovered from Sephadex 
G-25 gel filtration column were confirmed by established colorimetric assay of 
phosphorus analysis using Na2HPO4 as a standard and ammonium molibdate as 
reagent18,19. Chol stock solution concentration was determined gravimetrically with a 
high precision balance (Mettler Toledo UMT2, Columbus, OH). Probe concentrations 
were determined spectrophotometrically using ε for (i) t-PnA, set at 299.4 nm in ethanol 
as 89x103 M-1 cm-1; (ii) DPH, set at 355 nm in chloroform as 80.6x103 M-1 cm-1; and (iii) 
TMA-DPH set at 355 nm in methanol as 74.1x103 M-1 cm-1.  All solutions were kept at -
20ºC protected from light. 
2.2. Large unilamellar vesicles (LUV) preparation  
Multilamellar lipid vesicles (MLV) were first prepared by a thin-film hydration freeze-
thawing method. To this, different aliquots of the desired lipid or lipid mixture (POPC, 
DPPC, POPC:DPPC (1:1), POPC:POPS (7:3), POPC:Chol (7:3), POPC:C24:1Cer 
(7:3), POPC:C16Cer (8:2), POPC:SM:Chol (1:1:1)) in chloroform were evaporated to 
dryness under a nitrogen stream with or without probes (DPH, TMA-DPH, CF). 
Residual chloroform was further removed overnight under vacuum. The resultant lipid 
film was then hydrated with the appropriate buffer ((A) PBS: 10 mM NaHPO4 with 150 
mM of NaCl, pH 7.4; (B) PBS: 10 mM NaHPO4 with 150 mM of Na2SO3, pH 7.4; (C) 10 
mM HEPES with 150 mM NaCl, pH 7.4; (D) 10 mM HEPES with 150 mM Na2SO3, pH 
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7.4;) and vigorously shaken with a vortex mixer. The MLV suspension was then freeze-
thawed for 6 cycles and the resulting suspension was extruded 22 times through 
polycarbonate filters of 100 nm pore size (nucleopore, Pleasanton CA, USA) 
maintained at proper temperature (25-70oC) above the transition temperature of lipids 
being used. The dead volume was reduced during extrusion by pre-wetting the 
extruder with the same buffer being used. In lipid models with t-PnA, the probe was 
added to the LUV only after extrusion.  
2.3. Dynamic light scattering (DLS) and electrophor etic measurements  
The average size (Z-average and number size) and zeta-potential of LUV were 
measured on ZetaSizer Nano ZS equipment (Malvern Instruments). The DLS 
measurements were carried using a 90oC scattering optics at 25oC with parameters set 
for a viscosity of 0.890 cP and refractive index of 1.330, equilibration time of 1 min, and 
each sample was measured for 3 successive runs. All measurements were carried 
using LUV at concentrations between 0.1-1 mM.  
The zeta-potential (ζ) was determined from the electrophoretic mobility of LUV with and 
without incorporation of cisplatin by means of the Helmholtz-Smoluchowski correlation. 
Measurements were carried using a disposable zeta cell at a concentration range of 
0.1-0.5 mM and the sample was maintained at 25oC.  
2.4. Fluorescence spectroscopy  
Fluorescence anisotropy of DPH (lipid:probe (l:p) ratio of 1:200), TMA-DPH (l:p ratio of 
1:200) and t-PnA (l:p ratio of 1:500) in the different LUV (total lipid concentration of 1 
mM) was measured in a SLM Aminco 8100 series 2 spectrofluorimeter. Measurements 
were carried in a thermostat cell holder maintained at 25oC by a Julabo F25 circulated 
water bath. Samples were placed in a 0.5 cm x 0.5 cm quartz cuvette under magnetic 
stirring and fluorescence anisotropy was obtained by using 5-7 scans. The slit 
bandwidth was 8 nm for both excitation and emission beams for DPH and TMA-DPH, 
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and 16 nm for t-PnA. The excitation (λexc)/emission (λem) wavelengths were set up to 
358 nm/430 nm for DPH and TMA-DPH, and to 305 nm/405 nm for t-PnA. Background 
noise was tested by measuring the fluorescence in the same buffer and lipid 
concentration without probe. Platinum(II) complexes were then added in small aliquots 
to a final concentration of 15, 35, 100 and 300 µM. The steady-state fluorescence 
anisotropy was calculated through the expression in equation 1: 
 = 	 =>>?=>@=>>A=>@                                                               (eq. 1) 
In which the different intensities are the steady-state when both excitation and emission 
polarization are vertical (VV) and when emission is aligned horizontally (VH). Time-
resolved fluorescence of t-PnA (λexc/ λem of 295/405) and DPH (λexc/ λem of 360/430) 
were obtained by laser pulse excitation as previously described19. The fitting on the 
experimental decays were analyzed using TRFA software (Scientific Software 
Technologies Center, Minsk, Belarus) by nonlinear least squares iterative reconvolution 
method. The mean fluorescence lifetime was described as a sum of exponentials as 
follows: 
⟨E⟩ = ∑ HIJIKI∑ HIJII                                                              (eq. 2) 
Where α is the normalized exponentials (amplitude) and τ is the lifetime of decay 
component i. 
2.5. UV spectroscopy  
The UV spectra of DPH, TMA-DPH and t-PnA in LUV composed of different lipids were 
measured at different time points (0, 30 min, 4h, 12h, 24h, 48h, 72h) in Hitachi Model 
U-2000 instrument in the 250-550 nm range using quartz cells with a 0.5 cm path 
length and temperature of 25oC. The derivative spectra were calculated using the 
Savitzky-Golay method in which a second-order polynomial convolution of 13 points 
was employed20.  
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2.6. LUV leakage studies 
LUV at a lipid concentration of 2 mM were prepared as described above with 40 mM of 
CF in 10 mM HEPES buffer at pH 7.4. The suspension containing LUV and non-
encapsulated CF was then centrifuged (Ultracentrifuge Hitachi CP80NX with P70AT 
rotor) at 41000 rpm for 2 hours. The supernatant was removed and the pellet was re-
suspended in 1 mL of 50 mM HEPES buffer (pH 7.4) and filtered through a Sephadex 
G-25 gel filtration column with the same buffer. The vesicles containing CF were mainly 
obtained in fraction 3 and 4 (0.5 mL each) as verified by DLS and UV-
spectrophotometry. The recovered LUV suspension was then diluted in a 96-well plate 
to a final lipid concentration of 0.17-0.25 mM (total volume of 0.250 mL) in order to get 
an optimal magnitude of the fluorescence signal over the required experimental time. 
Cisplatin and AqCis were then added to each well and the fluorescence intensity was 
read in a microplate reader SpectraMAX GeminiEM every 2 min at 25oC for 14 hours 
(λexc/ λem of 492/530 with a cutoff at 515 nm). After this time, 10 µL of TX-100 were 
added to each well to disrupt the vesicles, and 10 intensity reads were performed for 
each well after approximately 30 minutes. The extent of CF release was determined as 
follows: 
LM	%	OPOQRO = 	 ST?SUSVWXUU?SU Y	100                                        (eq. 3) 
Where Ft represents the fluorescence intensity at time t, F0 represents the fluorescence 
intensity at first measurement and FTx100 represents the fluorescence intensity after 
addition of TX-100.   
3. Results 
3.1. Characterization of LUV by DLS 
Cisplatin in aqueous solutions exists as an equilibrium of multiple neutral and charged 
species, commonly named “aquated” species, which depends on both pH and 
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concentration of chloride. At high chloride concentrations, cisplatin remains neutral 
whereas at low chloride concentration if forms positively charged species. Therefore, 
the cationic AqCis were formed in chloride-free buffers at pH 7, which according to 
previous reports21, should represent a mixture of 70% neutral species and 30% 
positively charged species. The formation of these charged species was verified by 
measuring the zeta potential of POPC:POPS (7:3) LUV containing the negatively 
charged POPS lipid (Figure 1A). As it can be observed, increased amounts of AqCis 
increased the zeta potential of these vesicles, which was attributed to charge 
neutralization at the surface. This was supported by the addition of cisplatin at the 
same concentrations, which did not significantly alter the zeta potential (-22.66 ± 0.98 
mV and -23.16 ± 2.11 mV for 35 µM and 300 µM respectively). On the other hand, the 
zeta potential of POPC:POPS (7:3) prepared in buffer A (high chloride) in the presence 
of AqCis was similar to the control after 24 hours, indicating a transient effect possibly 
due to reversal of AqCis back to cisplatin. Finally, in zwitterionic models of POPC, 
POPC:DPPC (1:1), DPPC and POPC:Chol (7:3) LUV, the presence of both cisplatin 
and AqCis did not significantly alter the zeta potential (Figure 1B). 
 
Figure 1 – Effect of cisplatin and AqCis on the Zeta  potential of LUV with different lipid 
composition. A) variation of the zeta potential of POPC:POPS (7:3) LUV in the absence (black line) and 
in the presence of AqCis at concentrations of 35 µM (orange line) and 300 µM (red line). B) The effect of 
300 µM of Cisplatin (red solid bars) and AqCis (red grid bars) on the zeta potential of LUV containing 




The stability of the different LUV (POPC, POPC:DPPC, DPPC, POPC:POPS and 
POPC:Chol) in the presence of cisplatin or AqCis was also evaluated by measuring 
their average size after 24 and 48 hours. No significant changes in size were observed 
in the presence of cisplatin or AqCis up to concentrations of 600 µM, with Zaverage sizes 
ranging from 88 to 150 nm. Therefore, since no alterations in size were found and the 
size of both cisplatin and AqCis are very small in comparison, the curvature effect of 
the LUV surface on the interaction can be disregarded. Moreover, these results further 
indicate that interaction of AqCis and cisplatin with the LUV do not induce aggregation 
and/or fusion of the vesicles. 
3.2. Effect of platinum complexes in the phase beha vior of different 
phospholipid mixtures 
The fluidity of lipid membranes upon addition of platinum complexes was evaluated by 
measuring the fluorescence anisotropy of three different probes (DPH, TMA-DPH and 
t-PnA). The fluorescence anisotropy of these probes provides information regarding the 
fluidity of the membranes. These probes were selected because they have different 
partition coefficients towards fluid or gel phases and, in addition, are located at different 
depths of the hydrophobic region, thus reporting the behavior of the lipid acyl chains at 
different depths of the bilayer22,23. In this regard, both DPH and TMA-DPH partition 
equally between gel and fluid phases16. However, DPH is located in the center of the 
bilayer whereas TMA-DPH is anchored at the surface and is more sensitive to 
hydration24.  On the other hand, t-PnA has a higher partition and quantum yield in the 
gel phase compared to liquid ordered and disordered phases16.  
Figure 2A shows  the distribution of fluorescence anisotropy of DPH in POPC LUV 
measured every 5 minutes for 30 minutes upon addition of cisplatin and AqCis at 
different concentrations (15, 35, 100 and 300 µM). A normal distribution around the 
initial control values (<r> of 0.1020 ± 0.0035) was observed for all concentrations 
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tested, except for the lowest concentration of cisplatin (15µM) where a slightly lower 
average anisotropy was obtained (<r> of 0.1000 ± 0.0014), and the anisotropy profile 
distribution was shifted towards lower values. On the other hand, between 60-100 
minutes a very small concentration-dependent effect that resulted in increased 
anisotropy of DPH was observed, particularly for the highest cisplatin concentration 
(Figure 2B-F). At this time range a small shift in the DPH anisotropy profile towards 
higher values was observed, compared to the first 30 min for the different 
concentrations tested (Figure 2B-D). In this regard, DPH anisotropy profile revealed the 
presence of two populations with anisotropy values centered at 0.1010 and 0.1050 and 
the contribution of the population with higher anisotropy increased overtime for all 
cisplatin concentrations studied (Figure 2C- F). These results suggest that cisplatin 
induces a very small increase in the packing of the lipid acyl chains, likely due to a slow 
penetration of the molecules to the interior of the bilayer. This effect was however 
transient and the distribution of anisotropy values were similar to the control throughout 
the rest of the measurements, as shown for the highest cisplatin concentration after 72 
hours upon addition to the vesicles (Figure 3). 
Contrary to cisplatin, the addition of increasing concentrations of AqCis to POPC LUV 
did not result in significant differences in DPH fluorescence anisotropy up to 24 hours 
even for the highest concentration (Figure 3). No further measurements were however 
carried after this time point since the high concentration of chloride in solution is likely 
to reverse the AqCis equilibrium back to cisplatin. Furthermore, no differences were 
observed in the UV spectra of POPC LUV at different time points upon addition of both 
cisplatin and AqCis (data not shown), which further evidenced the low influence of the 







Figure 2 – Density distribution of anisotropy value s of DPH in POPC with different concentrations 
of cisplatin.  Fluorescence anisotropy distribution of DPH between (A) 5-30 minutes (t1) and (B) 60-100 
minutes (t2) after adding 15 (blue), 35 (orange), 100 (green) and 300 µM (red) of cisplatin. Comparison 
between t1 (solid line) and t2 (dashed line) for POPC LUV in presence of (C) 15 µM and (D) 300 µM of 
cisplatin showed an increase in the contribution of a second peak of higher anisotropy at t2. (E) DPH 
anisotropy as a function of cisplatin concentration at t2. (F) ratio between DPH anisotropy at the secondary 
peak over the primary peak (●). This ratio increased at the same time that the ratio between the primary 
peaks at t1/t2 decreased (♦). The average fluorescence anisotropy of POPC LUV prior to cisplatin addition 
was determined to be 0.1020 ± 0.0035. 
Similarly to POPC, the effects of cisplatin and AqCis in a variety of LUV with different 
lipid composition (POPC:Chol (7:3), POPC:POPS (7:3) and POPC:DPPC (1:1)) also 




both cisplatin and AqCis at different concentrations (Figure 3). Moreover, extending the 
interaction of cisplatin with these LUV for 72 did not show any significant alteration in 
fluorescence anisotropy as well as in the UV spectra (data not shown), suggesting that 
the effects of the platinum complexes in the fluidity of these membranes are negligible.  
 
Figure 3 – Fluorescence anisotropy of DPH in LUV with  different composition after addition of 
cisplatin and AqCis. Results show that DPH anisotropy recovered to control values 72 hours after 
addition of cisplatin to POPC. In contrast, AqCis did not induce any changes in DPH anisotropy over a 
period of 24h. Moreover, the average anisotropy between 30 min and 3 hours after addition of both 
cisplatin and AqCis to LUV of different composition showed no differences compared to control. Solid bars: 
cisplatin; dash bars: AqCis; Grey: control; Blue: 15 µM platinum; Orange: 35 µM platinum; Green: 100 µM 
platinum; Red: 300 µM platinum;  
The interaction of cisplatin and AqCis with POPS and its possible changes in the 
membrane fluidity were further characterized with t-PnA and TMA-DPH probes in 
POPC:POPS (7:3) LUV. No significant differences in t-PnA anisotropy were observed 
up to 24 hours after addition of cisplatin (0.1426 ± 0.0049, for 300 µM) and AqCis 
(0.1414 ± 0.0075, for 300 µM) in buffer A (high chloride) compared to control (0.1399 ± 
0.0063). Furthermore, no differences in the mean fluorescence lifetime of t-PnA was 
observed between control samples and 24 hours after addition of 35 µM of cisplatin or 
AqCis to POPC:POPS LUV. However, marked differences were observed for the long 
lifetime component of the fluorescence intensity decay of t-PnA, where a significant 
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shorter component was measured in the presence of cisplatin (8.84 ns) compared to 
control samples (16.47ns) and samples containing 35µM of AqCis (15.51 ns). In order 
to maintain the AqCis equilibrium and promote charge-charge interactions, 
measurements of the anisotropy of DPH and TMA-DPH in POPC:POPS (7:3) LUV 
were also carried in buffer B (low chloride) to an extended period of 120 hours. 
However, no differences in the fluorescence anisotropy of both probes were observed 
for both platinum(II) complexes at different concentrations tested (Figure 4 showcases 
a typical result for the highest concentration of 300 µM). These results suggest that 
both cisplatin and AqCis did not change the fluidity of this model membrane at different 
depths of the membrane.  
 
Figure 4 – Effect of charged AqCis in the fluidity o f POPC:POPS (7:3).  Fluorescence anisotropy of (A) 
TMA-DPH  and (B) DPH  in POPC:POPS (7:3) LUV in buffer B (low chloride) in the absence (black) and 
presence of 300 µM of cisplatin (red solid lines) and AqCis (red dash lines).  
To further evaluate if cisplatin effects were dependent on membrane phase properties, 
the interaction of both complexes was studied in gel-phase DPPC vesicles (Figure 5). 
Contrary to the other lipid models, both cisplatin and AqCis induced significant 
decrease in membrane fluidity as observed by the increase of DPH anisotropy, 
particularly at higher concentrations. Furthermore, contrary to POPC LUV, this 
concentration-dependent effect was sustained and was observed even 72 hours after 





Figure 5 – Effects of cisplatin and AqCis on the bio physical properties of gel phase DPPC model 
membranes.  Fluorescence anisotropy distribution of DPH in DPPC LUV between 5 min and 3 hours after 
addition of 15 (blue), 35 (orange), 100 (green) and 300 (red) µM of (A) cisplatin and (B) AqCis. The effects 
on increased anisotropy were observed throughout 72 hours (C) after addition of 300 µM of cisplatin (red 
line) compared to the control (grey). 
3.3. Influence of cisplatin and AqCis on the phase behavior of 
sphingolipid mixtures 
The probe t-PnA was used to study changes in the fluidity of lipid-raft model upon 
addition of platinum(II) complexes by using POPC:SM:Chol (1:1:1) LUV. Preliminary 
results for both cisplatin and AqCis suggested no significant changes in the 
fluorescence anisotropy of t-PnA up to 3 hours (Figure 6A). Similarly, no significant 
changes in the long lifetime component and mean fluorescence lifetime of t-PnA were 
observed 24 hours after addition of 35 µM cisplatin or AqCis to the LUV 
(supplementary Table 1).  
In a similar manner, Cer models were used to study the effects of platinum(II) 
complexes on ceramide-enriched platforms. No differences in t-PnA fluorescence 
anisotropy were observed in POPC:C16Cer (8:2) LUV model, with an average 
anisotropy over the period of 3 hours of 0.2659 ± 0.0018 for control, 0.2662 ± 0.0037 
and 0.2654 ± 0.0031 for 300 µM of cisplatin and AqCis, respectively (Figure 6A). On 
the contrary, in POPC:C24:1Cer (7:3) LUV it was observed a small but noticeable 
transient increase in t-PnA fluorescence anisotropy 30 min after addition of the highest 
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concentration of cisplatin, which disappeared after one hour (Figure 6C). This effect 
was however not observed when AqCis was added to this model membrane (Figure 
6B). Furthermore, using the Savitzky-Golay method to smooth the UV spectra data, a 
small concentration-dependent effect was observed at 312 nm, 30 minutes after 
addition of cisplatin (Figure 6D). However, similar to the results in POPC, the effect of 
cisplatin was transient and no differences in t-PnA anisotropy were found after 3 hours 
(<r> of 0.2454 ± 0.0136, 0.2484 ± 0.0016 and 0.2453 ± 0.0029 for control and 300 µM 
of cisplatin and AqCis, respectively). Interestingly, analysis of the fluorescence intensity 
decay of t-PnA in POPC:C24:1Cer vesicles 24 hours after treatment with 35 µM of 
AqCis showed a longer mean fluorescence lifetime and long lifetime component 
compared to control samples and samples containing 35 µM of cisplatin 
(Supplementary Table 1). On the other hand, the amplitude of the decay components 
(αi) increased for both cisplatin and AqCis suggesting increase in the fraction of the gel 
phase25. Together these results suggest that cisplatin has an initial and transient effect 
in the packing of the lipid chains in bilayers containing C24:1Cer, while AqCis effects 
occur at longer times upon addition of the platinum complex to the membrane. 
Moreover, AqCis effects are likely to occur primarily in gel phase regions of the 
membrane, since changes in the photophysical parameters of t-PnA are mainly 
observed at the level of the long lifetime component of the fluorescence intensity 
decay, which is commonly associated to the t-PnA molecules emitting from the ordered 





   
Figure 6 – Effect of cisplatin and AqCis on the biop hysical properties of sphingolipid mixtures. 
Fluorescence anisotropy of t-PnA in (A) POPC:SM:Chol and POPC:C16Cer over 3 hours after addition of 
300 µM of cisplatin and AqCis; Fluorescence anisotropy of t-PnA in POPC:C24:1 (B) over 3 hours after 
addition of increasing concentrations of AqCis and (C) 30 minutes after addition of increasing 
concentrations of cisplatin. At the latter time point, a small increase in t-PnA anisotropy was observed at 
higher concentrations of cisplatin.(D) 2nd derivative of the UV spectra of t-PnA in POPC:C24:1Cer LUV in 
the absence (grey) and 30 min after addition 15 (blue), 35 (orange), 100 (green)  and 300 (red) µM of 
cisplatin where a small concentration-dependent effect was observed. 
3.4. Leakage assay to study membrane permeability  
Membrane integrity was evaluated using a leakage assay on different LUV (POPC, 
POPC:Chol, POPC:POPS, POPC:DPPC, DPPC). The CF leakage assay from LUV is 
an established method to evaluate the membrane permeability in the presence of 
various molecules26–28. The influence of platinum complexes on the permeability of 
model membranes can be determined by the increase in the fluorescence intensity of 
CF that results from the release of the probe from the interior of the vesicles. This is 
because at high local concentration CF fluorescence intensity is lower due to self-






increases as a consequence of decreased local concentration, and therefore of CF 
self-quenching Figure 7A-B shows that at 35 µM both cisplatin and AqCis did not 
induce significant effects on the release of CF from POPC vesicles.  However, at 
concentrations of 300 µM both platinum(II) complexes induced increase in the release 
of CF from these vesicles. In particular, AqCis showed a very prominent release with 




Figure 7 – CF release from LUV with different lipid composition after addition of different 
concentrations of cisplatin and AqCis. Release of CF was measured from (A-B) POPC, (C-D) 
POPC:Chol; (E-F) POPC:POPS; (G-H) POPC:DPPC; and (I-J) DPPC LUV in the presence of (A,C,E,G, I) 
cisplatin and (B,D,F,H,J) AqCis respectively for each pair of graphs. Grey: Control; Blue: 15 µM platinum; 
Orange: 35 µM platinum; Red: 300 µM platinum. 
POPC:Chol vesicles displayed an intrinsic higher permeability to CF compared to 
POPC, which did not significantly changed upon addition of AqCis (Figure 7C-D). 
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However, cisplatin at 35 µM and 300 µM had a small faster rate (<10%) of CF release 
that converged to an extent of CF release similar to the control at the end point (Figure 
7C). On the other hand, cisplatin and AqCis induced release of CF from POPC:POPS 
(7:3) LUV in a non-linear concentration-dependent manner (Figure 7E-F). At the lower 
concentration of 15 µM no differences in the release of CF were observed compared to 
the control. On the other hand, at increased concentrations of 35 µM both cisplatin and 
AqCis increased the CF release, with a significant higher release in vesicles treated 
with cisplatin (Figure 7E). However, at higher concentrations of 300 µM, both cisplatin 
and AqCis showed lower CF released compared to the 35 µM concentration. In 
particular, AqCis showed to reduce the release of CF compared to control (Figure 7F).  
This interplay between cisplatin and AqCis at different concentrations suggests the 
involvement of the serine headgroup particularly due to charge-charge interactions.  
Finally, in model membranes containing gel phase, i.e. POPC:DPPC (1:1) (Figure 7G-
H) and DPPC (Figure 7I-J) LUV no significant differences were observed for both 
platinum complexes except for the highest concentration of cisplatin in the 
POPC:DPPC (1:1) LUV, which showed to completely release the CF within the time 
tested (Figure 7G). On the other hand, in the gel phase DPPC membranes almost no 
release of CF was observed, with only 4-5% of CF released after 14 hours for both 
control and platinum complexes (Figure 7I-J). 
4. Discussion  
4.1. Effects of cisplatin and AqCis on fluid and ge l phase phospholipid 
model membranes 
Drug-lipid interactions are complex and a variety of factors such as lipid type, lipid 
chain length and saturation, hydrophobic character of both the drug and the lipid 
headgroup can have a significant contribution. Moreover, cell plasma membranes are 
dynamic and heterogeneous which can change the response to drug interactions. In 
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addition, drugs can interact with specific types of lipids and induce structural and 
biophysical changes in the membrane. In this regard, the plasma membrane fluidity 
has been shown to be involved in many cellular events including protein clustering at 
the surface and play a significant role in drug diffusion. In the case of platinum(II) 
compounds, these have shown to induce lipid phase changes, as well as mixing of 
plasma membrane components, and modulate the lipid metabolism and membrane 
composition29–32. These events are however complex and not fully understood.  
To further elucidate the interactions of platinum(II) complexes with lipid membranes, 
the fluidity, surface charge and integrity of lipid models with different lipid composition 
and phase properties were studied. Previous studies in DMPC LUV showed that 
cisplatin accumulated at the headgroup region of the membrane and induced ordering 
of the acyl chains with decrease in area per lipid molecule and membrane elasticity17. 
However, other study using DPH and Laurdan as probes on DMPC LUV showed no 
significant differences in the anisotropy and general polarization, respectively, up to 10 
mM of cisplatin33. This is in line with the results obtained for cisplatin and AqCis on the 
different models tested in the present study. The results suggest that in fluid phase 
model membranes both cisplatin and AqCis have very minor influence on the fluidity 
measured at the interior of the membrane, even at “infestation” concentrations. 
However, at these high concentrations significant alterations in the permeability of 
POPC and POPC:DPPC membranes were observed. These effects cannot be 
attributed to the collapse of the membrane since the size of LUV as measured by DLS 
in presence of both platinum complexes at this concentration did not change. For 
POPC this effect was higher for AqCis, which suggests the involvement of the 
zwitterionic headgroups in the interaction established with this positively-charged 
platinum complex. In contrast, in POPC:DPPC increased membrane permeability was 
only observed for cisplatin, which suggests that this effect may be related to an 
increase in membrane packing defects due to cisplatin incorporation at the interface 
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between the fluid and gel phases. In the latter, the cationic species may be not favored 
for interaction at this interface due to the hydrophobic characteristics created by height 
mismatch between lipids. Previous studies have already reported that several platinum 
complexes, including cisplatin and AqCis, were able to increase the permeability of 
erythrocyte membrane to small molecules34. Similar observations were made in planar 
model membranes of hen’s egg yolk (mostly composed of phospholipids of PC and 
PE), where the increase in membrane permeability by platinum complexes was 
attributed to the creation of small holes35. Our results suggest that indeed the 
permeability of the membrane is increased without major alterations of the lipid phase 
properties and thus further studies should be carried in these membranes to 
understand if this is due to the creation of small holes, or small packing defects that are 
formed upon interaction of the platinum complexes with the membrane. 
. Chol is an important component of the plasma membrane, which due to its planar 
rigid structure intercalates within the hydrocarbon chain and increases the order of the 
fluid phase and reduces the formation of gel phase36–38. It was previous shown that 
digitonin, a compound that interacts with cholesterol, increases the permeability of the 
membrane9 and consequently increases cisplatin uptake9,12. In our POPC:Chol model 
system, where both the liquid disordered (ld) and liquid ordered (lo) phases coexist39,40, 
the overall rate of intrinsic membrane permeability was considerably higher in 
comparison to POPC. Under these experimental conditions, it is therefore difficult to 
evaluate the effects that cisplatin and AqCis have in the permeability of these 
membranes in comparison to POPC. Indeed, it was observed a small faster release 
(<10%) of CF for 35 and 300 µM of cisplatin but not AqCis, but it converged to similar 
values of control. It should however be stressed that, in contrast to the observed in 
POPC membranes, cisplatin was unable to induce transient changes in the fluidity of 
POPC:Chol membranes, which might suggest that Chol might prevent the transient 
and modest ordering effect that cisplatin might have in the lipid hydrophobic chains.  
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Regarding platinum(II) complexes interactions with gel phase phospholipid 
membranes, previous studies suggested that cisplatin interacts with the headgroup of 
DPPC forming a 2:1 lipid-platinum complex with the phosphate groups and causes 
rearrangements that result in lower mobility of the headgroup41. This effect resulted in 
alteration of the pre-transition temperature but not the main transition temperature. 
Similarly, AqCis was shown to strongly interact with the DPPC lipid headgroup 
consistent with binding to the headgroup, and induce structural alterations of the 
glycerol moiety7,11. The results obtained with cisplatin and AqCis in DPPC LUV by 
measuring the fluorescence anisotropy of DPH showed that both complexes were able 
to induce small but significant concentration-dependent increase in the order of DPPC 
membranes. This effect was noticeable within the first minutes and was maintained 
throughout 72 hours. Since formation of Pt-O-P complexes seems to be transient 
occurring only after 2.5 hours and disappearing after 12 hours10, these results suggest 
that the formation of the complex may not be necessary for the observed changes in 
DPPC membrane fluidity. The increase in the packing of the DPPC acyl chains might 
indeed be a result of the incorporation of platinum complexes within the membrane, 
which occurs without strong perturbations of the structure of the membrane, as shown 
by the lack of changes in the permeability of the membrane in the presence of platinum 
complexes.    
4.2. Platinum(II) complexes interactions with POPS.  
Phosphatidylserines are anionic phospholipids mostly located in the inner leaflet of the 
plasma membrane of non-cancer cells and have a crucial role in many cellular events 
including activity of proteins4,42–44. However, in some cancer cells this type of lipid is 
increased in the outer leaflet of the plasma membrane45,46. This shift in membrane lipid 
composition can promote changes on membrane surface charge and lipid packing, and 
influence its interactions with drugs and response to chemotherapy. In particular, 
platinum(II) complexes have shown to specifically interact with anionic lipids including 
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POPS, and AqCis charge may be the determining factor for the binding7,17,21,47,48. 
Indeed, literature reports have shown that AqCis was able to increase the main 
transition temperature of anionic DPPG lipid but not of the zwitterionic DPPC, which 
was attributed to the electrostatic interactions that lead to a more rigid and less fluid 
membrane21. Platinum complexes are also able to coordinate with the serine group of 
phospholipids. Contrary to DPPC, it was not the phosphate group but rather the 
carboxyl and amine group of the serine headgroup stabilized by the phosphate that 
complexed with platinum(II) complexes49. However, at room temperature this process 
is very slow with half-life of formation around 70h49.  
The obtained results suggest that the interaction between AqCis was rapidly 
established in POPC membranes containing the anionic lipid POPS, strongly 
suggesting that the electrostatic forces drove direct binding to the surface resulting in 
charge neutralization. Calculating the partition coefficient from zeta potential50,51 
suggests that these charged species accounted for approximately 40% and 51% of 
POPS neutralized by 35 and 300 µM of AqCis respectively. From a biological 
perspective, this surface charge neutralization can have important consequences in 
cells since this potentially changes the overall surface charge of the membrane, 
affecting its interaction with proteins and other membrane-associated cellular events. 
The results further suggest that if the coordination complex was formed, it is reversed 
by increased chloride concentration, since the zeta potential returned to values similar 
to the control sample. Furthermore, charge neutralization has been regarded as the 
mechanism by which platinum compounds rigidify the membrane, similarly to effects 
observed for charged ions, such as, Mg2+ and Ca2+ cations21,52. Moreover, charge 
neutralization might also increase gel-to-fluid transition temperatures21,53, likely due to 
decreased electrostatic repulsion between the lipid headgroups, and consequent 
increase in the lipid packing. However, using different fluorescent probes no 
differences in the fluidity in the POPC:POPS model membranes was observed by 
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addition of both cisplatin and AqCis, even for an extended period of time. These results 
suggest that both the charge neutralization or/and the platination of the serine 
headgroup did not have a significant influence in the phase properties of this model 
membrane. However, a complex behavior in the permeability properties of these 
vesicles was observed within the first 14 hours, suggesting that both cisplatin and 
AqCis are able to specifically interact with POPS. As to why increasing amounts of both 
cisplatin and AqCis resulted in lower release of CF and in particular for the highest 
concentration of AqCis is yet to be determined. It is possible that the coordination to the 
serine groups promotes aggregation of CF at the surface and thus induces self-
quenching effects.  
This complex behavior was further evidenced by the fluorescence decay of t-PnA 
where the long lifetime component 24 hours after addition of 35 µM of cisplatin was half 
of that measured for the control and for 35 µM of AqCis. This suggests that cisplatin 
induced a more disordered membrane16 and in comparison to AqCis induced a higher 
release of CF, which could be attributed by increased defects in the membrane core 
that do not involve phase change. 
4.3. Effect of platinum complexes on sphingolipid m ixtures 
Lipid rafts are fundamental for many cell signaling pathways. In particular, lipid raft 
integrity was shown to be required for cisplatin-induced apoptosis in cells13,54,55 and is 
also involved in mechanisms of cisplatin-resistance56. These domains are the primary 
site for aSMase action and in response to stress stimulus, such as cisplatin, this 
enzyme converts SM to Cer leading to ceramide-enriched domains formation and 
clustering of receptors at these lipid platforms13,15,55,57. In particular, in HT29 human 
colon carcinoma cells, cisplatin-induced aSMase activation (via NHE1-dependent 
intracellular acidification) was concomitant with an induced transient increase in 
membrane fluidity for both bulk membrane and lipid rafts that led to reorganization of 
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the lipid domains and clustering of CD95 receptors and subsequent apoptosis55. 
However, these observations contrast with the expected alterations in membrane 
properties upon Cer generation. Indeed, Cer is highly hydrophobic and prone to form 
tightly packed gel phase domains, which cause a decrease in the overall fluidity both of 
model and biological membranes15,16,58–61. Such evidence suggests that other factors 
besides Cer formation, might be responsible for the observed cisplatin-induced 
increase of membrane fluidity. To gain further insight into cisplatin and AqCis 
interactions with lipid raft- and Cer platform-like domains, three representative mimetic 
systems (POPC:SM:Chol, POPC:16Cer and POPC:24:1Cer) were studied.   
Interestingly, platinum complexes had a transient effect on the properties of 
membranes containing C24:1Cer, causing a further decrease in its fluidity. This was 
due to an increase in the fraction of the gel phase observed upon interaction both with 
cisplatin and AqCis, and due to an increase in the packing of the C24:1Cer-enriched 
gel domains promoted by AqCis. No changes in the fluidity of the other lipid systems 
were observed. Many factors might contribute to these observations. First the gel 
phase formed by C24:1Cer is less rigid than the one formed by C16Cer. This might 
facilitate the incorporation of the platinum molecules within the membrane. Moreover, 
the presence of an unsaturation at the membrane interior might cause packing defects 
that might further increase the partition of cisplatin and AqCis to the membrane. 
Furthermore, the chain mismatch in C24:1Cer determines its ability to form 
interdigitated gel phases22,59. The interaction of platinum complexes with this partially 
interdigitated phase, could promote a reorganization of the hydrophobic chains, or even 
a transition to another more rigid gel phase. On the other hand, cisplatin and AqCis 
might also be able to partition to membranes enriched in C16Cer gel domains. 
However, because these are already highly ordered, further decrease in membrane 
fluidity might not be noticeable. It should however be stressed that such interaction do 
not induce a decrease in the fluidity of the membranes, suggesting that these platinum 
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complexes do not compromise the overall packing of C16Cer gel phase. Therefore, 
other factors may contribute to the observed increase in fluidity at lipid rafts in HT29 
cells13. In particular, cisplatin is known to easily exchange its chlorides with other 
biomolecules with particular high affinity for thiols3,7, and therefore these could 
potentially interact differently with lipid bilayers. 
5. Conclusions  
This work indicates that the interaction of platinum(II) complexes with lipid membranes 
is complex and a multitude of factors contribute to this interaction. These effects result 
from combination of membrane lipid composition, fluidity and surface charge of the lipid 
membrane, as well as, the type of platinum(II) complex. Overall, both cisplatin and 
AqCis did not induce a substantial increase in membrane fluidity. On the contrary, 
these complex seem to promote further ordering of gel phases, particularly in 
membranes composed of DPPC and POPC:C24:1Cer. However, the interaction of 
these complexes with the membrane resulted in changes in membrane permeability to 
an extent that depends on the concentration and type of the platinum complex, as well 
as, on the lipid composition and properties of the membranes. These results thus 
suggest that the molecular mechanism underlying cisplatin interaction with biological 
membranes is not straightforward and generalization of the effects of cisplatin in the 
properties of biological membrane should be made with caution.   
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Supplementary table 1 – Fluorescence decay component s of t-PnA 24 hours after addition of 
cisplatin or AqCis to sphingolipid mixtures  
System ⟨τ⟩ (ns) Long life time component (ns) 
POPC:SM:Chol (control) 22.07 28.85 
POPC:SM:Chol + 35 µM cisplatin 21.57 28.82 
POPC:SM:Chol +35 µM AqCis 21.63 28.62 
POPC:24:1Cer (control) 25.26 34.58 
POPC:24:1Cer + 35 µM cisplatin 25.63 34.87 
POPC:24:1Cer + 35 µM AqCis 30.86 40.83 
 
 
Figure S1 – Effect of cisplatin on fluorescence aniso tropy of DPH in DPPC LUV. After 24 hours upon 
of addition of 15 µM (blue), 35 µM (orange) and 100 µM (green) cisplatin to DPPC LUV, a concentration-
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Chapter V – Final remarks, ongoing work and future 
perspectives 
 
Despite the tremendous amount of work in nanomedicine, it is still relatively difficult to 
design novel DDS. A fundamental problem is that there is a lack of knowledge on how 
these interact within the biological milieu and in particular at the cellular interfaces such 
at the lipid membranes. In this regard, dendrimers are suitable tools to study these 
interactions due to their versatility. Therefore, this thesis uses a multidisciplinary 
approach to design fluorescent dendrimers to be used as DDS. In summary this work 
describes: (i) computational methods developed to reliable build molecular models of 
different dendrimers; (ii) simulation of different PG dendrimers and evaluation of their 
ability to carry a fluorophore in their core protected from the external environment; (iii) 
the synthesis of PG dendrimers suggested by modeling studies and evaluation of the 
best synthetic route to incorporate the fluorophore; and (iv) evaluation of cisplatin 
effects on the biophysical properties of lipid membranes including phase behavior and 
permeability, to further guide the design of dendrimers. 
Dendrimers are complex structures with still fairly unknown behavior. To this, molecular 
modeling and simulation methods provide useful tools to study dendrimers structure at 
the atomic level. However, building in silico models of different dendrimers is still not an 
easy task, particularly for higher generations. In this thesis, improved methods to 
reliable build different classes of dendrimers were developed in python language. 
These tools improved previously published protocols1 and were able to quickly and 
reliably generate different dendrimers. These tools were then used to test different PG 
topologies and simulate these dendrimers with different terminal groups. Simulations 
allowed the characterization of PG dendrimers at the atomic level and the results 
suggested that at least generation 4 was necessary to incorporate a small fluorescent 
probe in the interior of these dendrimers. Moreover, the simulation of these dendrimers 
also showed that changes of the terminal groups strongly change the dynamics and the 
behavior of their surface.  
Due to the versatility of these tools to readily create dendrimer topologies, these were 
currently used to model polyurea (PURE) dendrimers of generation 3 to 5 (Figure 5.1). 
These type of dendrimers were shown to have inherent fluorescent properties at higher 
generations and thus were useful to track their behavior in vitro2,3. Similar to PG 
dendrimers, these dendrimers were assembled using the same methods and are 
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currently being simulated to understand their structure and compare it to PG 
dendrimers. 
One of the current problems with computational models of dendrimers is that there is 
no dedicated force field for this type of macromolecules. In the case of PG dendrimers, 
parameterizations were “borrowed” from the CHARMM force field designed for amino 
acids. Moreover, simulations were run surrounded by water molecules whereas 
reactions were carried in organic solvents. These have tremendous effects on the 
conformation of dendrimers scaffold and therefore could be the reason why limitations 
in the synthesis were observed. Therefore, development of dendrimers force field is an 
interesting approach to pursue. There has been increasing data on both crystal 
structure and supramolecular analysis of dendrimers and thus could be used for 
validation. Furthermore, despite the tool herein described performed well at creating 
models it still required significant knowledge on how to use it because it uses external 
software for the assembly. Therefore, future work should include further automatization 
and increased user friendly interfaces. Moreover, further development of a web 
application should be pursed so that this tool can be used for by other researchers with 
ease. 
 
Figure 5.1 – From left to right: 3D structure of PUR E G3, G4 and G5. Dendrimers were created using 
the same protocol for PG dendrimers in chapter 1. The topology files was carried using XPLOR-NIH and 
were modified with ParamChem parameters. Dendrimers were then loaded to Maestro and automatic 
attribution of atom types was carried. 
The synthesis of PG G4 candidates from molecular modelling was then carried out 
using classical peptide coupling methods. Despite several optimized reaction 
conditions were successful at synthesizing small generations, these failed to generate 
the necessary generation 4. In general, the various coupling reagents tested resulted 
in: (i) defective dendrimers; (ii) dendrimers complexed with impurities; (iii) poor yields of 
recovery. Contrary to carbodiimide reagents, CDI and Uronium salts were shown to be 
viable alternatives as coupling reagents to grow the dendrimer since they were easier 
to purify. Nevertheless, due to the amount of reactions of coupling and de-protection 
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needed and the increasingly lower yields obtained till G2, the synthesis of PG G4 was 
shown to be unviable. These difficulties were attributed to the steric constraints due to 
the short side chain of glutamic acid. Therefore, new architectures of PG dendrimers 
should be explored based on the information obtained in this thesis.  
On the other hand, the reactions used for PG dendrimers translated well into other 
types of monomers. In fact, the synthesis of different terminal groups using CDI 
showed good yields. However, these reactions also shown that the derivative of the 
monomer is of utmost importance when being selected since solubility problems were 
observed that would hinder their use. Finally, this thesis also describes the 
incorporation of a small fluorophore (NBD) into the core GLU. The results showed that 
the incorporation of the NBD should be carrier early on the synthetic route since the 
overall bulkiness even for small dendrimers resulted in steric effects and low yield of 
recovery. Moreover, new GLU derivatives were synthesized to further attach the NBD 
to GLU and prevent the core amine from further reaction when growing the dendrimer. 
Two successful candidates for the core were obtained and further work should be 
carried on using these.  
Finally, in the last chapter of this thesis, cisplatin was used as a model anti-cancer drug 
to study its effects on the biophysical properties of the lipid membrane. The results 
showed that cisplatin had little influence in the properties of several lipid membranes, 
inducing a small decrease in membrane fluidity in gel phase model membranes. 
Despite the small effects in membrane fluidity, cisplatin was able to induce changes in 
the permeability of most of the membrane model systems studied. The rate and extent 
of membrane permeability was dependent on the lipid composition and cisplatin 
concentration. In particular, a higher release of CF was observed for POPC and 
POPC:DPPC (1:1) model vesicles when treated with high concentration of cisplatin . 
On the other hand a complex behavior was observed for POPS, which was attributed 
to the complexation of cisplatin at the lipid headgroup. Furthermore, a small but 
noticeable effect was observed for gel phase models of ceramide-enriched membranes 
where cisplatin induced ordering of the membrane. This is clear contrast to studies with 
cellular membranes where addition of cisplatin induced production of ceramide by 
conversion of SL at lipid rafts that resulted in increasing the membrane fluidity. 
Therefore, this suggests that the interaction of cisplatin with cells is complex and 
multiple factors contribute to the lipid phase change. 
Currently, studies are being conducted using AFM to further characterize the cisplatin-
lipid bilayer interactions. Preliminary results obtained on POPC:DPPC (1:1) model 
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membranes suggest that at high concentrations, cisplatin extended the defective pores 
observed at the fluid and gel phase interface (Figure 5.2), which might be the cause 
underlying the high leakage observed for these vesicles  
 
Figure 5.2 – AFM of supported lipid bilayer compose d of POPC:DPPC (1:1) . Images were obtained 
(A) before and (B) after addition of 300 µM of cisplatin. Blue arrows point towards some examples where 
cisplatin expanded existing defects at the interface of fluid and gel phase. In situ tapping-mode imaging 
were performed at room temperature using a Multimode Nanoscope IIIa Microscope (Digital Instruments, 
Veeco) using a similar protocol previously established4. Scale: 5.5x5.5 µm 
Finally, it should be mentioned that based on these results, an interesting approach to 
pursue in cisplatin delivery would be the combination with a synergistic molecule in the 
same DDS, such as a dendrimer scaffold. In fact, combining cisplatin and ceramide in 
a dendrimer could circumvent the resistance mechanisms associated with platinum 
accumulation and promote the induction of apoptosis. With this in mind, PURE 
dendrimers G3, G4 and G5 were kindly provided by Dr. Vasco Bonifácio to further 
evaluate their behavior with lipid membranes and their potential use for DDS. 
Preliminary results of all three generations showed that these dendrimers fluorescence 
intensity was pH- and generation-dependent (Figure 5.3). These properties are 
valuable to study since they can measure the pH differences inside cells and provide 
valuable information regarding their surroundings. Further studies with these 
dendrimers also showed that they were able to complex with carboxyfluorescein 
without changing their fluorescence spectrum. This property can be useful to further 
validate the molecular modeling studies by quantifying the amount of CF that 
complexes with these dendrimers both by computational and bench methods. Indeed, 
ongoing simulations are currently being undertaking to understand how CF binds to 
PURE dendrimers. The characterization of this property will also allow the study of 
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affinity of different drugs (including cisplatin) to these dendrimers by competitions 
assays.  
 
Figure 5.3 – Fluorescence intensity of PURE G3 (green ), G4 (red) and G5 (blue) dendrimers under 
the same experimental conditions (final concentrati on of 0.1 mM). The fluorescence intensity of both 
emission (A) and excitation (B) increased with pH decrease and were dependent on the generation of 
PURE dendrimers.  
Finally, PURE dendrimers were also tested on their effect to modulate the permeability 
of different model bilayers similarly to the methods used for cisplatin (Figure 4). 
Preliminary results showed that similar to the effects described above, CF strongly 
interacts with PURE dendrimers, making it difficult to clearly evaluate the effects of the 
dendrimers on the permeability of the lipid membranes. Nevertheless, for low 
concentrations of 1% mol dendrimer/lipid, where the effects of complexation are 
minimized it is possible to observed that both G4 and G5 (but not G3) significantly 
increased the permeability of POPC to CF. On the other hand, in POPC:POPS (7:3) 
model, all three concentrations increased the permeability of the membrane. On the 
contrary, for POPC:DPPC (1:1) all three concentrations reduced the release of CF 
compared to the control. It is unlikely that this effect can be explained by complexation 
of CF to PURE dendrimers. Instead, based on the results obtained for cisplatin, it is 
possible that PURE dendrimers intercalate at the interface between the fluid and gel 
phase and “cover” the defects, therefore preventing the release of CF. However, further 
studies are necessary, likely using different strategies to evaluate the permeability of 
model membranes by PURE, for instance, by encapsulating other fluorophores, such 





Figure 5.4 – Release of CF from control (black) of (A) POPC; (B) POPC:POPS (7:3) and (C) 
POPC:DPPC (1:1) with 1 mol% of PURE dendrimers G3 (red),  G4 (green), G5 (purple)  
Overall, this thesis provides a proof-of-concept methodology on how to approach the 
design of new DDS. The methods herein described allow a multidisciplinary approach 
from computational models to the understanding of the behavior of both the drug and 
carrier at the lipid interface. Results suggested that the effects of cisplatin at 
therapeutic concentrations are minimal on both the lipid phase changes and 
permeability of the membrane and that dendrimers could provide a good platform to 
increase the permeability of the membrane. Finally, the synthetic approach taken for 
PG dendrimers clearly demonstrated new avenues and possible alternatives that need 
to be taken for the design of PG dendrimers.  
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